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ABBREVIATIONS 
A1: BCL-2 related gene A1 
ABB: annexin binding buffer 
ACC: acetyl-CoA carboxylase 
ActD: actinomycin D 
AICAR: 5-aminoimidazole-4-carboxamide 
riboside 
AK: adenosine kinase 
AMPK: AMP-activated protein kinase 
APAF-1: apoptotic protease-activating factor-1 
APC: allophycocyanin 
ATIC: AICAR transformylase IMP 
cyclohydrolase 
ATM: ataxia telangiectasia-mutated 
BAD: BCL-2 antagonist of cell death  
BAK: BCL-2-antagonist/killer-1 
BAP-37: B-cell-receptor-associated protein 37 
BAX: BCL-2-associated X protein 
BCA: bicinchoninic acid 
BCL-2: B-cell lymphoma-2 
BCL-XL: BCL-2-related gene, long isoform  
BCR: B-cell receptor 
BH: BCL-2 homology 
BID: BH3-interacting domain death agonist  
BIK: BCL-2 interacting killer  
BIM: BCL-2-like-11  
BIR: baculovirus IAP repeat 
BMF: BCL-2-modifying factor 
BN-PAGE: blue native-polyacrylamide gel 
electrophoresis 
BOK: BCL-2-related ovarian killer 
BTK: Bruton tyrosine kinase 
CAMKKβ: Ca2+/calmodulin-activated protein 
kinase kinases β 
Carbamoyl-Asp: carbamoyl-aspartate 
Carbamoyl-P: carbamoyl-phosphate 
CARD: caspase recruitment domain 
Caspases: cysteine-dependent aspartate-directed 
proteases 
CBB: Coomassie Brilliant Blue 
CDP-DAG: cytidine diphosphate 
CICD: caspase-independent cell death 
CL: cardiolipin 
CLL: chronic lymphocytic leukemia 
CML: chronic myelogenous leukemia 
CMP: cytidine monophosphate 
CNT: concentrative nucleoside transporter 
CRE: cAMP response element 
DAG: diacylglycerol 
DD: death domain 
DED: death effector domain 
Del: deletion 
DHE: dihydroethidium 
DISC: Death-Inducing Signaling Complex 
DKO: double knockout 
DR: death receptor 
DTT: Dithiothreitol 
ENT: equilibrative nucleoside transporter 
ER: endoplasmic reticulum 
ERK: extracellular signal-regulated kinase  
FADD: Fas-associated death domain  
FBS: fetal bovine serum 
FCR: fludarabine + cyclophosphamide + 
rituximab 
Fig: Figure 
FITC: fluorescein isothiocyanate  
FL: follicular lymphoma 
HIF: hypoxia-inducible factor 1α 
HRK: hara-kiri 
 4 
HTNC: His-TAT-NLS-Cre recombinase 
HtrA2: high temperature requirement protein 
A2/OMI 
IAP: inhibitor of apoptosis 
IGHV: immunoglobulin heavy chain variable 
region 
IM: inner membrane 
IMM: inner mitochondrial membrane 
IMS: intermembrane space 
IPTG: Isopropyl β-D-1-thiogalactopyranoside 
JNK: c-Jun N-terminal kinase 
KO: knockout 
LB: lysogeny broth 
MAPK: mitogen-activated protein kinases  
MCL: mantle cell lymphoma 
MCL-1: myeloid cell leukemia 1 
MEFs: mouse embryonic fibroblasts 
MFI: mean fluorescence intensity 
MLKL: mixed lineage kinase domain-like 
protein 
MM: multiple myeloma 
MOMP: mitochondrial outer membrane 
permeabilization 
NBTI: nitrobenzylthioinosine 
NF-κB: nuclear factor kappa B cells 
NLS: nuclear localization signal 
NT: nucleoside transporter 
OMM: outer mitochondrial membrane 
OMP: orotidine monophosphate 
OPA1: optic atrophy 1 
P/S: penicillin/streptomycin 
PA: phosphatidic acid  
PARP: poly(ADP-ribose) polymerase 1 
PBS: phosphate buffered saline 
PC: phosphatidylcholine 
PE: phycoerythrin 
PEA: phosphatidylethanolamine 
PG: phosphatidylglycerol 
PGP: phosphatidylglycerol phosphate 
PHB: prohibitin 
PI: propidium iodide 
PI3K: phosphatidylinositol-3-kinase 
PIN: phosphatidylinositol 
PKA: protein kinase A 
PKC: protein kinase C 
PMA: prohibitin/mAAA protease 
supercomplexes 
PoS: ponceau staining 
PRPP: phosphoribosyl-pyrophosphate 
PS: phosphatidylserine  
PUMA: p53-upregulated modulator of 
apoptosis 
PVDF: polyvinyl difluoride 
RCD: regulated cell death 
REA: repressor of estrogen receptor activity 
RIPK: receptor-interacting protein kinase 
Roc-A: Rocaglamide-A 
ROS: reactive oxygen species 
RT: room temperature 
RT-MLPA: retrotranscriptase multiplex 
ligation-dependent probe amplification 
RT-qPCR: real-time quantitative polymerase 
chain reaction 
SB: sample buffer (Laemmli) 
SC: scramble 
SDS: sodium dodecyl sulfate 
SEM: standard error of the mean 
SKO: SLP-2 knockout 
SLP-2: stomatin-like protein 
SMAC/DIABLO: second mitochondria-
derived activator of caspases/direct IAP-
binding protein with low PI 
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SMZL: splenic marginal zone B-cell lymphoma 
SPFH: stomatin-prohibitin-flotilin-HflC/K  
STS: staurosporine 
Syk: Spleen tyrosine kinase 
tBID: truncated BH3-interacting domain death 
agonist 
TBS: tris-buffered saline 
TBS-T: TBS-Tween 
TM: transmembrane 
TMP: thymidine monophosphate 
TNF: tumor necrosis factor 
TNFR: tumor necrosis factor receptor 
TRADD: TNFR-associated death domain 
protein 
TRAIL: TNF-related apoptosis-inducing ligand 
UMP: uridine monophosphate 
UMPS: UMP synthase 
WT: wild-type 
XO: xanthine oxidase 
z-VAD.fmk: benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone
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1. APOPTOSIS AND CANCER 
1.1. TYPES OF CELL DEATH 
According to the Nomenclature Committee on Cell Death, cell death can be operationally categorized 
in two major groups: accidental and regulated. On the one hand, accidental cell death is induced upon 
exposure to severe insults, such as mechanical, chemical or physical stimuli, which results in 
immediate loss of cell structural integrity. Its commitment does not involve a specific molecular 
mechanism; thus accidental cell death cannot be targeted by pharmacologic or genetic interventions 
(Galluzzi et al. 2014). 
In clear contrast, regulated cell death (RCD) is a controlled mechanism of removing superfluous or 
damaged cells within multicellular organisms. It requires a genetically encoded molecular machinery 
which can be pharmacologically or genetically modulated. Various cell death processes are included in 
this category, being apoptosis and regulated necrosis the most relevant ones (Galluzzi et al. 2014). 
 
1.1.1. THE APOPTOTIC PROCESS 
Apoptosis is the best-characterized type of RCD. It is highly conserved throughout evolution as it is 
required for embryogenesis, development of the immune system and tissue homeostasis. Within a 
completely physiologic context, apoptosis is generally referred to as programmed cell death. In 
addition, apoptosis can also be induced after perturbations of the microenvironment or the cellular 
homeostasis (Galluzzi et al. 2014). Aberrant regulation of apoptosis has severe clinical implications. 
In this sense, premature cell loss may contribute to the development of neurodegenerative disorders 
and immunodeficiency, whereas continuous cellular survival would promote autoimmunity and 
cancer (Fig. I.1) (Hotchkiss et al. 2009). Indeed, resistance to cell death was reported as one of the 
hallmarks of cancer development and progression (Hanahan and Weinberg 2011). Deregulation of 
the apoptotic pathway not only can promote tumorigenesis, but can also render cancer cells resistant 
to conventional anti-cancer agents (Fernald and Kurokawa 2013). 
Apoptosis and cancer 
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Figure I.1. Apoptosis maintains tissue homeostasis by keeping the balance between proliferation and cell 
death. Deregulated apoptotic machinery disrupts the balance, which may result in various diseases. Adapted from 
Walensky 2006 and modified in Pérez-Perarnau 2013. 
 
Apoptotic cells can be recognized by characteristic morphological changes (Fig. I.2). Cells undergoing 
apoptosis first shrink, become rounded and retract from neighboring cells, which is accompanied by 
plasma membrane blebbing. The Golgi apparatus, endoplasmic reticulum (ER) and mitochondrial 
networks suffer pronounced fragmentation, and numerous proteins are released from the 
mitochondrial intermembrane space. The activation of proteolytic enzymes mediates the cleavage of 
multiple protein substrates, which usually determine the integrity and the shape of the cytoplasm or 
organelles. In the nucleus, the DNA is also cleaved into a ladder of fragments of 200 base pairs or 
multiples thereof. This pattern of fragmentation is the result of endonuclease-mediated chromatin 
cleavage at internucleosomal sites, and is typically accompanied by chromatin condensation. 
Importantly, the plasma membrane integrity is maintained during apoptosis, which avoids the release 
of cellular contents and minimizes tissue inflammation and damage to neighboring cells. Apoptosis 
frequently culminates in the fragmentation of the plasma membrane blebs into small vesicles called 
apoptotic bodies, which contain condensed chromatin, fragmented organelles and cytosol (Taylor et 
al. 2008). Phosphatidylserine (PS) is a phospholipid confined to the inner layer of the plasma 
membrane, but it is exposed to the outer layer during apoptosis. This becomes an eat me signal for 
macrophages, which will rapidly engulf the apoptotic bodies (Fadok and Henson 2003, Taylor et al. 
2008). 
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Figure I.2. Biochemical and morphological features of apoptosis. Adapted from Kumar et al. 2014. 
 
Apoptosis can be divided into distinct phases according to these biochemical and morphological 
characteristics. First, pro-apoptotic stimuli trigger the activation of the central molecular machinery of 
apoptosis, the caspases (initiation phase). Second, during the effector phase, the molecular 
executioner machinery becomes fully activated. Third, the degradation phase is characterized by the 
loss of cellular integrity and the display of the typical biochemical and morphological changes of 
apoptosis (Vaux and Strasser 1996). 
 
1.1.2. OTHER TYPES OF REGULATED CELL DEATH 
Necrosis is morphologically characterized by cytoplasmic granulation and organelle swelling (oncosis), 
condensation of the chromatin into small and irregular patches and dilatation of the plasma 
membrane (Fig. I.3). Induction of the necrotic process leads to the loss of membrane integrity and 
the release of cellular contents into the extracellular space. Consequently, there is damage of the 
surrounding cells and a strong inflammatory response in the tissue.  
 
Figure I.3. Biochemical and morphological features of necrosis. Adapted from Kumar et al. 2014. 
Apoptosis and cancer 
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Although historically seen as an accidental cell death program, recent genetic and pharmacological 
evidences revealed the existence of multiple pathways of regulated necrosis (Vanden Berghe et al. 
2014, Galluzzi et al. 2014). Different cell death types share the necrotic morphological features, 
leading to the appearance of several neologisms, such as necroptosis, ferroptosis, or pyroptosis. Each 
type of necrotic cell death is induced by specific stimuli, such as hyperactivation of poly(ADP-ribose) 
polymerase 1 (PARP1), mitochondrial permeability transition, or NADPH oxidases, and is 
transmitted through specific signaling pathways (Vanden Berghe et al. 2014).  
One of the most studied processes of regulated necrosis is necroptosis, which is mediated by 
receptor-interacting protein kinase (RIPK) 3, mixed lineage kinase domain-like protein (MLKL) and, 
in some contexts, RIPK1. Several pro-apoptotic stimuli, under conditions of inhibition of the 
apoptotic machinery, can trigger necroptosis. Necrostatin-1 blocks the kinase activity of RIPK1 and 
thus is a potent inhibitor of necroptosis (Linkermann and Green 2014, Vanden Berghe et al. 2014). 
In addition, the role of autophagy in cell death has been long debated. Autophagy is a lysosome-
dependent process in which the cytosolic content is engulfed into an autophagosome, leading to the 
digestion of the material for its recycling. As autophagy is a pro-survival stress response, some insults 
that induce cell death are preceded by extensive autophagy in an attempt to face the unfavorable 
conditions. Thus, in most instances, autophagy only correlates, but not causes, cell death. However, in 
some circumstances, inhibition of autophagy blocks the onset of cell death, supporting the existence 
of autophagic cell death (Tait et al. 2014, Galluzzi et al. 2014). 
Of note, the identification of the cell death type based on the morphology of the cell is difficult, as 
there are some cell death processes (such as autoschizis) that show both apoptotic and necrotic 
features (Vanden Berghe et al. 2014). Furthermore, the signal transduction pathways that lead to 
apoptosis, necroptosis and autophagic cell death are highly interconnected (Tait et al. 2014). 
 
1.2. THE APOPTOTIC MACHINERY 
1.2.1. CASPASES 
Apoptosis is orchestrated by a family of cysteine-dependent aspartate-directed proteases (caspases). It 
is estimated that activated caspases can cleave over 700 substrates (http://bioinf.gen.tcd.ie/casbah/) 
to promote the morphological and biochemical features that typically occur in apoptosis. Caspases 
target key structural components of the cytoskeleton and nucleus, as well as numerous proteins 
involved in housekeeping functions within the cell. (Taylor et al. 2008). The domain structure of 
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caspases includes an N-terminal peptide or pro-domain, and two subunits, one large and one short, 
sometimes separated by a linker peptide (Fig. I.4) (Taylor et al. 2008, Shalini et al. 2014). 
The caspases that are involved in apoptosis can be classified into two main groups: 
1. Initiator caspases: these include caspases 2, 8, 9 and 10. They are the first to be activated after the 
apoptotic stimulus. Initiator caspases are characterized by the presence of a caspase-recruitment 
domain (CARD) or death effector domain (DED) at their N-terminus, which mediate their 
dimerization and/or assembling into larger complexes to promote their activation. 
2. Effector or executioner caspases: these include caspases 3, 6 and 7. They are activated by the 
initiator caspases and are responsible for the proteolytic events that result in apoptosis. 
 
Figure I.4. Functional classification and domain structure of placental mammalian caspases. Caspases 11 
and 13 are the murine and bovine orthologues of caspase 4, respectively. Caspase 16 has a similar sequence to 
caspase 14. CARD, caspase recruitment domain; DED, death effector domain; L, large subunit; S, small subunit; S*, 
short form; L*, long form. Taken from Shalini et al. 2014. 
 
In addition to apoptosis, caspases also play a role in other processes. Caspases 1, 4, 5, 11 and 12 are 
called inflammatory caspases as they regulate the innate immune response. In addition, caspases 1 and 
11 mediate inflammatory cell death by pyroptosis in response to acute viral or bacterial infection. 
Caspase 8 has dual role in cell death, its activation results in apoptosis but in its absence necroptosis 
can occur. Along the same lines, caspase 14 is only expressed in differentiating keratinocytes and 
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offers protection of underlying layers of the skin. Other caspase-regulated processes include tissue 
differentiation and regeneration, cell proliferation, autophagy inhibition, synaptic plasticity, 
metabolism and aging. Some of these functions involve induction of apoptosis, although some others 
are independent (Creagh 2014, Shalini et al. 2014). 
In healthy cells, caspases are present as zymogens with little or no protease activity. Initiator caspases 
are present as monomers and are activated by dimerization through the pro-domains. Effector 
caspases exist as pre-formed dimers and are activated by the cleavage of the linker between the two 
subunits. Following activation, additional proteolytic events may occur to generate more mature and 
stable forms of the caspases (Fig. I.5) (Taylor et al. 2008, Pop and Salvesen 2009). 
 
Figure I.5. Activation mechanisms of initiator and effector caspases. Taken from Pop and Salvesen 2009. 
 
1.2.2. THE IAP FAMILY 
The inhibitors of apoptosis (IAP) proteins negatively regulate caspases. IAPs comprise a family of 
proteins that shares the baculovirus IAP repeat (BIR) domain, a zinc-binding fold of ~70 amino acids 
that promotes protein-protein interactions. Some IAPs also have a carboxy-terminal RING domain, 
which provides them with E3 ubiquitin protein ligase activity (Fulda and Vucic 2012). In addition to 
apoptosis, the IAP family is also involved in cell signaling of NF-κB pathways, proliferation, mitosis 
and protein tagging for proteasome degradation (Gyrd-Hansen and Meier 2010). 
The main members of this family are XIAP, hIAP1, hIAP2 and Survivin. XIAP is the only member 
that serves as a specific inhibitor of caspases 3, 7 and 9. hIAP1 and hIAP2 bind to second 
mitochondria-derived activator of caspases (SMAC)/direct IAP-binding protein with low PI 
(DIABLO) and OMI/high temperature requirement protein A2 (HtrA2). These IAP antagonists are 
constitutively expressed but sequestered to mitochondria. During apoptosis, they are released to the 
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cytosol where they bind to the BIR domain of IAPs and block their interaction with caspases, 
ultimately allowing caspase activation (Gyrd-Hansen and Meier 2010, Fulda and Vucic 2012). 
 
1.3. APOPTOTIC SIGNALING PATHWAYS 
In mammals, the stimuli that trigger the apoptotic process can activate different initiator caspases 
through distinct signaling pathways, namely the extrinsic and the intrinsic apoptotic pathways. Both 
converge in the activation of the executor caspases, and there might be crosstalk between the two 
signaling pathways in some contexts (Fig. I.6). 
1.3.1. EXTRINSIC APOPTOTIC PATHWAY 
The extrinsic apoptotic pathway is initiated by the binding of extracellular ligands to cell surface death 
receptors (DRs). DRs belong to tumor necrosis factor (TNF) receptor (TNFR) superfamily which 
comprises more than 20 proteins involved in various cellular functions such as regulation of cell 
death, survival and immunity. To date, six DRs have been identified: TNFR1 (TNFRSF1A), Fas (also 
known as CD95, APO-1 or TNFRSF6), DR3 (TNFRSF12), DR4 (also known as TRAILR1 or 
TNFRSF10A), DR5 (also known as TRAILR2 or TNFRSF10B) and DR6 (TNFRSF21). DRs 
specifically interact with death ligands, comprising TNF, FasL, and TRAIL to sense and transmit 
extracellular stress signals resulting in downstream caspase activation and apoptosis (Gonzalvez and 
Ashkenazi 2010). These transmembrane receptors are diverse in primary structure, but all of them 
contain cysteine-rich extracellular subdomains that enable to recognize their ligands with specificity. 
DRs also share a unique cytoplasmic domain called death domain (DD), which mediates protein-
protein interactions. The adaptor proteins, such as Fas-associated death domain (FADD) or TNFR-
associated death domain protein (TRADD), also contain a DD so that they can interact with DRs to 
propagate the apoptotic signal (Fig. I.6). Importantly, death ligands can also interact with the decoy 
receptors, which do not possess cytoplasmic DD and thus cannot activate the apoptotic pathway 
(Mahmood and Shukla 2010). 
On ligand binding, the DRs recruit the adaptor proteins, which in turn recruit and aggregate several 
molecules of pro-caspase 8, forming the Death-Inducing Signaling Complex (DISC). In this 
activating platform, the molecules of pro-caspase 8 are in close proximity, allowing its autoprocessing 
and activation. Active caspase 8 then proteolytically processes and activates the executor caspases 3 
and 7, promoting further caspase-mediated events that culminate in apoptosis (Taylor et al. 2008, 
Czabotar et al. 2014). In type I cells, the activation of caspase 8 may be sufficient to execute cell 
death. Type II cells require further mitochondria-based signal amplification by enabling the crosstalk 
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with the intrinsic apoptotic machinery. This amplification loop involves the caspase 8-mediated 
cleavage of a pro-apoptotic protein of the B-cell lymphoma-2 (BCL-2) family, called BH3-interacting 
domain death agonist (BID). Its truncated form (tBID) contributes to the release of mitochondrial 
factors that will activate effector caspases (Tait and Green 2010). 
 
Figure I.6. Extrinsic and intrinsic apoptotic pathways. The extrinsic pathway is initiated with death receptors 
activation and the subsequent recruitment of the adaptor proteins FADD and/or TRADD, leading to caspase 8 
activation. In type I cells, caspase 8 directly triggers apoptosis by activating effector caspases. In type II cells, further 
signal amplification through mitochondria is required. The intrinsic or mitochondrial pathway is activated upon 
different stresses, which result in the permeabilization of the mitochondrial outer membrane, the release of 
cytochrome c to the cytosol and the activation of the effector caspases. Adapted from Czabotar et al. 2014. 
 
1.3.2. INTRINSIC APOPTOTIC PATHWAY 
The main pathway for caspase activation in vertebrates is the intrinsic pathway, in which 
mitochondria play a central role (Green and Kroemer 2004). It is initiated in response to various 
external or internal stress stimuli, such as DNA damage, ER stress, reactive oxygen species (ROS) 
production, exposure to cytotoxic drugs or radiation, among others. These insults eventually trigger 
an intracellular cascade of events that result in the mitochondrial outer membrane permeabilization 
(MOMP), which is required for most apoptotic stimuli to induce caspase activation (Youle and 
Strasser 2008, Tait and Green 2010, Czabotar et al. 2014). MOMP allows the subsequent release of 
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several apoptogenic factors from the mitochondrial intermembrane space into the cytosol, including 
cytochrome c, SMAC/DIABLO, OMI/HtrA2, apoptosis-inducing factor and endonuclease G (Table 
I.1) (Tait and Green 2010). 
 
IMS FACTORS ROLE IN APOPTOSIS 
Cytochrome c Apoptosome activation 
SMAC/DIABLO XIAP antagonist 
OMI/HtrA2 XIAP antagonist 
Apoptosis-inducing factor Chromatin condensation and DNA fragmentation. Contributes to CICD 
Endonuclease G DNA fragmentation. Contributes to CICD 
 
Table I.1. Intermembrane space (IMS) proteins released upon mitochondrial outer membrane 
permeabilization and their role in apoptosis. Some of these factors contribute to caspase-independent cell death 
(CICD) (Adapted from Tait and Green 2010). 
 
Besides being a key component of electron transport during oxidative phosphorylation, cytochrome c 
is necessary for the activation of caspases following MOMP. In the cytosol, cytochrome c binds the 
apoptotic protease-activating factor-1 (APAF-1) and activates it in an ATP-dependent manner, 
inducing APAF-1 conformational changes and oligomerization into a heptameric, wheel-like 
structure, the apoptosome. This complex recruits pro-caspase 9 and facilitates its dimerization and 
further activation, which in turn activates the effector caspases (Youle and Strasser 2008, Tait and 
Green 2010). Given the crucial role of the apoptosome in mediating cell death, a number of proteins 
and small molecules have been reported to regulate its function, including XIAP, Hsp70 or AKT 
(Tait and Green 2010, Bratton and Salvesen 2010). To counteract this inhibition, SMAC/DIABLO 
and OMI/HtrA2 are released from the mitochondria to inhibit XIAP. This allow the activation of the 
effector caspases, which finally proteolyze regulatory and structural cellular substrates to induce the 
apoptotic phenotype (Youle and Strasser 2008, Tait and Green 2010). 
After MOMP, cell death can also be engaged even in the absence of caspase activity, a process termed 
caspase-independent cell death (CICD). Its morphologic, biochemical and kinetical features are 
different to the apoptotic ones and may vary between cell types. MOMP allows the release of 
intermembrane space factors which might actively trigger cell death independently of caspases. In 
addition, the mitochondrial function is gradually impaired, including a loss of the respiratory chain 
function and a drop in the membrane potential and the ATP synthesis. Ultimately, this leads to 
bioenergetics crisis and cell death (Pradelli et al. 2010b, Tait et al. 2014). 
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1.4. BCL-2 FAMILY MEMBERS 
Mitochondrial integrity and the intrinsic apoptotic pathway are controlled by the evolutionarily 
conserved BCL-2 family of proteins, which can be classified into three groups based on structural and 
functional homologies (Fig. I.7) (Czabotar et al. 2014, Moldoveanu et al. 2014). 
 
Figure I.7. Schematic representation of the structure of BCL-2 family proteins. BH, BCL-2 homology domain; 
TM, transmembrane domain. Adapted from Czabotar et al. 2014. 
 
Anti-apoptotic proteins (BCL-2-like) 
This subfamily includes BCL-2 related gene A1 (A1/BFL-1), BCL-2, BCL-2-related gene-long 
isoform (BCL-XL), BCL-W, myeloid cell leukemia-1 (MCL-1) and BCL-B. All members share four 
BCL-2 homology (BH) domains (BH1-4). Most of them also contain a transmembrane (TM) domain 
for anchoring to organelles, mainly to mitochondria, but are also found in the ER and the cytosol. 
The domains BH1, BH2 and BH3 are folded to form a hydrophobic surface groove that allows 
interaction with other pro-apoptotic members. The BCL-2-like proteins are critical for cell survival as 
they preserve the integrity of the outer mitochondrial membrane (OMM) through inhibiting other 
pro-apoptotic members of the family. When overexpressed in transgenic mice, all the anti-apoptotic 
proteins of the BCL-2 family confer resistance to a wide range of apoptotic stimuli (Czabotar et al. 
2014, Moldoveanu et al. 2014). Some of these proteins are required for the survival of certain cell 
types; for instance, BCL-2 and MCL-1 are necessary to extend the life of mature B and T 
lymphocytes (Strasser 2005). 
Pro-apoptotic multi-domain proteins (BAX-like) 
This subfamily includes BCL-2-associated X protein (BAX) and BCL-2-antagonist/killer-1 (BAK). 
Originally, they were reported to contain BH1, 2 and 3, but recently the BH4 domain has also been 
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identified (Kvansakul et al. 2008, Czabotar et al. 2014, Moldoveanu et al. 2014). In healthy cells, BAX 
and BAK exist as monomers. Upon a pro-apoptotic stimulus, these proteins get activated and 
oligomerize at the OMM to enable MOMP and the subsequent release of apoptogenic factors. In 
stark contrast to the previous group, overexpression of BAX-like proteins induces apoptosis. Mice 
lacking Bax and Bak have serious abnormalities caused by defects in developmentally programmed 
cell death. BCL-2-related ovarian killer (BOK) shares similar structure to BAX and BAK and is 
known to have a pro-apoptotic function. Nevertheless, mice lacking BOK are largely normal, so the 
exact role of this BAX-like protein in apoptosis remains to be fully elucidated (Czabotar et al. 2014, 
Moldoveanu et al. 2014). 
Pro-apoptotic proteins with only the BH3 domain (BH3-only) 
This subfamily comprises BCL-2 antagonist of cell death (BAD), BCL-2-like-11 (BIM), BCL-2 
interacting killer (BIK), BID, harakiri (HRK, aslo known as DP5), BCL-2-modifying factor (BMF), 
NOXA and p53-upregulated modulator of apoptosis (PUMA). As indicated by their name, the BH3-
only proteins share a single region with other BCL-2 family members, the BH3 domain, which is 
essential for their pro-apoptotic activity. Through the BH3 domain, these pro-apoptotic proteins 
interact with other BCL-2 family members creating a complex regulatory network to control cell 
survival and death in response to different stresses.  
 
Several other proteins have been reported to contain a BH3-only domain within their structures and 
possess pro-apoptotic activity and/or the ability to interact with anti-apoptotic BCL-2 family 
proteins. These include BNIP3/NIX, BNIP3L or MOAP-1, the autophagy effector Beclin 1, or the 
E3 ligase MULE/ARF-BP1, among others (Lomonosova and Chinnadurai 2008). 
Alternative splicing of BCL-2 family members may completely change their function. Some examples 
of anti-apoptotic proteins whose splicing variants are pro-apoptotic include BCL-XS or MCL-1S 
(Boise et al. 1993, Bae et al. 2000). On the contrary, alternative splicing of the BH3-only BIDEL or 
BIDL generates BIDS, which lacks the BH3 domain and thus plays an anti-apoptotic role (Renshaw et 
al. 2004). Many studies have achieved the knockout or overexpression mouse model of the BCL-2 
family members, allowing the study of their physiological role, redundancy and interactions in vivo and 
their contribution to tumor progression and resistance to therapy (Czabotar et al. 2014). In addition, 
various non-apoptotic roles have been suggested for the BCL-2 family members. MCL-1 has different 
roles depending on its localization. In the OMM, it exerts an anti-apoptotic function, while a 
truncated form of MCL-1 in the mitochondrial matrix facilitates normal mitochondrial function. On 
the other hand, BCL-2 translocates to the ER and sequesters Beclin-1, thereby inhibiting autophagy. 
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When a BH3-only protein binds to BCL-2, it releases Beclin-1 and allows the induction of autophagy 
(Czabotar et al. 2014, Renault and Chipuk 2014). 
 
1.4.1. INTERACTIONS BETWEEN BCL-2 FAMILY MEMBERS 
The apoptotic threshold is set by the interactions between the BCL-2 family members. The BH3 
amphypatic helix of the BH3-only proteins binds to the hydrophobic groove of the pro-survival 
proteins. Due to subtle differences in these interacting surfaces, BH3-only proteins bind pro-survival 
BCL-2 proteins with different affinities. Specifically, BIM, PUMA and tBID can bind to all pro-
survival proteins; while other BH3-only are selective for subsets of their pro-survival relatives (Fig. 
I.8) (Czabotar et al. 2014, Moldoveanu et al. 2014). 
 
Figure I.8. The functional interaction network between pro- and anti-apoptotic BCL-2 family members. 
Adapted from Moldoveanu et al. 2014. 
 
Three models addressing the interactions between BCL-2 family members have been proposed (Fig. 
I.9). In the direct activation model, certain BH3-only proteins termed activators (namely BIM, tBID 
and PUMA) bind to and directly activate the effectors BAX and BAK. Pro-survival BCL-2-like 
proteins bind to and inhibit the activator proteins. The other BH3-only proteins (BIK, BMF, HRK, 
BAD and NOXA) are called sensitizers. They lack the activator function, and the pro-apoptotic 
effects are exerted by neutralizing pro-survival BCL-2-like proteins, thereby releasing the bound BH3-
only activators to allow BAX/BAK activation (Fig. I.9A). In contrast, the indirect model considers 
that pro-survival BCL-2-like proteins inhibit the effectors BAX and BAK. The BH3-only proteins 
bind to and neutralize the pro-survival proteins, allowing the release and subsequent activation of 
BAX and BAK (Fig. I.9B). Nowadays, the current consensus accepts that both models can occur 
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depending on the context. This unified model considers that pro-survival BCL-2-like proteins can 
neutralize both BH3-only and effector proteins (Fig. I.9C). 
 
 
Figure I.9. Models of interaction among BCL-2 family members that control the apoptotic outcome. (A) 
The direct activation model. BH3-only sensitizers, such as BAD, bind to pro-survival proteins, like BCL-2, to release 
BH3-only activators (e.g. BIM) and allow the activation of the effectors (BAX and BAK). (B) The indirect activation 
model. BH3-only proteins, such as BAD and BIM, neutralize pro-survival BCL-2 proteins and allow the activation of 
the effectors. (C) The unified model combines the direct and the indirect models. BH3-only proteins interact with 
pro-survival BCL-2 proteins to release the BH3-only activators (mode 1) or activated BAX/BAK (mode 2). Taken 
from Czabotar et al. 2014. 
 
1.4.2. ACTIVATION OF BH3-ONLY PROTEINS BY VARIOUS STIMULI 
As the BCL-2 family members mediate the induction of the mitochondrial apoptotic pathway, their 
expression and function are tightly regulated by transcriptional and post-transcriptional mechanisms, 
including modulations of gene expression, protein stability and conformational changes (Adams and 
Cory 2007, Kelly and Strasser 2011). 
The multiplicity of BH3-only proteins allows a precise control over the induction of apoptosis. In this 
sense, although they can have partially redundant physiological functions, each BH3-only member 
responds to specific insults. Among these insults, there are both physiological stimuli, such as 
deprivation of cytokines, signaling receptors or loss of adhesion to the matrix cells (a type of cell 
death called anoikis); as well as signals induced by activated oncogenes, DNA damage, 
chemotherapeutic agents, UV or γ radiation (Fig. I.10).  
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Figure I.10. Activation of BH3-only proteins by various stimuli. Adapted from Kelly and Strasser 2011. 
 
1.4.3. PORE FORMATION DURING APOPTOSIS 
In healthy cells, BAK is already inserted in the OMM, whereas BAX is mainly cytosolic. BAX 
constantly migrates from the cytosol to the OMM, but it accumulates at the OMM during apoptosis. 
BH3-only activators trigger the exposure of the BH3 domain of both BAX and BAK, fostering the 
dimerization. Through an unknown mechanism, dimers join to form oligomers of unknown size that 
permeabilize the membrane (Czabotar et al. 2014, Westphal et al. 2014). The nature of the pore that 
BAX and BAK form to promote MOMP is still under debate. Initially, it was thought that the two 
pro-apoptotic proteins could enhance the permeability of existing proteinaceous or lipidic pores, such 
as VDAC or ceramide channels. In contrast, BAX and BAK could be also forming a pore without 
requiring other proteins. More recent findings suggest that BAX, BAK and mitochondrial lipids 
cooperate to engage MOMP (Fig. I.11) (Renault and Chipuk 2014).  
 
Figure I.11. Models of BAX and BAK pore formation during apoptosis. Taken from Renault and Chipuk 2014. 
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1.5. APOPTOSIS IN CANCER 
Tissue homeostasis is the maintenance of normal tissue morphology and function, which relies on the 
accurate regulation of cell proliferation, stem cell activity, differentiation, quiescence and cell death. 
The balance among these processes is the result of the integration of a variety of intracellular and 
extracellular signals. In some cases, such balance is altered with abnormal accumulation of cells, 
which can lead to cancer (Hanahan and Weinberg 2011). 
Throughout the sequential evolution towards becoming malignant, cells acquire several common 
capabilities to circumvent the principle barriers that prevent uncontrolled cell expansion. These 
attributes are the so-called hallmarks of cancer, which include sustained proliferative signaling, 
evasion of growth suppressors, resistance to cell death, replicative immortality and activation of 
angiogenesis, invasion and metastasis. Underlying these hallmarks are genome instability, which 
causes the genetic diversity that accelerates their acquisition; and inflammation, which promotes 
multiple hallmark functions. Advances in understanding cancer biology identified two emerging 
hallmarks of potential generality, namely reprogramming of energy metabolism and evading immune 
destruction. In addition, the acquisition of hallmark traits is fostered by the tumor microenvironment, 
a repertoire of recruited, apparently normal cells surrounding the tumor (Fig. I.12) (Hanahan and 
Weinberg 2011). 
 
Figure I.12. The hallmarks of cancer. Eight hallmark capabilities and two enabling characteristics. Adapted from 
Hanahan and Weinberg 2011. 
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Apoptosis plays an important role in tumor growth, tumor progression and resistance to therapy. 
Hence, genes that suppress or induce physiological cell death are often deregulated in cancer 
(Hanahan and Weinberg 2011). Defects in the mechanisms of apoptosis induction allow tumor cells 
to survive beyond their physiological life, to avoid the need of extracellular factors for survival and to 
resist hypoxia and cell stress caused within the tumor. In addition, resistance to apoptosis gives room 
for the accumulation of genetic alterations that can contribute to deregulation of cell cycle, alteration 
of the tissue differentiation pattern, stimulation of angiogenesis, or increase in cell mobility and 
invasiveness (Reed 2003, Labi and Erlacher 2015). 
Mechanisms of apoptosis induction are complex and involve numerous signaling pathways. 
Consequently, cancer cells may acquire resistance to cell death through various strategies. On the one 
hand, cancer cells may evade apoptosis through transcriptional, translational and post-translational 
modifications of the BCL-2 family proteins. In some cases, cancer cells may increase the expression 
of anti-apoptotic genes and/or decrease the pro-apoptotic genes. Alternatively, resistance to 
apoptosis may be acquired through stabilizing or destabilizing anti- or pro-apoptotic proteins, 
respectively. In addition, post-translational modifications of apoptotic proteins may change their 
function, resulting in defective apoptosis (Fernald and Kurokawa 2013, Czabotar et al. 2014). 
Another mechanism to overcome apoptosis is the inactivation of p53 pathway, which was found 
mutated in half of human cancers, demonstrating its importance in cancer development (Vousden 
and Lane 2007). However, many pharmacological interventions used in cancer therapy relied, at least 
partially, on p53 pathway activation to induce apoptosis, which finally results in chemoresistance. 
Other alterations involved in resisting apoptosis include loss of DNA damage or hypoxia sensors, or 
alterations in survival pathways, including mitogen-activated protein kinases (MAPK), 
phosphatidylinositol-3-kinase (PI3K)/AKT, protein kinase C (PKC) or nuclear factor of kappa light 
polypeptide gene enhancer in B-cells (NF-κB) routes (Adams and Cory 2007). 
 
1.5.1. THE ROLE OF APOPTOSIS IN CANCER THERAPY 
Nowadays, the combination of surgery, radiation and chemotherapy is used to restore the normal 
signaling pathways to induce cell cycle arrest and/or apoptosis. Many current chemotherapeutic 
agents are inductors of apoptosis. Indeed, activation of the mitochondrial apoptotic pathway seems to 
be required for the therapeutic efficacy of most conventional chemotherapeutic agents (Czabotar et 
al. 2014). Depending on the nature of such apoptotic stimuli and the cellular context, distinct 
signaling pathways employ specific BH3-only proteins to induce apoptosis. A wide range of anti-
cancer agents, including DNA damaging compounds, proteasome inhibitors or glucocorticoids, may 
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trigger mRNA or protein expression changes of several BCL-2 family members and, in particular of 
BH3-only proteins, to induce apoptosis (Fig. I.13) (Labi et al. 2006, Walensky 2006, Czabotar et al. 
2014) 
 
Figure I.13. Anti-cancer agents and their known ability to engage BH3-only proteins. Solid arrows indicate a 
strong activation, dashed arrows indicate weak activation. Adapted from Labi et al. 2006, Walensky 2006. 
 
Unfortunately, although these drugs and therapeutic methods should have the potential to eliminate 
cancer cells, few strategies for cancer treatment are truly effective (Hanahan and Weinberg 2011, 
Czabotar et al. 2014). Therefore, it has become crucial to develop new therapeutic strategies based on 
the design and study of specific anti-cancer molecules able to overrule the apoptotic machinery that 
render cells resistant to apoptosis. 
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2. CHRONIC LYMPHOCYTIC LEUKEMIA 
2.1. CLL BIOLOGY AND DIAGNOSIS 
Chronic lymphocytic leukemia (CLL) represents the most common adult leukemia in the western 
world, mainly affecting elderly individuals. It is a malignant lymphoproliferative disorder of 
monoclonal B lymphocytes that accumulate in the blood, bone marrow, lymph nodes and other 
lymphoid tissues (Zenz et al. 2010). As a result of this abnormal expansion, CLL cells can account for 
up to 99% of circulating peripheral blood mononuclear cells (Chen and McMillan 2008). CLL cells 
are morphologically mature but functionally immature, showing a deficient production of antibodies, 
which favors the appearance of infectious and autoimmune diseases (Chiorazzi et al. 2005, Zenz et al. 
2010). 
CLL can be functionally considered as a dual disease. On the one hand, it involves a quiescent 
circulating population present in peripheral blood. These CLL cells are arrested in G0/G1 phase of 
the cell cycle and they can survive for a few months. Therefore, lack of proper apoptotic signaling 
pathways was considered the main cause for B cell accumulation. However, it is now widely 
recognized that quiescent CLL cells present in the periphery have undergone several rounds of 
proliferation compared to their normal counterparts, as shown by shortened telomeres (Chiorazzi 
2007, Hayden et al. 2012). Indeed, survival of CLL cells depends on interactions with the 
microenvironment, consisting of T cells, macrophages, and stromal cells, which induce the activation 
of survival and proliferative signaling pathways. These interactions can occur in proliferating centers 
within the solid tissues, including bone marrow and the lymph nodes (Zenz et al. 2010, Hayden et al. 
2012). 
CLL can be diagnosed if the lymphocyte counts in the blood are higher than 5x109/L, with a 
characteristic immunological profile defined by the expression of CD5, CD19, CD20 and CD23 
along with low expression of CD10, IgM, IgD and cyclin D1. CLL is characterized by an extremely 
heterogeneous clinical course, ranging from indolent forms with very slow evolution to aggressive 
forms with short course. Therefore, the use of prognosis factors is especially important to adopt the 
most appropriate decision in the patient management and also to predict the disease evolution and 
the response to treatment. The current criteria are based on clinical stage (Binet and Rai 
classification), serum markers (for example, thymidine kinase, β2-microglobulin and soluble CD23), 
cell marker expression (CD38 and zeta-associated protein 70) and various genetic parameters (Zenz et 
al. 2010, Hallek 2015). In fact, two subsets of CLL cases have been identified according to the status 
of somatic hypermutations in the immunoglobulin heavy chain variable region (IGHV) genes, clearly 
presenting different prognostication and treatment. Specifically, CLL cells with unmutated IGHVs 
can activate key signaling pathways upon B-cell receptor (BCR) activation and are genetically more 
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unstable, which may explain the poorer overall survival of the patients. On the contrary, IGHV-
mutated CLL cells weakly activate BCR signaling and are relatively anergic, which can explain the 
better overall survival of this subset of CLL patients (Zenz et al. 2010). 
 
2.2. GENETIC ABERRATIONS AND GENE MUTATIONS IN CLL 
Deletion (del) of 13q14 is the structural aberration most frequently found in CLL, occurring in ~55% 
of all cases. The presence of only this abnormality often implies a benign course of the disease. Two 
microRNAs, miR-15a and 16-1, were identified in the critical region of del(13q14). In addition, 
trisomy 12 is one of the most frequent aberration (10–20% of patients with CLL), though the genes 
involved in the pathogenesis of CLL are unknown (Zenz et al. 2010, Hallek 2015) and its prognostic 
importance remains controversial (Seiffert et al. 2012). 
Although they are rarely found in early-stage disease, patients with advanced or chemotherapy-
resistant disease frequently show deletions in 11q, which harbors the gene ATM; and in 17p13, which 
harbors the gene TP53 (Zenz et al. 2010, Hallek 2015). Interestingly, the recently reported whole 
genome sequencing project in CLL has revealed various recurrent somatic gene mutations, which 
include the genes TP53, ATM, among others (Puente et al. 2011, Quesada et al. 2012). It is 
noteworthy that p53 and ATM are key proteins in DNA damage signaling and DNA repair (Jackson 
and Bartek 2009). The fact that different genetic alterations, i.e. deletions and mutations, in these two 
genes appear more frequently in patients with secondary resistance to DNA-damaging chemotherapy 
(Puente et al. 2011, Quesada et al. 2012) highlights the critical role of these two proteins in mediating 
apoptosis in response to DNA damage in CLL cells. 
 
2.3. TREATMENT OF CLL 
Most patients are asymptomatic at diagnosis of CLL, and treatment starts upon progression to the 
symptomatic disease. Historically, CLL was treated with chemotherapy including an alkylating agent 
and a purine analogue. The addition of a monoclonal antibody against CD20 to the classical 
chemotherapy improved the survival of CLL patients. This triple combination, known as 
chemoimmunotherapy, has become the currently recommended front-line treatment for CLL 
patients. Specifically, the purine analogue fludarabine, the alkylating agent cyclophosphamide and the 
anti-CD20 monoclonal antibody ritixumab (FCR) appear to be the most preferred treatment of 
choice in young, fit patients with good renal function. Other regimens are more applicable in elder 
and/or frailer patients who are unlikely to tolerate it (Nabhan and Rosen 2014, Hallek 2015). 
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Recently, the Food and Drug Administration has approved the use of ibrutinib, idelalisib and 
obinutuzumab, three new agents for the treatment of CLL. Ibrutinib and idelalisib inhibit Bruton 
tyrosine kinase (BTK) and PI3Kδ, respectively. These kinases are involved in the BCR signaling, 
which is crucial for the survival of CLL cells. In addition, a new monoclonal anti-CD20, 
obinutuzumab, has proved efficacy in patients that cannot properly tolerate more aggressive 
chemoimmunotherapies (Sanford et al. 2015). Another promising new therapeutic agent is ABT-199, 
a BH3-mimetic that inhibits BCL-2 protein (Souers et al. 2013). Treatment with ABT-199 results in a 
high rate of durable remission in patients with relapsed or refractory CLL, as well as in patients with 
impaired p53 pathway (Hallek 2015).  
TYPES OF TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA 
Alkylating agents Chlorambucil 
 Cyclophosphamide 
 Bendamustine 
  
Purine analogues Fludarabine 
 Pentostatin 
 Cladribine 
  
Monoclonal antibodies (anti-CD20) Rituximab 
 Alemtuzumab 
 Obinutuzumab 
  
B-cell receptor pathway inhibitors Ibrutinib (targets BTK) 
 Idelalisib (targets PI3Kδ) 
Table I.2. Drugs used in CLL therapy. Adapted from Nabhan and Rosen 2014. 
 
Although the overall survival of CLL patients has increased with the first-line therapy, the side-effects 
and the chemoresistance limit their efficacy, and eventually all patients relapse (Zenz et al. 2010). 
Therefore, it is necessary to identify new agents with selective toxicity for malignant B cells and to 
develop therapeutic strategies that overcome cellular resistance mechanisms to cytotoxic agents, 
which are often caused by inactive p53 pathway, in order to obtain sustained remission rates in 
patients with adverse prognostic factors. 
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3. NEW STRATEGIES FOR CANCER TREATMENT 
3.1. THE PURINE NUCLEOSIDE AICAR 
3.1.1. AICAR AS AN AMP-ACTIVATED PROTEIN KINASE ACTIVATOR 
AICAR (5-aminoimidazole-4-carboxamide riboside, acadesine or Acadra®, represented in figure I.14) 
is a cell-permeable purine nucleoside for which three pharmacological applications were identified 
about 20 years ago: i) stimulation of the cardiac production of adenosine under ischemic conditions; 
ii) inhibition of hepatic gluconeogenesis, with therapeutic potential in diabetes; and iii) activation of 
the AMP-activated protein kinase (AMPK), initially applied to inhibit the hepatic synthesis of 
triglycerides and cholesterol (Van Den Neste et al. 2010). 
 
Figure I.14. Structure of AICAR, 5-aminoimidazole-4-carboxamide riboside, acadesine or Acadra®. Taken 
from Van Den Neste et al. 2010. 
 
AMPK is a well-conserved eukaryotic serine/threonine protein kinase that acts as sensor of energy 
status. It is expressed in essentially all eukaryotic cells as heterotrimeric complexes, containing the 
catalytic α subunit and the regulatory β and γ subunits. AMPK plays a key role during metabolic 
stress, when AMP:ATP and ADP:ATP ratios increase. AMPK is activated allosterically by AMP or 
through increased phosphorylation in Thr172 of the catalytic α subunit by upstream kinases, namely 
LKB1 and Ca2+/calmodulin-activated protein kinase kinases β (CAMKKβ) (Hardie et al. 2012). In 
addition, recent work suggests non-canonical activation of AMPK induced by oxidative stress or 
genotoxic treatments. The main function of AMPK is to restore cellular energy homeostasis by 
switching on catabolic pathways and switching off ATP-consuming processes. Furthermore, AMPK 
is also crucial in the regulation of whole body energy balance, especially by mediating effects of 
hormones on the hypothalamus to promote feeding and circadian rhythms of metabolism and 
feeding behavior (Hardie et al. 2012). 
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3.1.2. AICAR AS A THERAPEUTIC AGENT FOR SEVERAL HEMATOLOGICAL 
MALIGNANCIES 
Our group described that AICAR induces apoptosis in various cell types, including CLL, mantle cell 
lymphoma (MCL), and splenic marginal zone B-cell lymphoma (SMZL) cells, without affecting 
primary T lymphocytes (Campàs et al. 2003, 2005). 
AICAR enters into the cells through nitrobenzylthioinosine (NBTI)-sensitive transporters, which 
mainly includes equilibrative nucleosides transporter 1 (ENT1). Then, AICAR is further 
phosphorylated to ZMP (also known as AICA-ribotide) by adenosine kinase. Both steps are required 
for AICAR-induced apoptosis in CLL cells (Campàs et al. 2003, Santidrián et al. 2010). ZMP has 
been described to activate AMPK by allosteric stimulation due to its structural analogy with AMP and 
by promoting its phosphorylation by upstream kinases (Corton et al. 1995, Suter et al. 2006). 
Accordingly, AICAR triggers the phosphorylation of AMPK at Thr172 in CLL, MCL and SMZL 
cells, correlating with induction of apoptosis (Campàs et al. 2003, Campàs 2004). Strikingly, AICAR 
was proved to induce cell death independently of AMPK. First, AICAR enters follicular lymphoma 
(FL) cells and induces phosphorylation of AMPK, but most FL samples tested are resistant to 
AICAR-induced apoptosis (Campàs et al. 2005). In Jurkat cells, AICAR induces apoptosis without 
inducing the phosphorylation of AMPK neither requiring ZMP accumulation (López et al. 2003). In 
CLL cells, direct activation of AMPK does not induce apoptosis, and mouse B lymphocytes lacking 
Ampkα are sensitive to the pro-apoptotic effects of AICAR (Santidrián et al. 2010). In chronic 
myelogenous leukemia (CML) cells, AICAR triggered autophagic cell death in a PKC-dependent but 
AMPK-independent manner (Robert et al. 2009). 
Following AICAR treatment, apoptosis is induced through the intrinsic pathway, involving 
cytochrome c release and the activation of caspases 3 and 9. Importantly, the caspase inhibitor 
benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD.fmk) blocks AICAR-induced apoptosis 
(Campàs et al. 2003, Santidrián et al. 2010). Inhibitors of protein kinase A (PKA) or MAPKs, 
including inhibitors of p38, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase 
(JNK), are unable to block AICAR-induced apoptosis in CLL cells (Campàs et al. 2003). 
Fludarabine and other nucleoside analogues are highly effective in the treatment of CLL but they 
induce apoptosis of T cells (Bellosillo et al. 1999) leading to immunosuppression (Keating 1993). 
Hence, the higher sensitivity of B cells opens a therapeutic window for AICAR as a treatment for 
CLL. T cells from CLL patients are only slightly affected by AICAR at high doses. Intracellular levels 
of ZMP are higher in B cells than in T cells from CLL patients upon treatment with 0.5 mM AICAR 
(Campàs et al. 2003), which can explain the different sensitivity of the cells. 
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Defects in p53 are rare in newly diagnosed CLL patients, though its frequency increases among 
patients with advanced and chemotherapy-resistant disease (Shindiapina et al. 2014). Drugs that 
induce apoptosis in a p53-dependent manner induce the phosphorylation and subsequent 
accumulation of p53. Importantly, AICAR does not result in accumulation nor phosphorylation of 
p53 (Campàs et al. 2003) and induces apoptosis irrespective of TP53 or ATM mutational status in 
CLL cells (Santidrián et al. 2010). Accordingly, AICAR efficiently triggered apoptosis in mouse 
lymphocytes lacking p53 (González-Gironès 2012). This is a significant difference compared to other 
nucleoside analogues, such as fludarabine, that require p53 activation for apoptosis induction (Byrd et 
al. 2004). 
AICAR mechanism of apoptosis induction has been further characterized in CLL cells. Treatment 
with AICAR induces a ZMP-dependent increase in the mRNA levels of the BH3-only members BIM, 
BNIP3, BNIP3L, HRK, MOAP1, NOXA and PUMA, but not all genes are modified concomitantly 
in the same CLL sample (Santidrián et al. 2010, González-Gironès 2012). Interestingly, BIM and 
NOXA were reported to play a crucial role in AICAR-induced apoptosis. Mouse B lymphocytes and 
MEFs lacking Bim and Noxa were resistant to the pro-apoptotic effects of AICAR (Santidrián et al. 
2010, González-Gironès 2012). 
A multicenter phase I/II study of AICAR was performed in CLL patients, with a favourable efficacy 
and safety profile. Patients showed reduced number of CLL cells and lymphadenopathy (Van Den 
Neste et al. 2013). Although the results were variable because of the small population, AICAR 
emerged as a promising agent for the treatment of relapsed or refractory CLL patients. Interestingly, 
the pro-apoptotic effects of AICAR increased in combination with the most common 
chemotherapeutic agents for CLL treatment. Specifically, AICAR showed synergistic effects with the 
glucocorticoid dexamethasone, and additive effects with fludarabine, chlorambucil and mafosfamide 
in CLL cells (González-Gironès 2012). In MCL cells, AICAR showed synergistic effects in 
combination with rituximab both in vitro and in vivo, although it did not occur in CLL cells 
(Montraveta et al. 2014). 
The detailed description of the mechanism of induction of apoptosis gives room for the identification 
of targets that can establish novel strategies for cancer treatment. Therefore, one of the main goals of 
this thesis has been the characterization of AICAR-induced apoptosis. 
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3.2. THE NEW PROHIBITIN-BINDING COMPOUND FLUORIZOLINE 
Resistance to cell death is one of the hallmarks of cancer development and it compromises the 
efficacy of conventional anti-cancer agents (Hanahan and Weinberg 2011). Hence, there is need for 
the development of novel apoptosis-inducing compounds as potential therapies for cancer. With this 
aim, our group established a collaboration with Dr. Lavilla and Dr. Albericio (Barcelona Science Park 
- UB) to synthetize a library of new, potent, safe and selective apoptosis-inducing compounds. 
Specifically, two families of new chemical entities were prepared, based on fluorinated thiazole or 
fluorinated indole scaffolds. Their anti-cancer activity was assessed in various cancer cell lines as well 
as in primary CLL cells. Interestingly, the structure-activity relationship analysis permitted the rational 
optimization of those chemical structures with better biological activities to further improve their 
potency as pro-apoptotic compounds. Among all the compounds tested, the diaryl trifluorothiazoline 
PG10 or compound 1a, hereafter referred to as fluorizoline (Fig. I.15), was selected as the best 
apoptosis inductor (González-Gironès 2012, Pérez-Perarnau 2013, Pérez-Perarnau et al. 2014). 
 
Figure I.15. Chemical structure of compound 1a or fluorizoline, showing the trifluorinated thiazoline 
scaffold and the chiral carbon (*). 
 
Most biological molecules are optically active and present several enantiomers. Often only one of the 
enantiomers is responsible for the desired biological effects, while the other enantiomer is less active, 
inactive, or sometimes even responsible for adverse effects. Consequently, drugs composed of only 
one enantiomer (enantiopure) can be developed to enhance the biological efficacy (Smith 2009). 
Fluorinated thiazoles are prepared as racemic mixtures containing two enantiomers. The separation of 
the two enantiomers was achieved for compound 1b or PG0, proving that only one enantiomer is 
responsible for the pro-apoptotic activity (Pérez-Perarnau et al. 2014). Unfortunately, the racemic 
mixture separation of fluorizoline has not been performed. 
Fluorizoline induces apoptosis in a wide range of cancer cell lines, including prostate, breast, uterus, 
brain, pancreas, lung, and liver. Importantly, these cell lines have different p53 status, thus proving 
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that fluorizoline exerts its anti-tumor action in a p53-independent manner (Pérez-Perarnau et al. 
2014). This differentiates fluorizoline from other drugs currently used in cancer therapy, whose 
mechanism of action is mediated by p53, a tumor suppressor gene frequently mutated or deleted in 
many cancer types (Vousden and Lane 2007, Polager and Ginsberg 2009). In addition, treatment with 
fluorizoline resulted in mitochondrial fragmentation, cristae remodeling and cytochrome c release. Of 
note, apoptosis-related gene expression profile revealed that NOXA was consistently upregulated in 
various cancer cell lines. Its importance in fluorizoline mechanism of action was further proved by 
downregulating NOXA in HeLa cells, which conferred resistance to fluorizoline treatment (Pérez-
Perarnau 2013). Finally, our group collaborated with Dr. Handa (Tokyo Institute of Technology, 
Japan) to perform a high-performance affinity purification with magnetic nanobeads. This assay 
allowed the identification of the proteins that were directly binding to fluorizoline: prohibitin 1 and 2 
(PHBs) (Pérez-Perarnau et al. 2014). 
 
3.2.1. THE PROHIBITIN FAMILY 
PHB1 and PHB2 (also known as B-cell-receptor-associated protein 37 - BAP-37, or repressor of 
estrogen receptor activity - REA) are evolutionary conserved and ubiquitously expressed proteins that 
belong to the stomatin-prohibitin-flotilin-HflC/K (SPFH) superfamily, which share a domain of 
~160 amino acid residues known as SPFH or PHB domain. SPFH proteins tend to oligomerize and 
form large multimeric complexes localized in lipid rafts microdomains of different cellular 
membranes (Browman et al. 2007). Indeed, PHBs form a macromolecular structure of ~1.2 MDa at 
the inner mitochondrial membrane (IMM). PHB1 and 2 interact with each other to form a ring-like 
structure of 20-25nm, which is thought to contain about 12 to 16 PHB1 and PHB2 heterodimers. It 
has been proposed that the PHB mitochondrial complex anchores to the membrane through the N-
terminal domain, while the C-terminal coiled-coil domain facilitates oligomerization into the large 
complexes (Fig. I.16) (Merkwirth and Langer 2009). 
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Figure I.16. Schematic representation of PHB domain structures and dimer assembling into ring-like 
structures. (A) Domain structures of mammalian PHBs. Numbers refer to the respective amino acid residues in 
murine PHBs. (B) Dimers of PHB1 and PHB2 as building blocks of PHB complexes. Approximately 12-16 
heterodimers are thought to assemble into ring-like PHB complexes with alternating subunit composition. The 
average stoichiometry of the complex is speculative. (C) Suggested model of membrane-bound prohibitin complex. 
The PHB complex is anchored to the mitochondrial inner membrane (IM) via N-terminal hydrophobic stretches. 
PHB and coiled-coil domains are exposed to the intermembrane space (IMS). Modified from Merkwirth and Langer 
2009. 
 
PHBs ring-like structure and the sequence similarity to lipid-raft associated proteins of the SPFH 
family suggest a protein and lipid scaffold function for PHBs in the inner mitochondrial membrane 
(Osman et al. 2009b). In this sense, PHBs may contribute to the spatial organization of the IMM as 
protein scaffolds, by recruiting proteins to specific sites (Fig. I.17A), or by creating protein-free lipid 
areas (Fig. I.17B). As lipid scaffolds, PHBs may create lipid-enriched microdomains (Fig. I.17C). This 
compartmentalization of the membrane composition may serve as a mechanism for separating 
cellular functions within the cellular membranes (Browman et al. 2007, Osman et al. 2009b). 
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Figure I.17. Speculative models for PHBs as lipid and protein scaffolds. (A) PHBs complexes as protein 
scaffolds. (B) Fence-like function of PHBs complexes. (C) PHBs complexes as lipid scaffolds. 
Phoshpatidylethanolamine (PEA), cardiolipin (CL). Modified from Osman et al. 2009b. 
 
PHBs are interdependent at the protein level, thus depletion of one PHB leads to the loss of the 
other PHB without affecting its expression (Merkwirth and Langer 2009, Artal-Sanz and Tavernarakis 
2009, Osman et al. 2009b). Severe phenotypes are linked to the loss of PHBs in multicellular 
organisms. PHBs are essential for the development of higher eukaryotes, as their loss leads to 
embryonic lethality in Caenorhabditis elegans and mice (Artal-Sanz et al. 2003, Park et al. 2005, He et al. 
2008). At the cellular level, reduction in PHBs levels results in impaired proliferation (Kasashima et al. 
2006, Schleicher et al. 2008, Merkwirth et al. 2008, Sievers et al. 2010, Jiang et al. 2015), and increased 
sensitivity towards apoptotic stimuli (Merkwirth et al. 2008, Gregory-Bass et al. 2008, Patel et al. 
2010, Zhou et al. 2013a, Chowdhury et al. 2013). In this line, overexpression of PHBs confers 
resistance to pro-apoptotic stimuli (Fusaro et al. 2002, Zhou et al. 2013a, 2013b, Thuaud et al. 2013, 
Chowdhury et al. 2013, Han et al. 2014, Wang et al. 2014). 
Mitochondria are dynamic organelles that continuously change their shape, from spherical to 
elongated, as a consequence of fusion and fission (Kasahara and Scorrano 2014). The lack of PHBs 
has severe consequences for the reticular mitochondrial network and results in the accumulation of 
fragmented mitochondria with an altered ultrastructure of the cristae (Kasashima et al. 2006, 
Merkwirth et al. 2008). 
These morphological alterations observed in the absence of PHBs were attributed to the increased 
processing of optic atrophy 1 (OPA1), a dynamin-related GTPase in the IMM that that mediates 
mitochondrial fusion and maintains the cristae structure (Olichon et al. 2003, Arnoult et al. 2005, 
Merkwirth et al. 2008). There are up to eight variants of OPA1 generated by alternative splicing, 
being variants 1 and 7 the most dominantly expressed ones. Proteolytic cleavage results in 5 different 
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forms: a and b (long, L-OPA1), and c, d and e (short, S-OPA1) (Ishihara et al. 2006). OPA1 functions 
as a hetero-oligomeric complex of the large and the small forms (Ishihara et al. 2006, Frezza et al. 
2006) and ensures the correct closing of the cristae junctions, creating the intracristae space where 
most of the cytochrome c resides (Scorrano et al. 2002, Frezza et al. 2006). During apoptosis, OPA1 
complexes are disassembled (Frezza et al. 2006, Yamaguchi et al. 2008, Landes et al. 2010, Jiang et al. 
2014), allowing the reorganization of the mitochondrial cristae and facilitating cytochrome c release 
from the intracristae space to the intermembrane space (Fig. I.18) (Scorrano et al. 2002, Yamaguchi et 
al. 2008). Hence, the marked processing of OPA1 links the increased sensitivity to pro-apoptotic 
stimuli that was also observed in the absence of PHBs (Merkwirth et al. 2008).  
 
Figure I.18. OPA1 maintains cristae junctions and prevents cytochrome c release. OPA1 plays a critical role in 
maintaining the mitochondrial cristae structure. During apoptosis, OPA1 complexes are disassembled, cristae 
junctions widen and cytochrome c diffuses to the intermembrane space. MOMP allows cytochrome c release to the 
cytosol to trigger downstream events that will result in apoptosis. Adapted from Gottlieb, 2006 and further modified 
in Pérez-Perarnau 2013.  
 
All these findings point towards a key role for PHBs in the maintenance of the functional integrity of 
mitochondria, which ultimately allows proper cell and tissue homeostasis (Artal-Sanz and 
Tavernarakis 2009, Osman et al. 2009b, Merkwirth et al. 2012, Supale et al. 2013, Ising et al. 2015). 
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3.2.2. THE ROLE OF PROHIBITINS IN PHOSPHOLIPID HOMEOSTASIS 
In the inner mitochondrial membrane, PHBs were proposed to act as lipid scaffolds, which would be 
crucial for the homeostasis of mitochondrial glycerophospholipids (GPLs) (Osman et al. 2009b, 
Richter-Dennerlein et al. 2014). GPLs are the most abundant lipids, present in almost all mammalian 
membranes (Hermansson et al. 2011). GPLs consist of a hydrophilic head connected to a glycerol 
with two fatty acids (hydrophobic tails). There are different GPL classes, including 
phosphatidylcholine (PC), phosphatidylethanolamine (PEA), phosphatidylinositol (PIN), 
phosphatidylserine (PS), phosphatidylglycerol (PG) and cardiolipin (CL), which differ in the structure 
of their head group. Each class in turn contains diverse molecular species, which have the same head 
group but fatty acid acyl chains with different length and number of double bonds, and their synthesis 
is highly interconnected (Hermansson et al. 2011) (Fig. I.19). 
 
Figure I.19. Pathways of glycerophospholipid biosynthesis in mammalian cells. Phosphatidic acid (PA), 
diacylglycerol (DAG), phosphatidylethanolamine (PEA), phosphatidylcholine (PC), phosphatidylserine (PS), cytidine 
diphosphate (CDP)-DAG, phosphatidylinositol (PIN), phosphatidylglycerol phosphate (PGP), phosphatidylglycerol 
(PG), and cardiolipin (CL). Adapted from Hermansson et al. 2011. 
 
Due to the wide range of different alkyl chain combinations, each GPL class consists of many 
structurally different molecular species. The meaning of such diversity remains to be fully elucidated, 
but it may relate to the multiple functions of GPLs, such as signal transduction, vesicle trafficking and 
membrane fluidity (Hermansson et al. 2011, Hishikawa et al. 2014). 
New strategies for cancer treatment 
38 
The presence of PHBs is especially crucial for CL and PEA homeostasis (Osman et al. 2009a, 
Richter-Dennerlein et al. 2014). It was recently reported that mitochondria from PHBs-
downregulated HEK293 cells have impaired CL and PEA content (Richter-Dennerlein et al. 2014). 
Of note, CL has been linked to the execution of apoptosis. CL was suggested to act as a platform 
crucial for caspase 8 activation, as well as a docking site for tBID and BAX at the mitochondria. In 
addition, a portion of cytochrome c is bound to CL in the IMM. Consistently, decreased in CL levels 
or increased oxidation of the unsaturated CL acyl chains led to a reduction of the amount of 
membrane-bound cytochrome c, which facilitates its release to the cytosol (Schug and Gottlieb 2009, 
Raemy and Martinou 2014). 
 
3.2.3. PROHIBITINS AND CANCER  
The role of PHBs in cancer has been extensively debated, as evidences of both pro- and anti-
tumorigenic roles of PHBs have been described (Theiss and Sitaraman 2011, Thuaud et al. 2013). 
Low levels of PHBs were associated with enhanced tumor growth in prostate and gastric cancer, 
glioma and hepatocellular carcinoma (Liu et al. 2009, Ko et al. 2010, Fletcher et al. 2012, Dart et al. 
2012, Qian et al. 2013). In some cancer cells, PHB1 localizes in the nucleus and regulates the activity 
of various transcription factors. Specifically, PHB1 interacts with p53 to increase its activity in breast 
and prostate cell lines (Fusaro et al. 2003, Chander et al. 2010). It was also reported that PHB1 
represses the activity of E2F transcription factors by recruiting the Retinoblastoma protein and 
chromatin-remodeling molecules, leading to cell cycle arrest (Wang et al. 1999a, 1999b, 2002, Fusaro 
et al. 2002). In addition, PHBs reduce tumor growth by inhibiting the activity of androgen and 
estrogen receptors (Gamble et al. 2007, He et al. 2008, Kim et al. 2009, Dart et al. 2012). 
On the contrary, there is a growing body of evidences supporting a pro-tumorigenic role of PHBs in 
cancer growth and development. Of note, PHB1 localizes in lipid rafts in the plasma membrane and 
allows the activation of c-Raf by Ras to finally activate the MEK-ERK signaling pathway (Rajalingam 
et al. 2005), which requires the phosphorylation of PHB1 by AKT (Chiu et al. 2013). The ERK 
pathway plays a key role in promoting the survival, proliferation and metastasis of a high percentage 
of human tumors (Balmanno and Cook 2009, Samatar and Poulikakos 2014). Furthermore, high 
levels of PHB1 were increased in various tumor cells, likely due to the presence of a c-Myc regulatory 
element in the PHB promoter (Mishra et al. 2005, Theiss and Sitaraman 2011). PHBs mediate cell 
proliferation and anchorage-independent growth in several cancer cell lines (Sievers et al. 2010), 
strongly suggesting a potential role of PHBs in cancer progression. In chemoresistant ovarian cancer 
cells, PHB1 expression correlated with drug-resistance, and downregulation of PHBs increased the 
Introduction 
39 
sensitivity towards apoptotic stimuli in ovarian cancer cell lines (Gregory-Bass et al. 2008, Patel et al. 
2010). PHBs were reported to play a pro-survival role, not only against apoptosis but also towards 
other insults, such as oxidative stress or inflammatory responses (Theiss and Sitaraman 2011, Thuaud 
et al. 2013). This cytoprotective function provides support for a pro-tumorigenic role of PHBs. 
 
3.2.4. PROHIBITINS AS POTENTIAL THERAPEUTIC TARGETS FOR CANCER 
TREATMENT 
There are several drugs with anti-cancer effects that involve PHBs (reviwed in Thuaud et al. 2013). 
First, it was described that capsaicin, an active component of chili peppers, binds to PHB2 to induce 
cytochrome c release from mitochondria (Kuramori et al. 2009). Second, the marine depsipeptide 
aurilide, obtained from the sea hare Dolabella auricularia, was shown to selectively bind to PHB1 in 
mitochondria, leading to rapid mitochondrial fragmentation and the induction of apoptosis (Sato et 
al. 2011). Third, Rocaglamide-A (Roc-A), a member of the flavaglines class of compounds, binds to 
both PHB1 and PHB2 at the cell membrane to inhibit Raf activation and Raf-MEK-ERK-mediated 
cell cycle progression and cell proliferation in tumor cell lines, without inducing mitochondrial 
fragmentation (Polier et al. 2012). Interestingly, Roc-A and other related flavaglines have pro-
apoptotic activities both in vitro and in vivo in various cancer cells, yet it remains unknown whether 
PHBs are involved in their mechanism of apoptosis induction (Ribeiro et al. 2012, Thuaud et al. 
2013). Next, it was recently shown that the natural compound xanthohumol blocks the estradiol-
induced growth of breast cancer cells by disrupting BIG3-PHB2 interaction, thus allowing PHB2 to 
repress estrogen receptor transcriptional activity (Yoshimaru et al. 2014). The complexity of the 
synthesis or availability of these compounds may hinder their use in therapeutics. In contrast, 
fluorizoline synthesis is practical, versatile, short and reproducible, being amenable to gram-scale 
batches (Pérez-Perarnau et al. 2014). 
All in all, the implication of PHBs in cell proliferation and cancer, together with the evidence that its 
function can be modulated, strongly suggest that targeting PHBs would be a useful therapeutic 
approach for treatment of various diseases, including cancer. Consequently, the PHBs-binding 
compound fluorizoline emerged as a very interesting pro-apoptotic agent and we were encouraged to 
further study its mechanism of action. 
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The main objective of the doctoral thesis has been the analysis of new pro-apoptotic compounds that 
trigger the apoptotic signaling pathway independently of p53 in cancer cells. We aimed to further 
dissect the mechanism of apoptosis induction in order to provide novel targets that would facilitate 
the development of therapeutic strategies for cancer treatment and drug discovery. 
 
The main objective has been divided into the following specific points: 
1. Study of the pro-apoptotic effects of AICAR. 
a. Characterization of AICAR-induced apoptosis in mouse embryonic fibroblasts. 
b. Analysis of putative mechanisms of apoptosis induction by AICAR in chronic 
lymphocytic leukemia cells. 
 
2. Characterization of fluorizoline-induced apoptosis. 
a. Study of the requirement of prohibitins for the pro-apoptotic effects of fluorizoline. 
b. Analysis of the apoptotic pathway triggered by fluorizoline treatment. 
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1. Study of the pro-apoptotic effects of AICAR
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1.1. AICAR INDUCES APOPTOSIS IN A ZMP-DEPENDENT BUT AMPK-
INDEPENDENT MANNER IN MOUSE EMBRYONIC FIBROBLASTS 
One of the main objectives of this thesis has been the characterization of the mechanism of apoptosis 
induction by AICAR, a nucleoside analogue that induces apoptosis in chronic lymphocytic leukemia 
(CLL) cells. These primary cells are difficult to transfect, and thus it was necessary to find an 
alternative model to further study AICAR mechanism of action. Dr. González Gironès started to 
work with mouse embryonic fibroblasts (MEFs), being a useful model due to the possibility of 
obtaining knockout cell lines. First, it was necessary to validate MEFs as a suitable model for the 
study of AICAR-induced apoptosis. In other words, AICAR mechanism of action should be similar 
in both models. In CLL cells, AICAR is taken up into the cells through nitrobenzylthioinosine 
(NBTI)-sensitive transporters, and is further phosphorylated to ZMP by adenosine kinase. Both steps 
are required for AICAR-induced apoptosis and modulation of the apoptosis-related gene expression 
profile in CLL cells (Campàs et al. 2003, Santidrián et al. 2010).  
In MEFs, AICAR entrance to the cell was necessary to induce apoptosis (González-Gironès 2012). 
Together with Dr. González Gironès, we studied whether AICAR phosphorylation to ZMP was 
required for AICAR pro-apoptotic effects in MEFs, as observed in CLL cells. To this end, WT MEFs 
were pre-incubated with the adenosine kinase inhibitor 5-iodotubercidin and then treated with 1 mM 
AICAR for 48 hours. AICAR-induced apoptosis was completely blocked by 5-iodotubercidin, 
indicating that ZMP formation is necessary for AICAR cytotoxic effects in MEFs (Fig. 1.1A). We 
then analyzed AICAR-mediated changes in the mRNA expression profile of apoptosis-related genes 
in MEFs by retrotranscriptase multiplex ligation-dependent probe amplification (RT-MLPA). 
Incubation of WT MEFs with 1 mM AICAR for 24 h increased Noxa and Apaf mRNA levels, and 
decreased Bcl-2 and Survivin mRNA levels, correlating with the apoptotic outcome. We also observed 
significant downregulation of Moap1, Bok and Htra2 mRNA levels, as well as an increase in Hiap1 
mRNA levels (Fig. 1.1B). Interestingly, all these changes were ZMP-dependent as they were 
suppressed with 5-iodotubercidin pretreatment. 
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Figure 1.1. AICAR-induced apoptosis and modulations of apoptosis-related genes require phosphorylation 
to ZMP. WT MEFs were untreated (CT) or pretreated with 0.2 μM 5-iodotubercidin (I) for 30 min and then 
incubated with 1 mM AICAR for 24 h and 48h. (A) Viability was measured after 48h of treatment with 1mM 
AICAR by flow cytometry and it is expressed as the percentage of non-apoptotic cells (annexin V-/PI-negative). (B) 
mRNA levels of apoptosis-related genes were analyzed by RT-MLPA upon 24 h of treatment with 1 mM AICAR. 
Data are shown as mean ± SEM (n=3, including data obtained by Dr. González Gironès). *p < 0.05, **p < 0.01. 
 
AICAR has been widely used as an AMPK activator, as ZMP mimics AMP activating effects on 
AMPK (Corton et al. 1995, Suter et al. 2006). Nevertheless, there are many reports showing AMPK-
independent effects of AICAR (Martelli et al. 2012). In this line, direct activation of AMPK in CLL 
cells did not induce apoptosis, and mouse lymphocytes lacking Ampkα underwent apoptosis 
following AICAR treatment (Santidrián et al. 2010). Accordingly, Dr. González Gironès had 
previously shown that AICAR could effectively induce apoptosis in MEFs lacking the two catalytic 
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subunits of AMPK, α1 and α2 (Ampkα DKO MEFs). In fact, Ampkα DKO MEFs were more 
sensitive than WT MEFs, suggesting a pro-survival role of AMPK in MEFs (González-Gironès 
2012). Thus, we sought to analyze whether AICAR-induced modulations in apoptosis-related gene 
expression profile in MEFs were mediated by AMPKα. Ampkα DKO MEFs and their corresponding 
WT MEFs were treated with 2 mM AICAR for 24 h and cell viability was assessed as a control of 
AICAR treatment. In agreement with previous results, WT MEFs did not undergo apoptosis upon 
treatment with AICAR at 24 h. In contrast, lack of AMPKα sensitized cells to AICAR treatment, 
proving that AICAR does not require AMPKα for apoptosis induction (Fig. 1.2A). Next, we analyzed 
the relative expression of apoptosis-related genes by RT-MLPA. AICAR induced the upregulation of 
Noxa, Hiap1 and Apaf as well as the downregulation of Bcl-2 mRNA levels in both WT and Ampkα 
DKO MEFs (Fig. 1.2B). These results demonstrate that AICAR induces mRNA modulations of 
these apoptosis-related genes in an AMPK-independent manner. 
 
Figure 1.2. AICAR induces apoptosis and changes in the apoptosis-related gene expression profile in an 
AMPK-independent manner. WT and Ampkα1-/-/Ampkα2-/- (DKO) MEFs were untreated (CT) or treated with 2 
mM AICAR for 24 h. (A) Viability was measured by flow cytometry and it is expressed as the percentage of non-
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apoptotic cells (annexin V-/PI-negative). (B) Cells were lysed and then mRNA levels of apoptosis-related genes 
were analyzed by RT-MLPA as described in ‘‘Patients, materials and methods’’. Data are shown as mean ± SEM (in 
A, n=5; in B, n=3 including data obtained by Dr. González Gironès). *p < 0.05, **p < 0.01. 
 
To further prove that AICAR was inducing apoptosis independently of AMPK, we assessed whether 
direct activation AMPK could trigger apoptosis in MEFs. AICAR triggered efficient apoptosis, while 
the direct AMPK activator A-769662 failed to induce apoptosis in WT MEFs (Fig. 1.3A). In contrast, 
both AICAR and A-769662 induced phosphorylation of AMPKα and its substrate acetyl-CoA 
carboxylase (ACC), which indicates activation of AMPK (Fig. 1.3B). These results show that AICAR-
mediated apoptosis does not require AMPK activation. 
 
Figure 1.3. Direct activation of AMPK does not induce apoptosis in WT MEFs. (A) WT MEFs were untreated 
(CT) or treated with either 2 mM AICAR (A) or 50 μM of the direct AMPK activator A-769662 for 48 h. Viability 
was measured by flow cytometry and it is expressed as the mean ± SEM (n=3) of the percentage of non-apoptotic 
cells (annexin V-/PI-negative). ** p < 0.01, ***p < 0.001. (B) WT MEFs were untreated (CT) or treated with either 
2 mM AICAR (A2) or 50 or 100 µM A-769662 for 24 hours. Protein levels of phospho-acetyl-CoA carboxylase at 
Serine 79 (P-ACC), phospho-AMPKα at Threonine 172 (P-AMPKα), and total AMPKα were analyzed by western 
blot. ERK2 was used to standardize protein levels. 
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1.2. STUDY OF THE BCL-2 FAMILY MEMBERS INVOLVED IN AICAR-INDUCED 
APOPTOSIS IN MEFs 
Our group reported that BIM, NOXA and PUMA are involved in AICAR-induced apoptosis in CLL 
cells (Santidrián et al. 2010). However, RT-MLPA analysis of AICAR treatment in MEFs showed no 
significant changes on Bim and Puma expression levels (Fig. 1.1B). We further characterized the 
modulation of these genes upon different times of AICAR treatment by real time quantitative PCR 
(RT-qPCR). As a control, we included Noxa and Bcl-2, which are significantly modulated upon 
AICAR treatment. MEFs were incubated for 3, 6, 9, 12 and 24 h with AICAR and mRNA levels were 
analyzed. Bim mRNA levels were significantly increased from 6 h until 24 h of AICAR treatment, 
while Puma mRNA levels were only induced after 24 h of AICAR treatment. As expected, AICAR 
treatment significantly induced increases in Noxa and downregulation of Bcl-2 mRNA levels (Fig. 1.4).  
 
Figure 1.4. AICAR modulates Bim, Puma, Noxa and Bcl-2 mRNA levels in WT MEFs. WT MEFs were 
untreated or treated with 2 mM AICAR for 3, 6, 9, 12 and 24 h. Bim, Puma, Noxa and Bcl-2 mRNA levels were 
measured by RT-qPCR. The mRNA levels of all genes were normalized to those of Gapdh and referenced to the 
untreated cells of the corresponding time. Data are shown as mean ± SEM (n=3). *p < 0.05, **p < 0.01, ***p < 
0.001 AICAR-treated versus untreated MEFs. 
 
Next, we analyzed whether the modulation of these genes at the transcriptional level could lead to 
changes on the corresponding protein levels. NOXA and PUMA protein levels could not be analyzed 
due to lack of proper antibodies detecting the mouse protein in MEFs. Importantly, we detected 
significant increases of BIMEL and BIML protein levels upon 24 h of AICAR treatment (Fig. 1.5A-B). 
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AICAR did not significantly modulate BCL-2 protein levels despite the reduction on Bcl-2 mRNA 
levels, a finding consistent with the long half-life of this protein (Merino et al. 1994).  
 
Figure 1.5. AICAR induces BIM protein levels in WT MEFs. WT MEFs were untreated or treated with 2 mM 
AICAR for 6, 9, 12 and 24 h. (A) BIM and BCL-2 protein levels were analyzed by western blot. ERK2 was used to 
standardize protein levels. This is a representative image of three independent experiments that were performed. (B) 
Protein levels were quantified by densitometry using ImageJ software, normalized to ERK2 protein levels and 
referenced to untreated cells of the corresponding time. Data are shown as mean ± SEM (n=3). *p < 0.05 AICAR-
treated versus untreated MEFs. 
 
In order to study the contribution of PUMA in AICAR-induced cell death, we assessed the effect of 
AICAR treatment in MEFs lacking this BH3-only protein. The loss of Puma not only failed to protect 
MEFs from AICAR-induced apoptosis, but slightly sensitized them (Fig. 1.6).  
 
Figure 1.6. Loss of Puma does not confer resistance to AICAR-induced apoptosis. WT and Puma-/- MEFs 
were untreated or treated with 0.5, 1, 2 and 4 mM AICAR for 24 and 48 h. Viability was measured by flow cytometry 
and it is expressed as the mean ± SEM (n=4) of the percentage of non-apoptotic cells (annexin V-/PI-negative).  
*p < 0.05. 
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Interestingly, results from our group showed that Bim-/-/Noxa-/- MEFs were highly resistant to 
AICAR treatment compared to the corresponding WT MEFs (González-Gironès 2012). All together, 
these data demonstrate that both BIM and NOXA, but not PUMA, are key players in AICAR-
induced apoptosis in MEFs. 
 
1.3. ROLE OF p53 IN AICAR-INDUCED APOPTOSIS IN MEFs 
p53 was proposed to mediate the anti-proliferative effects of AICAR (Jones et al. 2005, Tang et al. 
2011). In order to analyze its role in MEFs, we decided to use p53-/- MEFs and compare their 
response to WT MEFs. In these experiments, we treated MEFs with a wider range of doses of 
AICAR than we usually did. Strikingly, we observed that 0.15 and 0.25 mM AICAR were inducing 
high rates of apoptosis in WT MEFs, while 0.5 mM AICAR triggered apoptosis to a lesser extent. 
From 0.5 mM AICAR and on, apoptosis was induced in a dose-dependent manner. Of note, the 
induction of apoptosis upon treatment with low doses of AICAR seemed to be p53 dependent, as 
p53-/- MEFs were undergoing apoptosis just with doses higher than 0.5 mM AICAR. In contrast, 
higher doses of AICAR were able to induce apoptosis in a p53-independent manner, because WT and 
p53-/- MEFs underwent apoptosis alike (Fig. 1.7). 
 
Figure 1.7. Role of p53 in AICAR-induced apoptosis. WT and p53-/- MEFs were untreated or treated with 
increasing doses of AICAR for 24 and 48 h. Viability was measured by flow cytometry and it is expressed as the 
mean ± SEM (n=4) of the percentage of non-apoptotic cells (annexin V-/PI-negative). **p < 0.01, ***p < 0.001. 
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In view of such peculiar results, we sought to analyze how other WT MEFs would respond to low 
doses of AICAR in order to discard clone specific behaviors. We used four different WT MEFs that 
we had in the laboratory: 
A) WT MEFs from Dr. Korsmeyer’s laboratory, provided by Dr. Jacint Boix (Universitat de Lleida). 
B) WT MEFs from Dr. Korsmeyer’s laboratory, provided by Dr. Cristina Muñoz (IDIBELL). 
C) WT MEFs from Dr. Villunger (Medical University Innsbruck). 
D) WT MEFs from Dr. Benoit Viollet’s laboratory, provided by Dr. Aramburu (Universitat Pompeu 
Fabra). 
Interestingly, the latter cell line (D) had been immortalized with the C-terminal domain of p53, which 
inactivates the pathway. Thus, we expected that WT D MEFs would respond as p53-/- MEFs. The 
different MEFs were untreated or treated with increasing doses of AICAR and viability was assessed 
by flow cytometry. Although A, B and C WT MEFs presented different sensitivity to AICAR 
treatment, the three cell lines displayed the same profile of apoptosis induction: low doses of AICAR 
had higher pro-apoptotic capacity than 0.5 mM AICAR, and higher doses were again capable of 
inducing apoptosis. As expected, WT D MEFs and p53-/- MEFs underwent apoptosis only after 
treatment with high doses of AICAR (Fig. 1.8). All together, these results show that low doses of 
AICAR trigger apoptosis in a p53-dependent manner, though higher doses are able to trigger 
apoptosis independently of p53. 
 
Figure 1.8. Low doses of AICAR induce p53-dependent apoptosis in MEFs. Different WT MEFs (A: WT 
MEFs from Dr. Korsmeyer’s laboratory, provided by Dr. Jacint Boix; B: WT MEFs from Dr. Korsmeyer’s 
laboratory, provided by Dr. Cristina Muñoz; C: WT MEFs from Dr. Villunger; D: WT MEFs from Dr. Viollet’s 
laboratory, provided by Dr. Aramburu), and p53-/- MEFs were untreated or treated with increasing doses of AICAR 
(mM) for 24 and 48 h. Viability was measured by flow cytometry and it is expressed as the percentage of non-
apoptotic cells (annexin V-/PI-negative). Data are shown as mean ± SEM (n=2 for WT A, B, C and p53-/- MEFs; 
n=1 for WT D MEFs). 
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1.4. PYRIMIDINE STARVATION AS A PUTATIVE MECHANISM OF ACTION OF 
AICAR 
In 2013, a manuscript was published proposing a new model for AICAR mechanism of action in 
multiple myeloma (MM) cells (Bardeleben et al. 2013). AICAR triggered ZMP-dependent but AMPK-
independent apoptosis in different MM cell lines. A metabolomics screen revealed that AICAR led to 
increased purine metabolism and decreased pyrimidine metabolism. Specifically, two intermediates in 
de novo pyrimidine synthesis showed altered levels: orotate was increased while UMP was decreased, 
suggesting an inhibition of the UMP synthase (UMPS) enzyme (see steps 5 and 6 in Fig. 1.9). AICAR-
induced apoptosis was blocked by addition of uridine and cytidine, and thymidine partially did it. The 
authors proposed that AICAR reduces phosphoribosyl-pyrophosphate (PRPP) levels, one of the 
substrates of UMPS, resulting in a pyrimidine starvation that finally induces apoptosis in MM cells. 
 
Figure 1.9. Pathways of pyrimidine metabolism. De novo pyrimidine synthesis: 1, carbamoylphosphate synthetase 
II; 2, ATCase; 3, dihydroorotase (1, 2 and 3 comprise CAD); 4, dihydroorotate dehydrogenase; 5, orotate 
phosphoribosyl-transferase; 6, OMP decarboxylase (5 and 6 comprise UMP synthase); 7, ribonucleotide diphosphate 
reductase; 8, thymidilate synthase. Pyrimidine salvage: 9, thymidine kinase 1; 10, uridine/cytidine kinase. Pyrimidine 
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catabolism: 11, cytidine deaminase. Carbamoyl-P, carbamoyl-phosphate; Carbamoyl-Asp, carbamoyl-aspartate; 
PRPP, phosphoribosyl-pyrophosphate; OMP, orotidine monophosphate; UMP, uridine monophosphate; TMP, 
thymidine monophosphate; CMP, cytidine monophosphate. Based on Balasubramaniam et al. 2014. 
 
In view of such interesting results, we decided to assess whether addition of pyrimidines could rescue 
AICAR-induced apoptosis in CLL cells. To this end, CLL cells were co-treated with AICAR and 
uridine or cytidine for 48 hours and viability was assessed by flow cytometry. Low doses of uridine 
and cytidine (in the range used in the MM manuscript) could not abolish AICAR pro-apoptotic 
effects. Interestingly, if uridine concentration was increased 100 times, AICAR-induced apoptosis was 
effectively inhibited (Fig. 1.10). 
 
Figure 1.10. Low doses of uridine or cytidine do not block AICAR-induced apoptosis. CLL cells were 
untreated or treated with 0.25 mM or 0.5 mM AICAR, in the presence or absence of increasing doses of uridine (U) 
(A) and cytidine (C) (B) for 48 hours. Viability was measured by flow cytometry and it is expressed as the percentage 
of non-apoptotic cells. Data are shown as mean ± SEM (0.25 mM AICAR, n=2; 0.5 mM AICAR, n=3). *p < 0.05 
AICAR-treated versus AICAR and uridine-treated cells. 
 
These results suggested that the used doses were too low and thus not enough to block AICAR-
induced apoptosis. Therefore, we assessed the viability of CLL cells treated with AICAR in the 
absence or presence of high doses of uridine and cytidine. In addition, we included a wide range of 
doses of thymidine, because it was shown that this pyrimidine can partially inhibit AICAR-induced 
apoptosis in MM cells (Bardeleben et al. 2013). Interestingly, uridine and thymidine inhibited AICAR-
induced apoptosis in a dose-dependent manner in CLL cells (Fig. 1.11A, C, D). In contrast, high 
doses of cytidine were inducing apoptosis by themselves, even enhancing AICAR-induced apoptosis 
in some conditions (Fig. 1.11B). 
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Figure 1.11. High doses of uridine or thymidine, but not cytidine, block AICAR-induced apoptosis. CLL 
cells were untreated or treated with 0.25 mM or 0.5 mM AICAR, in the presence or absence of increasing doses of 
uridine (U) (A) or cytidine (C) (B) for 48 hours; or thymidine (T) for 24 (C) and 48 hours (D). Viability was 
measured by flow cytometry and it is expressed as the percentage of non-apoptotic cells (annexin V-/PI-negative). 
Data are shown as mean ± SEM (for uridine, 0.25 mM AICAR, n≥5; 0.5 mM AICAR, n≥3. For cytidine, 0.25 mM 
AICAR, n=4; 0.5 mM AICAR, n=2. For thymidine, n=2). *p < 0.05, **p < 0.01, ***p < 0.001 AICAR-treated versus 
AICAR and pyrimidine-treated cells. 
 
These data show many differences in the inhibition of AICAR-induced apoptosis mediated by 
addition of pyrimidines in CLL cells compared to MM cells. Apart from the used doses, cytidine was 
able to block AICAR-induced apoptosis in MM cells (Bardeleben et al. 2013) but not in CLL cells. In 
addition, thymidine could only partially abolish AICAR-induced apoptosis in MM cells (Bardeleben et 
al. 2013) but efficiently blocked it in CLL cells. It is conceivable that AICAR mechanism of action is 
different in these two cell types. Nonetheless, as we were using experimental methods that differed 
from the ones used in the aforementioned report, we decided to use the MM cell line RPMI 8226, 
one of the cell lines that were studied by Bardeleben and collegues, as a control for our experiments. 
They measured active caspase 3 by flow cytometry and observed around 40% of caspase 3 positive 
cells after 48 hours of treatment with 0.25 mM AICAR in RPMI 8226 cells (Bardeleben et al. 2013). 
Strikingly, in our hands RPMI 8226 cells were much more resistant to AICAR as measured by 
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phoshpatidylserine (PS) exposure (Fig. 1.12). Treatment with 0.25 mM AICAR reduced the mean 
viability from 93% to 80%. 
 
Figure 1.12. Dose-response of AICAR in RPMI 8226 cells. RPMI 8226 cells were treated with different doses of 
AICAR for 48 hours. Viability was measured by flow cytometry and it is expressed as the mean ± SEM (n=3) of the 
percentage of non-apoptotic cells (annexin V-/PI-negative). *p < 0.05, **p < 0.01, ***p < 0.001 treated versus 
untreated cells. 
 
We next analyzed the rescue of AICAR-induced apoptosis by pyrimidine addition in RPMI 8226 cells. 
Incubation with different doses of uridine could block the small reduction in viability induced by 
treatment with 0.25 mM AICAR (Fig. 1.13A), in agreement with the results previously reported 
(Bardeleben et al. 2013). Nevertheless, uridine could not revert the effects of higher doses of AICAR, 
in which higher rates of apoptosis were observed. In fact, uridine increased the pro-apoptotic effects 
of treatment with 2 mM AICAR, which were absent in the treatment with uridine alone. Of note, the 
doses of uridine that were used in these experiments were much higher than the ones reported in the 
paper (0.5 to 5 versus 0.05 and 0.1 mM). Thus, the incapacity to inhibit apoptosis cannot be attributed 
to a limited amount of uridine.  
In the MM cells report, low doses of cytidine could prevent AICAR-induced apoptosis, yet higher 
doses increased AICAR-induced apoptosis despite not being cytotoxic on their own. In our hands, 
none of the used doses of cytidine were capable of inhibiting AICAR-induced apoptosis. In fact, 
addition of cytidine enhanced the pro-apoptotic effects observed after treatment with 2 mM AICAR 
despite not being cytotoxic on their own (Fig. 1.13B). 
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Figure 1.13. Viability assay after treatment with AICAR and uridine or cytidine in RPMI 8226 cells. RPMI 
8226 cells were treated with different concentrations of AICAR in the presence or absence of uridine (A) or cytidine 
(B) for 48 hours. Viability was measured by flow cytometry and it is expressed as the percentage of non-apoptotic 
cells (annexin V-/PI-negative). Data are shown as mean ± SEM (for uridine, 0 and 0.25 mM AICAR, n=3; 1 mM 
AICAR, n=1; 2 mM AICAR, n=2. For cytidine, 0 and 0.25 mM AICAR, n=2; 1 and 2 mM AICAR, n=1), *p < 0.05 
AICAR-treated versus AICAR and uridine-treated cells. 
 
Despite the lack of consistency between the results in RPMI 8226 obtained by Bardeleben and us, the 
fact that high doses of uridine and thymidine could block AICAR-induced apoptosis in CLL cells 
encouraged us to further study the involvement of pyrimidines. 
Nucleosides uptake into the cell is mediated by the nucleosides transporter (NT) proteins. There are 
two main NTs families: concentrative NT (CNT) and equilibrative NT (ENT). The former comprises 
hCNT1, hCNT2 and hCNT3 proteins, that exert their function in a Na+ coupled manner. The latter 
includes hENT1 and hENT2 proteins, which mediate the transport depending on the relative 
substrate concentrations across the membrane. hENT1 and hENT2 can be distinguished according 
to their sensitivity to inhibition by NBTI, being hENT1 much more sensitive than hENT2 (Pastor-
Anglada et al. 2004, Fernández-Calotti et al. 2011, Young et al. 2013, Pastor-Anglada and Pérez-
Torras 2015). AICAR is a nucleoside analogue that is taken up into cells by NBTI-sensitive 
transporters (Campàs et al. 2003). Considering that AICAR and other nucleosides share the 
transporters that mediate their entrance to the cell, it is conceivable that the addition of nucleosides 
may impair AICAR influx. Indeed, previous results from our group showed that adenosine protected 
CLL cells from AICAR-induced apoptosis by blocking AICAR entrance to the cell (Campàs et al. 
2003). To test whether uridine and thymidine were acting likewise, we assessed phosphorylation of 
ACC, an indicator of AICAR entrance, in CLL cells treated with a combination of AICAR and 
uridine or thymidine. As a control, viability was measured by flow cytometry in each experiment. 
AICAR efficiently induced apoptosis in CLL cells, which was abrogated by treatment with uridine or 
thymidine (Fig. 1.14).  
Study of the pro-apoptotic effects of AICAR 
62 
 
Figure 1.14. Uridine and thymidine block AICAR-induced apoptosis. CLL cells from 9 patients were untreated 
or treated with 0.5 mM AICAR in the absence or presence of 5 mM uridine or thymidine for 24 and 48 hours. 
Viability was measured by flow cytometry and it is expressed as the mean ± SEM (n=9) of the percentage of non-
apoptotic cells (annexin V-/PI-negative). # p < 0.05 untreated versus AICAR-treated cells. ***p < 0.001 pyrimidine-
treated versus AICAR-treated cells. 
 
Samples from 3 different CLL patients were analyzed after 2, 4, 6, 9, 16, 20 and 24 hours of treatment 
with AICAR in combination with uridine or thymidine. A complete time course could not be 
performed with all the samples due to reduced available number of cells in the CLL samples. Figure 
1.15 summarizes the different experiments that were performed and the results obtained. 
 
Figure 1.15. Summary of the western blot analyses of ACC phosphorylation performed in different samples 
of CLL patients. CLL cells were untreated or treated with 0.5 mM AICAR (A) in the absence or presence of 5 mM 
uridine (U) or thymidine (T). ACC phosphorylation was assessed by western blot at different time points.  
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Figure 1.16 shows one of the time course experiments with one sample of a CLL patient.  
 
Figure 1.16. Western blot analysis of ACC phosphorylation in a sample of a CLL patient. CLL cells were 
untreated (C) or treated with 0.5 mM AICAR (A), in the absence or presence of 5 mM uridine (U) or 5 mM 
thymidine (T) for different times. Viability was measured after 24 h of treatment by flow cytometry and it is 
expressed as the percentage of non-apoptotic cells. This is one representative patient of three that were analyzed (see 
figure 1.15 with the list of patients analyzed). 
 
The initial time point and the intensity of ACC phosphorylation varied among the analyzed CLL 
patients. Nevertheless, we observed a general tendency: AICAR induced early and strong ACC 
phosphorylation, which was weaker at longer time points. Addition of thymidine completely blocked 
AICAR-induced ACC phosphorylation in all the time points analyzed, suggesting that thymidine 
inhibits AICAR entrance to the cell. On the other hand, addition of uridine seemed to delay ACC 
phosphorylation: it was inhibited at earlier time points, but it reached the levels induced by AICAR 
alone at longer time points. It is worth mentioning that, in most of the samples analyzed, 
combination of AICAR and uridine did not reach the high intensity of ACC phosphorylation 
observed in early time points of AICAR treatment, only the reduced ones observed at longer time 
points. It is difficult to know whether uridine-mediated delay in ACC phosphorylation can account 
for the inhibition of AICAR-induced apoptosis. It would have been interesting to perform an HPLC 
analysis to measure the levels of ZMP (as an indicator of AICAR entrance to the cell), as well as 
orotate and PRPP levels (as indicators of UMPS activity). These analyses would have given much 
more information about the modulation in pyrimidine metabolism after AICAR treatment. 
We decided to give up the study of the involvement of pyrimidine starvation in AICAR-induced 
apoptosis in CLL cells as the data obtained were pointing at an inhibition of AICAR entrance to the 
cell. 
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1.5. AICAR-INDUCED PRODUCTION OF REACTIVE OXYGEN SPECIES REQUIRES 
CASPASE ACTIVATION 
AICAR is an adenosine analogue that is metabolized within purine catabolism. Increased purine 
catabolism can lead to hyperuricemia and reactive oxygen species (ROS) generation as a consequence 
of high activity of xanthine oxidase. This enzyme is involved in the final steps of purine catabolism, it 
catalyzes hypoxanthine to xanthine and further to uric acid, generating ROS (Fig. 1.17) (Pacher et al. 
2006). Previous results from our group showed that CLL cells treated with AICAR had increased 
production of ROS, i.e., superoxide anion (O2.-) as detected by dihydroethidium (DHE) staining. 
AICAR-induced ROS production and apoptosis were partially blocked by treatment with allopurinol 
and febuxostat, two inhibitors of xanthine oxidase (González-Gironès 2012). These results suggested 
that AICAR could be inducing apoptosis through ROS production owing to hyperactivation of 
xanthine oxidase. 
 
Figure 1.17. Purine catabolism pathways and xanthine oxidase inhibitors. AK, adenosine kinase; ATIC, 
AICAR transformylase IMP cyclohydrolase; XO, xanthine oxidase. Modified from Pacher et al. 2006.  
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Nevertheless, it was reported that caspase activation results in ROS formation (Ricci et al. 2004). 
Hence, we sought to assess whether AICAR-mediated production of superoxide anion was a cause or 
a consequence of apoptosis induction. To this end, two samples from CLL patients were pre-treated 
with the pan-caspase inhibitor Q-VD-OPh and then treated with AICAR for 6, 9, and 24 hours. We 
observed a reduction in the viability of the cells and an increase in the production of superoxide upon 
24 hours of AICAR treatment, which were blocked by pre-treatment with Q-VD-OPh (Fig. 1.18). 
Therefore, AICAR-induced ROS production is an event occurring downstream of caspases activation 
and thus cannot be its mechanism of apoptosis induction.  
 
Figure 1.18. AICAR-induced apoptosis and ROS production require caspases activation. Samples from two 
CLL patients were pre-incubated in the absence (CT) or presence of 20 µM Q-VD-OPh for 30 minutes and then 
untreated or treated with 0.5 mM AICAR (A) for 6, 9 and 24 hours. (A) Viability was measured by flow cytometry 
upon 24 hours of AICAR treatment and it is expressed as the mean ± SEM (n=2) of the percentage of non-
apoptotic cells (annexin V/PI-negative). *p < 0.05. (B) Superoxide production was detected at 6, 9 and 24 h by flow 
cytometry with DHE staining and it is shown as geometric mean of the fluorescence intensity (MFI) ± SEM (n=2). 
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2.1. OPA1 PROCESSING UPON FLUORIZOLINE TREATMENT 
Previous results from our group showed that fluorizoline binds directly to prohibitin (PHB) 1 and 2 
(Pérez-Perarnau et al. 2014). It was necessary to prove that PHBs were indeed mediating fluorizoline-
induced apoptosis. With this aim, our group first used an indirect strategy, based on the study of optic 
atrophy 1 (OPA1). This protein is a dynamin-related GTPase in the inner mitochondrial membrane 
(IMM) that mediates mitochondrial fusion and maintains the cristae structure (Olichon et al. 2003, 
Arnoult et al. 2005, Merkwirth et al. 2008). HeLa cells express mainly two transcripts of OPA1, 
variants 1 and 7, which are cleaved resulting in the accumulation of five OPA1 forms: two long (a and 
b, L-OPA) and three short forms (c, d and e; S-OPA) (Ishihara et al. 2006). Depletion of PHBs leads 
to increased processing of OPA1, as well as mitochondrial fragmentation and cristae disorganization 
(Merkwirth et al. 2008). This phenotype was also observed upon fluorizoline treatment (Pérez-
Perarnau 2013), which suggested that fluorizoline pro-apoptotic effects were indeed mediated by 
PHBs. OPA1 plays a key role in the maintenance of the mitochondrial cristae junctions, creating the 
intra-cristae space where the majority of cytochrome c resides. During apoptosis, OPA1 complexes 
are disassembled (Frezza et al. 2006, Yamaguchi et al. 2008, Landes et al. 2010, Jiang et al. 2014). This 
allows the reorganization of the mitochondrial cristae and facilitates cytochrome c release from the 
intracristae space to the intermembrane space (Scorrano et al. 2002, Yamaguchi et al. 2008). 
Taking into account such an important role of OPA1 in apoptosis induction, it is conceivable that not 
only fluorizoline but also other apoptotic stimuli induce OPA1 processing and cristae disorganization. 
This would discard OPA1 processing as a demonstration that PHBs mediate fluorizoline-induced 
apoptosis, because it would be a general apoptotic feature as well. 
To shed some light on this issue, we sought to analyze OPA1 protein levels upon treatment with 
different pro-apoptotic insults in HeLa cells. To this end, cells were treated with fluorizoline; 
staurosporine (STS), a cell death inducer control; capsaicin, which binds to PHBs and induces 
cytochrome c release (Kuramori et al. 2009); and Rocaglamide-A (Roc-A), which binds to PHBs and 
arrests cell cycle without apoptosis induction (Polier et al. 2012). Cell viability was assessed by flow 
cytometry, and OPA1 protein levels were analyzed by western blot. Interestingly, OPA1 processing 
correlated with apoptosis induction, regardless of the involvement of PHBs in the mechanism of 
action of the different drugs. Specifically, there was a clear reduction of L-OPA1 and an increase in S-
OPA1, mainly c and e forms (Fig. 2.1). 
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Figure 2.1. OPA1 processing correlates with apoptosis induction. HeLa cells were untreated (UT) or treated 
with 0.25 µM staurosporine (STS), 10 µM fluorizoline (F), 500 µM capsaicin (Cap), capsaicin vehicle control (ethanol, 
Et), 500 nM Rocaglamide-A (Roc-A) or Roc-A vehicle control (DMSO, D) for 24 hours. Viability was measured by 
flow cytometry and it is expressed as the percentage of non-apoptotic cells (annexin V-negative). Protein levels were 
analyzed by western blot. This is a representative experiment of two that were performed independently. 
 
As different pro-apoptotic insults were inducing OPA1 processing, we next studied whether it was an 
event occurring after caspase activation. With this aim, HeLa cells were pre-treated with the pan-
caspase inhibitor Q-VD-OPh and then treated with different pro-apoptotic stimuli: fluorizoline, 
actinomycin D (ActD), STS, Roc-A or capsaicin. Blocking caspase activation efficiently prevented 
fluorizoline- and ActD-induced apoptosis, while just partially blocked STS-induced cell death. HeLa 
cells treated with Roc-A showed only a minor decrease in viability, in agreement with previous results 
(Polier et al. 2012). Strikingly, the cytotoxic effects of capsaicin were not reverted by Q-VD-OPh pre-
treatment, suggesting that capsaicin treatment leads to caspase-independent cell death (Fig. 2.2A). 
Western blot analysis showed that fluorizoline, ActD, STS and capsaicin treatment induced OPA1 
processing, as seen by a reduction of L-OPA1 and accumulation of S-OPA1. Pre-treatment with Q-
VD-OPh did not block loss of L-OPA1, though it blocked accumulation of S-OPA1 (Fig. 2.2B). 
Thus, there were two treatments, ActD and fluorizoline, in which Q-VD-OPh was able to block 
phosphatidilserine exposure but could not prevent loss of L-OPA1. 
All these data suggest that disappearance of L-OPA1 is a common apoptotic event, upstream of 
caspase activation, which cannot be used as a proof that fluorizoline-induced apoptosis is mediated 
by PHBs. 
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Figure 2.2. Treatment with different pro-apoptotic agents triggers loss of L-OPA1 independently of caspase 
activation. HeLa cells were pre-incubated with or without 20 µM Q-VD-OPh for 30 minutes and then untreated 
(UT) or treated with 10 µM fluorizoline (F), 5 µg/mL ActD, 0.25 µM STS, Roc-A vehicle control (DMSO, D), 500 
nM Roc-A, capsaicin vehicle control (ethanol, Et), or 300 µM capsaicin (Cap) for 24 hours. (A) Viability was 
measured by flow cytometry and it is expressed as the percentage of non-apoptotic cells (annexin V-negative). Data 
are shown as mean ± SEM (n=2). ***p < 0.001. (B) Protein levels were analyzed by western blot (n=1, except for 
fluorizoline, n=3). Here we show short and long exposures of OPA1 blot. 
 
2.2. IN SEARCH OF A MODEL FOR PROHIBITINS DEPLETION 
In order to prove that the pro-apoptotic effects of fluorizoline require PHBs, we sought to analyze 
the response to fluorizoline treatment in the absence of PHBs. The first approach was the 
downregulation of PHBs by siRNA transfection in HeLa cells. Nevertheless, loss of PHBs led to 
morphological changes and cell detachment (Pérez-Perarnau 2013). This is in consistence with other 
reports which described similar phenotypes after PHB downregulation (Rajalingam et al. 2005, 
Kasashima et al. 2006, Sievers et al. 2010, Sato et al. 2011). 
With the aim of overcoming this technical drawback, our group established a collaboration with Dr. 
Thomas Langer (Institute for Genetics, CECAD, Cologne, Germany). They had previously 
developed a cell line of mouse embryonic fibroblasts (MEFs) conditional knockout (KO) for Phb2 
(Phb2fl/fl MEFs) (Merkwirth et al. 2008). In contrast with the morphologic changes observed after 
siRNA-mediated PHBs silencing in HeLa cells, MEFs with deleted Phb2 show impaired proliferation 
but maintain the cellular viability. This conditional KO model is based on Cre-lox system: exon 3 of 
Phb2 gene is flanked by two loxP sites, which will be recognized and digested by Cre recombinase, 
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deleting part of Phb2 gene. This abolishes Phb2 expression, as mRNA levels of Phb2 cannot be 
detected. At a protein level, PHB1 and PHB2 are interdependent, thus reduction of the levels of one 
protein entails the reduction of the other (Merkwirth et al. 2008). Hence, when using the conditional 
KO MEFs, deletion of Phb2 leads to a deletion of both PHB1 and 2, the two proteins that directly 
bind to fluorizoline. As a control, we used wild-type (WT) MEFs, in which Cre recombinase 
transduction does not modify PHBs protein levels (Merkwirth et al. 2008). 
A classical disadvantage of Cre-lox system is the low efficiency of Cre recombinase expression 
processes, e.g., virus transfection or plasmid overexpression. In order to improve this step, Langer 
and colleagues use a recombinant Cre recombinase called His-TAT-NLS-Cre (HTNC) (described at 
Peitz et al. 2002). The TAT peptide allows the cellular absorption of the enzyme, while the nuclear 
localization signal (NLS) allows its translocation to the nucleus. Thanks to histidines, the enzyme can 
be purified with nickel beads from a bacterial expression system. Thus, this system allows the direct 
administration of Cre recombinase to MEFs, dramatically increasing the efficiency of the gene 
deletion. All in all, MEFs conditional KO for Phb2 rose as a really useful tool for the analysis of pro-
apoptotic effects of fluorizoline in cells lacking their main molecular targets: PHB1 and 2. 
We first sought to optimize the amount of Cre recombinase required for Phb2 gene deletion. To this 
end, Phb2fl/fl MEFs were transduced with different concentrations of Cre recombinase for 20 hours 
and further grown for 72 hours. We then harvested the cells and assessed the efficiency of the 
deletion by PCR. As shown in figure 2.3, 6 µM Cre recombinase was the minimum concentration 
required for a total Phb2 gene deletion, and thus was established for further experiments. The 
optimization of the concentration had to be done every time that a newly synthetized Cre 
recombinase was used for the first time. 
 
Figure 2.3. PCR analysis of Phb2 gene deletion after Cre recombinase transduction. Phb2fl/fl MEFs were 
transduced with increasing doses of Cre recombinase for 20 hours. Afterwards, cells were washed with phosphate 
buffered saline (PBS) and grown with complete medium for 72 hours. Cells were harvested, DNA was isolated and 
PCR analysis was performed. Negative (N), WT (W), Phb2fl/fl (F) and Phb2fl/- (Δ) control amplification fragments are 
shown. 
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2.3. PROHIBITINS ARE REQUIRED FOR FLUORIZOLINE-INDUCED APOPTOSIS 
2.3.1. VALIDATION OF THE MODEL 
First of all, we sought to analyze WT and Phb2fl/fl MEFs basal response to fluorizoline treatment in 
the absence of Cre recombinase. It was important to find similar responses in the two cell lines so as 
further comparisons could be attributed to presence or absence of PHBs, not due to intrinsic 
sensitivity of the cell lines. Treatment with fluorizoline triggered apoptosis in WT and Phb2fl/fl MEFs 
in a similar manner in the absence of Cre recombinase. Actinomycin D (ActD), a cell death inducer 
control, was also capable of inducing similar rates of apoptosis in WT and Phb2fl/fl MEFs (Fig. 2.4A). 
Accordingly, western blot analysis revealed that fluorizoline and ActD treatment led to cleavage of 
caspase 3 and poly ADP-ribose polymerase (PARP), which indicate apoptosis induction, in WT and 
Phb2fl/fl MEFs likewise (Fig. 2.4B). Interestingly, PHBs levels were increased upon ActD or 
fluorizoline treatment in both cell lines, as previously observed in apoptotic conditions in rat cells 
(Chowdhury et al. 2007, 2011). 
OPA1 processing occurs during the apoptotic process (Alaimo et al. 2014, Jiang et al. 2014). This 
allows the remodeling of the mitochondrial cristae and facilitates cytochrome c release from the 
intracristae space to the intermembrane space (Scorrano et al. 2002, Yamaguchi et al. 2008). 
Consistently, both ActD and fluorizoline triggered OPA1 processing in the apoptotic conditions, 
where PARP and caspase 3 were also cleaved, in WT and Phb2fl/fl MEFs (Fig. 2.4B). Therefore, these 
results show that WT and Phb2fl/fl MEFs respond similarly to fluorizoline and thus are suitable for 
further studies. 
 
 
Figure 2.4. WT and Phb2fl/fl MEFs show similar apoptotic response to fluorizoline treatment. WT and 
Phb2fl/fl MEFs were untreated (UT) or treated with either 0.15 µg/mL ActD or increasing doses of fluorizoline (F) for 
24 hours. (A) Viability was measured by flow cytometry and it is expressed as the mean ± SEM (n≥3) of the 
percentage of non-apoptotic cells (annexin V-negative). (B) Protein levels were analyzed by western blot. This is a 
representative image of at least three independent experiments. 
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PARP and caspase 3 activation were indicating that apoptosis was occurring upon treatment with 
fluorizoline. Apoptosis is orchestrated by caspases, a family of cysteine/aspartate proteases that 
proteolyze hundreds of proteins in a controlled manner (Taylor et al. 2008). We next assessed 
whether caspases activation were required for fluorizoline-induced apoptosis in MEFs, as previously 
reported for HeLa cells (Pérez-Perarnau 2013). To this end, we performed a viability assay with the 
pan-caspase inhibitor Q-VD-OPh. Incubation with fluorizoline decreased viability in WT and Phb2fl/fl 
MEFs, which was abrogated by the pre-treatment with Q-VD-OPh (Fig. 2.5). Hence, induction of 
apoptosis by fluorizoline is dependent on caspase activation. 
 
Figure 2.5. Caspase activation is required for fluorizoline-induced apoptosis in WT and Phb2fl/fl MEFs. WT 
and Phb2fl/fl MEFs were pre-incubated with or without 20 µM Q-VD-OPh for 30 minutes and then treated with 20 
µM fluorizoline for 24 h. Viability was measured by flow cytometry and it is expressed as the mean ± SEM (n=3) of 
the percentage of non-apoptotic cells (annexin V-negative) relative to the control. **p < 0.01, ***p < 0.001. 
 
2.3.2. CRE RECOMBINASE MEDIATED LOSS OF PROHIBITINS 
Having validated WT and Phb2fl/fl MEFs as suitable models for the study of fluorizoline-induced 
apoptosis, we sought to analyze their response to fluorizoline in the absence of PHBs. To his end, 
WT and Phb2fl/fl MEFs were transduced with 6 µM Cre recombinase for 72 hours and then treated 
with increasing doses of fluorizoline for 24 hours. WT MEFs were sensitive to fluorizoline treatment, 
while loss of PHBs in Cre-transduced Phb2fl/fl MEFs (Phb2-/- MEFs) conferred strong resistance to 
fluorizoline-induced apoptosis. In contrast, both cell lines showed a similar response to ActD (Fig. 
2.6A).  
Consistently, fluorizoline treatment induced the cleavage of caspase 3 and poly ADP-ribose 
polymerase (PARP) in WT MEFs, whereas their processing was clearly reduced in Phb2-/- MEFs (Fig. 
2.6B). Contrary to fluorizoline, ActD triggered similar cleavage of caspase 3 and PARP in WT and 
Phb2-/- MEFs, providing support for the specificity of PHBs as targets of fluorizoline. 
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In agreement with former results, processing of OPA1 was observed in ActD- and fluorizoline-
treated WT MEFs, the same conditions in which PARP and caspase 3 were cleaved (Fig. 2.6B). Cre-
mediated depletion of Phb2 was accompanied by an increased processing of OPA1 in Phb2-/- MEFs 
(Fig. 2.6B), as previously described (Merkwirth et al. 2008). All together, these results show that 
absence of PHBs confers resistance to fluorizoline-induced apoptosis. 
 
Figure 2.6. Cre-mediated loss of PHBs confers resistance to fluorizoline pro-apoptotic effects in Phb2fl/fl 
MEFs. Cre recombinase was transduced in WT and Phb2fl/fl MEFs (Phb2-/-) for 72 hours. Then cells were untreated 
(UT) or treated with either 0.15 µg/mL ActD or increasing doses of fluorizoline (F) for 24 hours. (A) Viability was 
measured by flow cytometry and it is expressed as the percentage of non-apoptotic cells (annexin V-negative). Mean 
± SEM (n≥3). *p < 0.05, ***p < 0.001. (B) Protein levels were analyzed by western blot. These are representative 
images of at least three independent experiments. 
 
2.3.3. GENETIC RESCUE OF PROHIBITINS DEPLETION  
We sought to further corroborate that loss of PHBs was indeed the cause of resistance to 
fluorizoline-induced apoptosis. To this end, we used Phb2fl/fl::Phb2 MEFs, which harbor Phb2 gene 
downstream from a stop-cassette with flanking loxP sites. Cre recombinase transduction results in 
simultaneous deletion of genomic Phb2 along with the deletion of the floxed transcriptional stop-
cassete, which allows the expression of the transgene Phb2 (Fig. 2.7). Thus, this cell line would be an 
optimal control for Cre recombinase-mediated loss of PHBs. 
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Figure 2.7. Schematic representation of Cre-induced expression of Phb2 in Phb2fl/fl::Phb2 MEFs. Based on 
Merkwirth et al. 2008. 
 
First, we analyzed Phb2fl/fl::Phb2 MEFs basal response to fluorizoline treatment in the absence of Cre 
recombinase. It was important to find similar responses to WT or Phb2fl/fl MEFs so as further 
comparisons could be attributed to presence or absence of PHBs, not due to intrinsic sensitivity of 
the cell lines. However, Phb2fl/fl::Phb2 MEFs displayed less sensitivity to fluorizoline-induced 
apoptosis compared to WT or Phb2fl/fl MEFs (Fig. 2.8). In addition, ActD did not affect viability of 
Phb2fl/fl::Phb2 MEFs, showing that this cell line is generally less sensitive to apoptotic stimuli. Hence, 
we discarded Phb2fl/fl::Phb2 MEFs as a good genetic rescue model. 
 
Figure 2.8. Dose-response curve of fluorizoline in WT, Phb2fl/fl and Phb2fl/fl::Phb2 MEFs. WT, Phb2fl/fl and 
Phb2fl/fl::Phb2 MEFs were untreated (UT) or treated with 0.10 μg/mL ActD, or increasing doses of fluorizoline for 24 
hours. Viability was measured by flow cytometry and it is expressed as the percentage of non-apoptotic cells 
(annexin V-negative). This experiment was performed once. 
 
Recently, a manuscript from Dr. Langer’s group was published describing a similar cell line, namely 
Phb2fl/fl::CNAP-Phb2 MEFs. In this case, Cre recombinase transduction allowed endogenous Phb2 
gene deletion along with the re-expression of an exogenous Phb2 which was tagged to the epitope 
CNAP (Richter-Dennerlein et al. 2014). Again, we performed a viability assay to assess their response 
to fluorizoline treatment. Phb2fl/fl::CNAP-Phb2 MEFs were sensitive to fluorizoline pro-apoptotic 
effects, though to a smaller extent compared to WT and Phb2fl/fl MEFs (Fig. 2.9).  
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Figure 2.9. Dose-response curve of fluorizoline in WT, Phb2fl/fl and Phb2fl/fl::CNAP-Phb2 MEFs. WT, 
Phb2fl/fl and Phb2fl/fl::CNAP-Phb2 MEFs were untreated (UT) or treated with either 0.15 µg/mL ActD or increasing 
doses of fluorizoline for 24 hours. Viability was measured by flow cytometry and it is expressed as the percentage of 
non-apoptotic cells (annexin V-negative). This experiment was performed once. 
 
As the differences on the sensitivity to fluorizoline were not dramatic, western blot analysis were 
performed to characterize the apoptotic response in more detail. Treatment with ActD and 
fluorizoline triggered the processing of caspase 3 and PARP in WT and Phb2fl/fl MEFs alike, yet it was 
clearly reduced in Phb2fl/fl::CNAP-Phb2 MEFs (Fig. 2.10). These results show that Phb2fl/fl::CNAP-
Phb2 MEFs are more resistant to apoptotic stimuli and therefore, were also ruled out as genetic 
rescue model. 
 
Figure 2.10. Western blot analysis of WT, Phb2fl/fl and Phb2fl/fl::CNAP-Phb2 MEFs. These cell lines were 
untreated (UT) or treated with either 0.15 μg/mL ActD or increasing doses of fluorizoline (F) for 24 hours. Protein 
levels were analyzed by western blot. These are representative images of two independent experiments. Ponceau 
staining (PoS) was used as a loading control. 
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2.3.4. siRNA-MEDIATED DOWNREGULATION OF PROHIBITINS 
Having discarded both available genetic rescue cell lines as good models to study the mechanism of 
action of fluorizoline, we decided to corroborate the results obtained in Cre-mediated Phb2-/- by 
downregulating Phb2 levels using siRNA. In this way, another approach would be used in order to 
further prove that PHBs are required for fluorizoline-induced apoptosis. WT and Phb2fl/fl MEFs were 
transfected with Phb2 siRNA for 72 hours and then treated with fluorizoline for 24 hours. Consistent 
with the previous results, fluorizoline pro-apoptotic effects were blocked when PHBs were 
downregulated, as shown by viability analysis (Fig. 2.11).  
 
Figure 2.11. Viability assay in Phb2-downregulated WT and Phb2fl/fl MEFs. WT (A) and Phb2fl/fl (B) MEFs 
were transfected with scramble (SC) or Phb2 siRNA (siPhb2) for 72 hours. Afterwards, cells were treated with either 
2.5 µg/mL Actinomycin D (ActD) or increasing doses of fluorizoline for 24 hours. Viability was measured by flow 
cytometry and it is expressed as the percentage of non-apoptotic cells (annexin V-negative). Mean ± SEM (n≥3). **p 
< 0.01, ***p < 0.001. 
 
Next, we performed western blot analyses to further characterize the apoptotic response to 
fluorizoline treatment. Caspase 3 and PARP cleavage were induced by ActD and fluorizoline in 
scramble-transfected cells, while their cleavage was reduced in Phb2 siRNA-transfected cells in both 
WT and Phb2fl/fl MEFs (Fig. 2.12). In agreement with figure 2.6B, ActD and fluorizoline induced 
OPA1 processing in scramble-transfected cells, while downregulation of PHBs led to OPA1 
processing irrespective of the treatment. All together, these data prove that absence of PHBs confers 
resistance to fluorizoline-induced apoptosis. 
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Figure 2.12. Western blot analysis in Phb2-downregulated WT and Phb2fl/fl MEFs. WT (A) and Phb2fl/fl (B) 
MEFs were transfected with scramble (SC) or Phb2 siRNA (siPhb2) for 72 hours. Afterwards, cells were treated with 
either 2.5 µg/mL Actinomycin D (Act) or increasing doses of fluorizoline (F) for 24 hours. Protein levels were 
analyzed by western blot. These are representative images of at least three independent experiments. 
 
2.4. SLP-2 IS NOT INVOLVED IN FLUORIZOLINE-INDUCED APOPTOSIS 
PHBs belong to the stomatin-prohibitin-flotilin-HflC/K (SPFH) superfamily, whose members tend 
to oligomerize and form large multimeric complexes that localize in lipid rafts microdomains in 
various cellular membranes (Browman et al. 2007). Stomatin-like protein 2 (SLP-2) also belongs to 
this superfamily and has been described to interact with cardiolipin and PHBs in the IMM, forming 
membrane microdomains that facilitate mitochondrial biogenesis and function (Da Cruz et al. 2008, 
Christie et al. 2011). 
Considering the structural similarity of the SPFH family members, it is conceivable that fluorizoline 
may also affect other SPFH proteins apart from PHBs. As SLP-2 KO (SKO) MEFs were available at 
Dr. Langer’s laboratory, we decided to examine how these cells would respond to fluorizoline 
treatment. With this aim, Phb2fl/fl and SKO MEFs were incubated with different doses of fluorizoline 
for 24 hours and viability was measured by flow cytometry. Both cell lines displayed similar sensitivity 
to fluorizoline-induced apoptosis (Fig. 2.13), ruling out SLP-2 as a required target for fluorizoline 
mechanism of action. 
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Figure 2.13. Fluorizoline triggers apoptosis in Phb2fl/fl and SKO MEFs alike. Phb2fl/fl and SKO MEFs were 
untreated (UT) or treated with 0.15 µg/mL Actinomycin D (ActD), or increasing doses of fluorizoline for 24 hours. 
Viability was measured by flow cytometry and it is expressed as the percentage of non-apoptotic cells (annexin V-
negative). This experiment was performed once. 
 
2.5. GENERATION OF A Phb2-/- STABLE CELL LINE 
Although Phb2-/- MEFs were reported to have impaired proliferation (Merkwirth et al. 2008), after 
Cre recombinase transduction some cell proliferation was observed in Phb2fl/fl MEFs. This 
encouraged us to try to generate a stable cell line lacking Phb2 which could avoid the requirement of 
Phb2 depletion for each experiment. With this aim, Phb2fl/fl MEFs were transduced with Cre 
recombinase for 20 hours and further grown for 72 hours. Then, single cells were sorted separately in 
individual wells in a 96-well plate and allowed to grow for several days (Fig. 2.14).  
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Figure 2.14. Schematic representation of the generation of a Phb2-/- stable cell line. 
 
Among 192 clones that were seeded, 79 were selected and grown in bigger plates for further study. 
Considering that loss of Phb2 could result in impaired proliferation, clones were chosen at different 
days in order to include clones with different proliferation rates. We isolated DNA from 58 clones 
and performed a PCR analysis to assess the status of the Phb2 gene. None of the clones presented a 
complete deletion of the Phb2 gene. Of note, 47 clones had one allele depleted while the other one 
was still floxed (Phb2fl/-); while the other 11 had both alleles floxed (Phb2fl/fl). Figure 2.15 shows 
representative PCR analysis of different clones.  
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Figure 2.15. PCR analysis of Phb2 gene in different clones. DNA of five different Cre-transduced Phb2fl/fl clones 
was isolated and PCR analysis was performed. Negative (N), Phb2+/- (W), and Phb2fl/fl (F) control amplification 
fragments are shown. 
 
In spite of the lack of Phb2-/- clones, we sought to study how would heterozygous (Phb2fl/-) respond to 
fluorizoline treatment. To this end, we selected three heterozygous and two control homozygous 
(Phb2fl/fl) clones, incubated them with fluorizoline for 24 hours and analyzed the viability. This 
experiment was performed twice, and data from the clones with the same genetic status were pooled 
together in order to minimize the clone-specific differences unrelated to the Phb2 gene status. 
Strikingly, Phb2fl/- and Phb2fl/fl clones displayed similar sensitivity to fluorizoline treatment (Fig. 2.16). 
       
 
Figure 2.16. Phb2fl/fl and Phb2fl/- clones respond similarly to fluorizoline treatment. Three Phb2fl/- and two 
Phb2fl/fl clones were untreated (UT) or treated with increasing doses of fluorizoline for 24 hours. Viability was 
measured by flow cytometry and it is expressed as the mean ± SEM (n=2) of the percentage of non-apoptotic cells 
(annexin V-negative). Data from the clones with the same genetic status were pooled together (three heterozygous, 
two experiments, in one group; two homozygous, two experiments, another group) in order to minimize the clone-
specific differences unrelated to the Phb2 gene status. 
 
We then analyzed the protein levels of PHBs and OPA1 in the five selected clones (Fig. 2.17). 
Interestingly, Phb2fl/- showed lower levels of PHBs when compared to Phb2fl/fl. This reduction was 
accompanied by OPA1 processing (loss of L-OPA forms) as observed in those cells totally lacking 
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PHBs. Thus, Phb2fl/- clones have low levels of PHBs, which are not enough for blocking OPA1 
processing, yet are enough for fluorizoline to induce apoptosis as effectively as in Phb2fl/fl clones. 
 
Figure 2.17. Western blot analysis of Phb2 fl/fl and Phb2 fl/- clones. Three Phb2fl/- clones (A, B, and C) and two 
Phb2fl/fl clones (1 and 2) were untreated or treated with 10, 15 or 20 µM fluorizoline (F) for 24 hours. Protein levels 
were analyzed by western blot. This is a representative image of two independent experiments. 
 
To discard any putative problem with the Phb2 depletion in the first attempt to generate a Phb2-/- 
stable cell line, we decided to further try it by transducing again with Cre recombinase in three Phb2fl/- 
clones. Unfortunately, among 26 selected clones, none was Phb2-/- (data not shown). Hence, the 
difficulty to obtain a Phb2-/- clone provides further support for a key role of PHBs in proliferation, 
and thus those cells lacking PHBs have a clear proliferation disadvantage. 
 
2.6. EFFECTS OF FLUORIZOLINE ON PROHIBITINS COMPLEXES IN 
MITOCHONDRIA 
In the inner mitochondrial membrane, PHB1 and 2 form membrane-bound complexes of 0.8-1 MDa 
(Merkwirth and Langer 2009). In addition, PHBs interact with other proteins leading to the formation 
of the prohibitin/mAAA protease (PMA) supercomplexes (Richter-Dennerlein et al. 2014). It is 
conceivable that treatment with fluorizoline might be affecting these complexes, so we decided to 
study their assembly by non-denaturing blue native gel electrophoresis (BN-PAGE). As shown in 
figure 2.18, treatment with fluorizoline did not affect the assembly of PHBs complex neither the 
PMA supercomplex in Phb2fl/fl MEFs. It is worth mentioning that owing to the huge molecular weight 
of these complexes, subtle changes in their composition may not be detected by BN-PAGE, e.g., loss 
or incorporation of small proteins. Hence, further experiments would be necessary to characterize 
more precisely fluorizoline-induced changes in PHBs complexes. 
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Figure 2.18. Blue Native-PAGE analysis of prohibitins in Phb2fl/fl MEFs. These cells were untreated (UT) or 
treated with 20 µM fluorizoline (F) for 24 hours. Mitochondria were isolated and analyzed by Blue Native-PAGE, 
followed by immunoblotting with a mixed solution of PHB1 and 2 antibodies. This experiment was performed once. 
 
2.7. STUDY OF THE PHOSPHOLIPID COMPOSITION OF FLUORIZOLINE-
TREATED MEFs 
PHBs complexes and PMA have been suggested to act as lipid scaffolds in the IMM, which would be 
crucial for the homeostasis of mitochondrial phospholipids, especially for cardiolipin (CL) and 
phosphatidylethanolamine (PEA) (Osman et al. 2009b, Richter-Dennerlein et al. 2014). 
Therefore, we sought to examine whether fluorizoline treatment was leading to changes in the 
phospholipid composition. To this end, we analyzed untreated or fluorizoline-treated Phb2fl/fl MEFs, 
as well as Cre-transduced Phb2-/- MEFs. Dr. Takashi Tatsuta (Dr. Langer’s group, Institute for 
Genetics, CECAD, Cologne, Germany) performed the lipid analyses by mass spectometry, studying: 
- The amount of different phospholipid classes: PEA, CL, phosphatidylcholine (PC), 
phosphatidylinositol (PIN), phosphatidylserine (PS), phosphatidic acid (PA), and 
phosphatidylglycerol (PG). 
- The length and saturation profile of the acyl chains in each phospholipid species. 
Fluorizoline treatment or Cre-mediated loss of PHBs did not induce major changes in the 
phospholipidome of Phb2fl/fl MEFs. The only statistically significant modification was an increase of 
PEA content induced by Cre recombinase transduction (Fig. 2.19). 
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Figure 2.19. Phospholipidome of fluorizoline-treated or Cre-transduced Phb2fl/fl MEFs. Phb2fl/fl MEFs were 
untreated (UT), treated with 20 µM fluorizoline for 24 hours, or Cre-transduced for 72 hours (Phb2-/-). Amounts of 
phosphatidylcholine (PC), phosphatidylethanolamine (PEA), phosphatidylinositol (PIN), phosphatidylserine (PS), 
phosphatidic acid (PA), phosphatidylglycerol (PG) and cardiolipin were analyzed by quantitative mass spectrometry 
and are represented as the mean ± SEM (n=3) of the percentage of pmols relative to the total sum. *p < 0.05. 
 
This is in stark contrast with PHB-downregulated HEK293 mitochondrial phospholipid analysis, in 
which lack of PHBs correlated with a decrease in PEA and CL content as well as an increase in PIN 
content (Richter-Dennerlein et al. 2014). 
Regarding the length and the saturation of the acyl chains, fluorizoline treatment induced an increase 
in PEA chain length (Fig. 2.20). The same tendency was observed in Phb2-/- MEFs, though no 
statistical significance was observed. The acyl chains tended to present more double bonds in 
fluorizoline-treated and Cre-transduced MEFs, but again without statistical significance. 
 
Figure 2.20. Lenght and saturation of PEA acyl chains. Phb2fl/fl MEFs were untreated (UT), treated with 20 µM 
fluorizoline for 24 hours, or Cre-transduced for 72 hours (Phb2-/-). PEA acyl chains length and saturation were 
analyzed by quantitative mass spectrometry and are represented as the mean ± SEM (n=3) of the percentage of 
pmols relative to the total sum. Green arrows indicate statistically significant changes, blue arrows indicate a 
tendency. *p < 0.05. 
Characterization of fluorizoline-induced apoptosis 
86 
CL was reported to have longer and less saturated acyl chains when PHBs were downregulated in 
HEK293 cells (Richter-Dennerlein et al. 2014). In contrast, the acyl chain length was shorter in 
fluorizoline-treated MEFs, while Phb2-/- MEFs did not show any significant modification. Both 
conditions tended to have more saturated acyl chains with no statistically significant difference (Fig. 
2.21). 
 
Figure 2.21. Lenght and saturation of CL acyl chains. Phb2fl/fl MEFs were untreated (UT), treated with 20 µM 
fluorizoline for 24 hours, or Cre-transduced for 72 hours (Phb2-/-). CL acyl chains length and saturation were 
analyzed by quantitative mass spectrometry and are represented as the mean ± SEM (n=3) of the percentage of 
pmols relative to the total sum. Green arrows indicate fluorizoline-induced statistically significant changes, blue 
arrows indicate fluorizoline-induced tendency. *p < 0.05. 
 
PC, PIN and PS presented longer acyl chains in PHBs-downregulated HEK293 cells (Richter-
Dennerlein et al. 2014). Fluorizoline induced a significant increase in PC acyl chain length, and PIN, 
PS, PA, and PG showed a tendency to have longer chains as well (Fig. 2.22). In addition, PC double 
bonds were increased while PA double bonds were decreased upon fluorizoline treatment. Cre-
mediated loss of PHBs only induced an increase in the length and unsaturation of PIN acyl cahins 
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See next page for figure legend 
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Figure 2.22. Lenght and saturation of PC, PIN, PS, PA and PG acyl chains. Phb2fl/fl MEFs were untreated 
(UT), treated with 20 µM fluorizoline for 24 hours, or Cre-transduced for 72 hours (Phb2-/-). PC (A), PIN (B), PS 
(C), PA (D) and PG (E) acyl chains length and saturation were analyzed by quantitative mass spectrometry and are 
represented as the mean ± SEM (n=3) of the percentage of pmols relative to the total sum. Green arrows indicate 
fluorizoline-induced statistically significant changes, blue arrows indicate fluorizoline-induced tendency; orange 
arrows indicate Cre recombinase-induced changes, purple arrows indicate Cre recombinase-induced tendency. *p < 
0.05. 
 
To sum up, these data show that fluorizoline slightly increases the length of PEA and PC acyl chains 
but slightly decreases CL acyl chain length. Cre-mediated loss of PHBs increased PEA content as well 
as length and double bonds of PIN acyl chain length. On the whole, fluorizoline does not induce 
major changes in the whole cell phospholipid content. 
 
2.8. PROHIBITINS MEDIATE THE MODULATION OF THE EXPRESSION OF 
DIFFERENT BCL-2 FAMILY MEMBERS UPON FLUORIZOLINE TREATMENT 
Our group described that treatment with fluorizoline induces cytochrome c release and BAX/BAK 
dependent apoptosis (Pérez-Perarnau 2013, Pérez-Perarnau et al. 2014). These data suggest that 
fluorizoline triggers apoptosis through the mitochondrial apoptotic pathway. The execution of this 
apoptotic pathway depends on the balance between pro- and anti-apoptotic members of the BCL-2 
family (Czabotar et al. 2014). To gain insight into the mechanism of apoptosis induction upon 
fluorizoline treatment, changes in the overall apoptosis mRNA expression profile were analyzed by 
reverse transcriptase multiplex ligation dependent probe amplification (RT-MLPA) in Phb2fl/fl MEFs. 
After 24 hours of treatment with 20 μM fluorizoline, upregulations of the pro-apoptotic members 
Bim, Noxa, Bmf, Moap1 and Smac were observed, along with downregulations of the anti-apoptotic 
members Bcl-2, Bcl-X, Hiap1 and Survivin; correlating with the apoptotic outcome. In addition, 
fluorizoline increased Mcl-1, Flip and p21 and decreased Bak and Htra2 mRNA levels (Fig. 2.23A). 
Although RT-MLPA includes probes for housekeeping genes, they were not included in the analysis 
as significant modulations were observed upon fluorizoline treatment. 
As shown in figure 2.6, fluorizoline-induced decrease in viability requires the presence of PHBs. It is 
therefore conceivable that the modulations in apoptosis-related gene expression do not occur in cells 
lacking PHBs. To assess this, we transduced Phb2fl/fl MEFs with Cre recombinase for 72 hours and 
then treated them with 20 μM fluorizoline for 24 hours. Interestingly, Cre-mediated loss of PHBs 
abolished the modulations of mRNA levels triggered by fluorizoline (Fig. 2.23B). Therefore, the 
presence of PHBs is required for fluorizoline-induced changes in the apoptosis mRNA expression 
profile.  
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Figure 2.23. RT-MLPA analyses show PHB-dependent modulation of the expression of apoptosis related 
genes upon fluorizoline treatment. (A) Phb2fl/fl MEFs were untreated or treated with 20 µM fluorizoline for 24 
hours. (B) Phb2fl/fl MEFs were transduced with Cre recombinase for 72 h and then untreated or treated with 20 µM 
fluorizoline for 24 hours. (A, B) mRNA levels were analyzed by RT-MLPA. White bars correspond to untreated 
cells, and grey bars to fluorizoline-treated cells. Data show the mean values of three independent experiments relative 
to the mean of the control. *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Interestingly, treatment with fluorizoline increased BIM protein levels in WT and Phb2fl/fl MEFs in 
the absence of Cre recombinase, while they were not modulated in Cre-transduced Phb2fl/fl MEFs, 
which lack PHBs (Fig. 2.24). Consistently, PARP was cleaved upon fluorizoline treatment in WT and 
Phb2fl/fl MEFs, but not in Phb2-/- MEFs. It would have been very interesting to study NOXA protein 
levels, but they could not be analyzed due to lack of proper antibodies detecting the mouse protein.  
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Figure 2.24. Fluorizoline induces BIM in a PHBs-dependent manner. WT and Phb2fl/fl MEFs were transduced 
or not with Cre recombinase for 72 hours and then untreated or treated with 15 or 20 µM fluorizoline for 24 hours. 
Protein levels were analyzed by western blot. This is a representative image of at least three independent 
experiments. Western blot analyses were performed by Dr. Iglesias-Serret. 
 
There are more available antibodies to detect human BCL-2 family proteins, so we decided to further 
study fluorizoline-induced apoptosis by analyzing changes in the expression of BCL-2 family 
members in HeLa cells. To this end, we treated HeLa cells with 10 μM fluorizoline for 4, 8 and 24 
hours and the apoptosis-related gene expression profile was examined by RT-MLPA. Interestingly, 
BIM, PUMA, NOXA, and p21 mRNA levels were increased, while BMF, AIF and different IAP 
family members mRNA levels were downregulated after fluorizoline treatment (Fig. 2.25). FLIP 
mRNA levels are detected by two different probes; one of them increased yet the other one 
decreased upon fluorizoline treatment. Again, housekeeping genes were not included because 
fluorizoline significantly modulated their mRNA levels. 
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Figure 2.25. RT-MLPA analysis of apoptosis-related gene expression profile upon fluorizoline treatment in 
HeLa cells. HeLa cells were untreated (white bars) or treated with 10 µM fluorizoline (grey bars) for 4, 8 and 24 
hours. mRNA levels were analyzed by RT-MLPA. Data show the mean ± SEM relative to the mean of the control (4 
and 8 hours, n=2; 24 hours, n=3). *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Next, we sought to examine whether these modulations of the expression levels were leading to 
changes on the corresponding protein levels. We observed a time-dependent upregulation of BIM 
and NOXA protein levels as well as decreases in PUMA and MCL-1 (Fig. 2.26A). Despite dramatic 
decreases in BCL-2 mRNA levels, fluorizoline did not significantly modulate its protein levels, in line 
with its long half-life (Merino et al. 1994). PHBs levels were not modified upon fluorizoline 
treatment, as described for other pro-apoptotic stimuli in different cell types (Coates et al. 2001). 
PARP cleavage was blotted as a control for apoptosis induction, which was pretty clear at 8 hours. 
Interestingly, OPA1 processing occurred within a time frame similar to PARP. Fluorizoline induced 
significant modulations of Survivin and p21 mRNA levels. Nevertheless, after 24 hours of treatment, 
their protein levels were not modified (Fig. 2.26B). 
It was important to assess whether these modulations were the cause or the consequence of apoptosis 
induction. To distinguish between these events, we incubated HeLa cells with pan-caspase inhibitor 
Q-VD-OPh and then treated them with fluorizoline for 24 hours. BIM and NOXA increases 
preceded caspase activation, as pre-incubation with Q-VD-OPh could not block their upregulation 
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(Fig. 2.26C). In contrast, caspase inhibition abolished MCL-1 and PUMA decrease mediated by 
fluorizoline treatment, which suggests that this event is downstream of caspase activation. This is in 
agreement with previous reports caspase-dependent proteolysis of these proteins (Herrant et al. 2002, 
2004, Hadji et al. 2010). 
 
 
Figure 2.26. Fluorizoline induces changes in protein levels of various BCL-2 family members in HeLa cells. 
(A) HeLa cells were untreated or treated with 10 µM fluorizoline for 4, 8 and 24 hours. (B) HeLa cells were 
untreated or treated with 10 µM fluorizoline for 24 hours. (C) HeLa cells were pre-incubated with 20 µM caspase 
inhibitor Q-VD-OPh for 30 minutes and then treated with 10 µM fluorizoline for 24 hours. Viability was measured 
by flow cytometry and it is expressed as the percentage of non-apoptotic cells (annexin V-negative). Protein levels 
were analyzed by western blot. A and B, n≥3, except for p21 (n=1). C, n=3 except for PUMA (n=1). 
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1. CHARACTERIZATION OF AICAR-INDUCED APOPTOSIS 
AICAR INDUCES ZMP-DEPENDENT BUT AMPK-INDEPENDENT APOPTOSIS IN 
MOUSE EMBRYONIC FIBROBLASTS 
Our group has described AICAR-induced apoptosis in chronic lymphocytic leukemia (CLL) cells, 
though the exact mechanism of action remains unknown. CLL cells are difficult to transfect, which 
hinders the study of the mechanism at a molecular level. Here we propose mouse embryonic 
fibroblasts (MEFs) as an alternative model. AICAR induces cell cycle arrest and apoptosis in trisomic 
MEFs (Tang et al. 2011), while it inhibits proliferation without affecting the viability in primary WT 
MEFs (Jones et al. 2005). Our results show that AICAR induces ZMP-dependent but AMP-activated 
protein kinase (AMPK)-independent apoptosis in immortalized WT MEFs (also observed in 
González-Gironès 2012), consistent with the mechanism of action reported in CLL cells (Campàs et 
al. 2003, Santidrián et al. 2010). The reason why treatment with AICAR results in such different 
phenotypes in MEFs remains unknown.  
AICAR is widely known as an activator of AMPK. This kinase has been historically perceived as anti-
tumorigenic because it is the center of a signaling network that involves well-known tumor 
suppressors, such as LKB1 and TSC1/2. AMPK activation results in the inhibition of most of the 
metabolic changes that are necessary for rapidly proliferating cells (Hardie et al. 2012), which is 
consistent with an anti-tumorigenic role. Along the same lines, loss of AMPK induced the Warburg 
effect and accelerated MYC-induced lymphomagenesis (Faubert et al. 2013). Activation of the 
AMPK-mTOR pathway decreases MCL-1 protein levels, which leads to a sensitization to the 
extrinsic apoptosis (Pradelli et al. 2010a) or to ABT-737-induced apoptosis (Meynet et al. 2013). In 
addition, different drugs that activate AMPK, including AICAR, metformin or phenformin, can 
inhibit cancer cell growth and proliferation, which was initially understood as a proof that AMPK 
activation was indeed mediating the anti-tumorigenic effects (Hardie and Alessi 2013, Liang and Mills 
2013, Faubert et al. 2015).  
Nevertheless, our findings show that MEFs lacking AMPK are sensitive to AICAR treatment, 
proving an AMPK-independent mechanism for the induction of apoptosis. Recently, Vincent and 
colleagues studied the effect of AICAR in MEFs. Fully in keeping with our results, AICAR induced 
apoptosis and inhibited proliferation and glucose consumption in an AMPK-independent manner 
(Vincent et al. 2014). In addition, direct activation of AMPK failed to trigger apoptosis in MEFs (our 
results and Vincent et al. 2014), as observed in CLL cells (Santidrián et al. 2010), HEK293 cells 
(Vincent et al. 2014) and glioma cells (Liu et al. 2014). Other findings also point towards AMPK-
independent effects of AICAR. First, follicular lymphoma cells are resistant to AICAR-induced 
apoptosis despite presenting activation of AMPK (Campàs et al. 2005). In Jurkat cells, AICAR 
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triggers apoptosis without inducing the phosphorylation of AMPK neither requiring ZMP 
accumulation (López et al. 2003). Furthermore, AICAR inhibits respiration in intact rat hepatocytes 
(Guigas et al. 2007), increases the radiosensitization of prostate cancer cell lines (Isebaert et al. 2011), 
inhibits autophagy (Meley et al. 2006, Viana et al. 2008), blocks phosphatidylcholine synthesis (Jacobs 
et al. 2007) and protects from heat-induced sudden death in RyR1 mutant mice (Lanner et al. 2012) 
independently of AMPK. Consistent with these AMPK-independent effects of AICAR, the anti-
tumorigenic effects of other well-known AMPK activators, such as metformin, phenphormin or 2-
deoxyglucose, were proved to be independent of AMPK in a wide range of cell types, including MEF 
and CLL cells (Santidrián et al. 2010, Liu et al. 2014, Vincent et al. 2014).  
In fact, AMPK might be playing a survival role. We show that loss of AMPK sensitizes MEFs to 
AICAR-induced apoptosis, which was also observed by others in MEFs (Shaw et al. 2004, Vincent et 
al. 2014), as well as in mouse B lymphocytes (Santidrián et al. 2010, González-Gironès 2012), and in 
glioma cells (Liu et al. 2014). Consistently, it has been reported that AMPK promotes survival facing 
various stresses in MEFs (Jeon et al. 2012) and in other cell types (Ido et al. 2002, Lee et al. 2003, Liu 
et al. 2012, Estañ et al. 2012, Shackelford et al. 2013, Shao et al. 2014), although the exact mechanism 
remains unknown. It was proposed that AMPK promotes cell survival by redox regulation. AMPK 
activation maintains NADPH levels, which are critical for cell survival under energy stress conditions 
(Jeon et al. 2012). In this line, AMPK enhances SIRT1 activity by increasing NAD+ levels, resulting in 
the deacetylation and the consequent degradation of SIRT1 target proteins, such as p53 (Cantó et al. 
2009, Wang et al. 2012). Fully in keeping with the pro-survival role, AMPK has been linked to tumor 
development and progression (Hardie and Alessi 2013, Liang and Mills 2013, Faubert et al. 2015). 
Direct activation of AMPK by A769662 enhances cell proliferation under metabolic stress conditions 
(Vincent et al. 2014). Therefore, AMPK activation may facilitate tumor growth by providing cells the 
flexibility to adapt to the metabolic stresses that can occur along the tumor progression, such as 
anchorage-independent growth and glucose or oxygen limitation. 
Interestingly, we have also shown that AICAR required ZMP but not AMPK to induce changes in 
the apoptosis-related gene expression profile in MEFs. Treatment with AICAR upregulated Bim, 
Noxa, and Puma mRNA levels, while decreased Bcl-2 mRNA levels. The expression of BCL-2 family 
members was analyzed by RT-MLPA and RT-qPCR, being the latter more sensitive. In this regard, 
increases in Bim and Puma mRNA levels could only be detected by RT-qPCR but not by RT-MLPA. 
Despite increases in Puma mRNA levels, the lack of this BH3-only protein did not decrease the 
sensitivity to AICAR-induced apoptosis in MEFs. This result is consistent with the lack of resistance 
observed in Bim-/-/Puma-/- B and T lymphocytes from mouse spleen and in Noxa-/-/Puma-/- primary 
MEFs (González-Gironès 2012). Interestingly, MEFs lacking Bim and Noxa display high resistance to 
the pro-apoptotic effects of AICAR (González-Gironès 2012), in agreement with the role of these 
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BH3-only proteins in AICAR-induced cell death in CLL cells and mouse B lymphocytes (Santidrián 
et al. 2010).  
Noxa expression is regulated by different transcription factors, including p53, p73, hypoxia-inducible 
factor 1α (HIF1α), E2F-1, c-Myc, cAMP response element (CRE)-binding proteins and SP-1 
(Nikiforov et al. 2007, Ploner et al. 2008, Grande et al. 2012). Importantly, analysis of the regulation 
of Noxa promoter ruled out HIF, p53 and CRE as mediators of AICAR-induced increases of this 
gene (González-Gironès 2012). Regarding Bim, several transcriptional factors, including FOXO3a, 
E2F-1, and c-Jun, have been involved in its regulation (Piñon et al. 2008). Therefore, E2F-1 appears 
as the common factor regulating NOXA and BIM. However, E2F-1 seems not to be implicated here 
since AICAR induces apoptosis in wild-type and E2F-1-/- mouse lymphocytes alike (González-
Gironès 2012). Further experiments are required to elucidate how AICAR treatment modulates the 
expression of Bim and Noxa. For this purpose, MEFs are a useful cellular system for the elucidation 
of the mechanism of action of AICAR, as the induction of apoptosis in MEFs, CLL cells and mouse 
B lymphocytes is highly similar. 
 
THE ROLE OF p53 IN AICAR-INDUCED APOPTOSIS 
Treatment with AICAR induces a cell cycle arrest through AMPK activation and p53 
phosphorylation in primary MEFs (Jones et al. 2005). Similarly, p53 was proposed to mediate AICAR 
anti-proliferative effects in trisomic MEFs, although induction of apoptosis in trisomic cancer cell 
lines was independent of p53 mutational status (Tang et al. 2011). When we analyzed the role of p53 
in AICAR-induced apoptosis, we observed that the pro-apoptotic effects after treatment with high 
doses of AICAR were p53-independent. Strikingly, our results also show that low doses of AICAR 
required an active p53 pathway to induce apoptosis. Different effects of AICAR depending on the 
dose were also observed in primary MEFs. Treatment with 0.5 mM AICAR induces an increase in the 
size of the cell, while 2 mM AICAR fails to modify it (Jones et al. 2005). Therefore, the range of 
doses of AICAR seems to activate different pathways which may have different consequences for 
MEFs. 
Regardless of the dose-dependent differential effects, it is clear that the range of doses normally used 
in the rest of the experiments were inducing apoptosis independently of p53. This is consistent with 
previous results of our group, showing that AICAR efficiently triggers apoptosis in mouse 
lymphocytes lacking p53 (González-Gironès 2012). In addition, the pro-apoptotic effects of AICAR 
do not induce p53 phosphorylation or accumulation in CLL cells, and do not depend on the 
mutational status of p53 (Campàs et al. 2003, Santidrián et al. 2010). 
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A p53-independent mechanism of action is crucial for the successful outcome of treatments for CLL. 
Mutations in p53 are frequent among patients with advanced and chemotherapy-resistant disease 
(Shindiapina et al. 2014). Hence, AICAR constitutes an interesting therapeutic strategy for CLL 
patients with defects in the p53 pathway. 
 
PYRIMIDINE STARVATION AS A PUTATIVE MECHANISM OF ACTION OF AICAR 
It was reported that AICAR triggered apoptosis in multiple myeloma (MM) cells by inhibiting uridine 
monophosphate synthase (UMPS), which leads to pyrimidine starvation. AICAR pro-apoptotic 
effects were blocked by addition of uridine and cytidine, and thymidine partially did it (Bardeleben et 
al. 2013). A similar mechanism of action has been reported for several anticancer agents, such as 
methotrexate, 5-fluorodeoxyuridine or IMP dehydrogenase inhibitors, which inhibit dNTP synthesis. 
This causes imbalances in the nucleotide pool that impair DNA synthesis and repair, leading to severe 
DNA damage and cell cycle arrest. These agents are frequently used to treat different solid and 
hematological malignancies, either alone or in combination treatment regimens (Wilson et al. 2014).  
In CLL cells, we observed that addition of uridine and thymidine efficiently inhibited AICAR-
induced apoptosis. Compared to MM cells, higher doses of pyrimidines were required to abolish the 
apoptotic effects upon AICAR treatment in CLL cells. Different activities or expression levels of the 
nucleoside transporters (NTs) in MM or CLL cells could explain the differences in the required doses 
for blocking AICAR-induced apoptosis depending on the model. AICAR influx is mediated by 
NBTI-sensitive NTs, which basically includes equilibrative NTs (ENTs) (Campàs et al. 2003). CLL 
cells are known to express both concentrative NTs (CNTs) and ENTs, whose expression or activity 
can be modulated by different stimuli, including nucleoside-derived drugs (Pastor-Anglada et al. 2004, 
Fernández-Calotti et al. 2011). On the other hand, NTs expression in MM cells has been less studied. 
Interestingly, AICAR entrance to a MM cell line (U266) could be inhibited by NBTI (Baumann et al. 
2007), showing that at least NBTI-sensitive transporters are expressed. Uridine and thymidine can 
enter to the cell through both CNTs and ENTs (Young et al. 2013), while AICAR is mainly 
transported through ENTs (Campàs et al. 2003). As ENTs function according to the concentration 
of nucleosides at both sides of the membrane, addition of high doses of pyrimidines might saturate 
the NTs and thus block AICAR entrance to the cell. Considering that the cytotoxic activity of 
AICAR relies on its uptake (Campàs et al. 2003), it is conceivable that impaired uptake after 
pyrimidine addition may significantly modulate intracellular AICAR bioavailability, and therefore, its 
pro-apoptotic capacity. In agreement with this hypothesis, thymidine completely inhibited AICAR-
induced acetyl-CoA carboxylase (ACC) phosphorylation and apoptosis at any of the time points that 
were studied, suggesting that it was blocking AICAR uptake. Bardeleben and collegues did not check 
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whether addition of pyrimidines was blocking AICAR entrance to the MM cells. Hence, it cannot be 
discarded that the rescue observed after pyrimidine addition in MM cells is caused by an impairement 
of AICAR uptake. 
Strikingly, uridine delayed ACC phosphorylation in CLL cells, suggesting that it was somehow 
impairing AICAR entrance but not totally blocking it. Uridine is an intermediate in the de novo 
synthesis pathway of pyrimidines, which can be subsequently modified to generate UMP, TMP or 
CMP. Thus, addition of uridine alone may be able to counteract AICAR-induced pyrimidine 
starvation. Accordingly, patients with deficiencies in UMPS can be bypassed by treatment with 
uridine (Balasubramaniam et al. 2014).  
Cytidine is incorporated to pyrimidine metabolism through deamination to uridine, a reaction carried 
out by cytidine deaminase. Therefore, cytidine could theoretically generate CMP, UMP and TMP and 
rescue AICAR-induced pyrimidine starvation as effectively as uridine does. Nevertheless, addition of 
cytidine did not inhibit AICAR-induced apoptosis in CLL cells. In fact, we observed that addition of 
cytidine was increasing the apoptosis induced after treatment with 2 mM AICAR. One possible cause 
of this effect is that CLL cells may have impaired cytidine deaminase activity, being unable to use 
cytidine for the rescue of AICAR-induced apoptosis. Excessive cytidine along with inhibition of de 
novo pyrimidine synthesis was reported to enhance cell death due to an unbalanced ratio between CTP 
and UTP (Chan and Howell 1989), which could explain the enhanced pro-apoptotic effects that we 
observed. 
Other discrepancies have been observed comparing AICAR mechanism of action in CLL cells and 
MM cells. Adenosine abolished AICAR-mediated apoptosis in CLL cells (Campàs et al. 2003), but did 
not block it in MM cells (Bardeleben et al. 2013). In addition, treatment with AICAR results in the 
accumulation of ZMP and the consequent phosphorylation of AMPK and ACC in CLL cells 
(Campàs et al. 2003, Campàs 2004), though neither ZMP accumulation nor AMPK phosphorylation 
were observed upon AICAR treatment in two MM cell lines (Bardeleben et al. 2013). 
RPMI 8226 cells were used as a control for our experiments, as it is a MM cell line that was studied 
by Bardeleben and collegues. Nevertheless, the percentage of apoptotic cells varied largely between 
the two groups. One could think that the differences could be attributed to the viability assay 
(measure of active caspase 3 versus phosphatidylserine exposure). Nevertheless, another manuscript 
reported a percentage of annexin V-positive cells similar to Bardeleben (Baumann et al. 2007). Hence, 
it is possible that RPMI 8226 clones have evolved differently and now show different responses to 
AICAR.  
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All in all, it is obvious that AICAR induces apoptosis in MM and CLL cells through very distinct 
mechanisms, which could explain that addition of pyrimidines have different effects on AICAR pro-
apoptotic effects depending on the cell type analyzed. 
 
REACTIVE OXYGEN SPECIES PRODUCTION IN AICAR-TREATED CLL CELLS 
AICAR is an intermediate metabolite of the purine catabolism. Xanthine oxidase is involved in the 
last two steps, catalyzing hypoxanthine to xanthine and further to uric acid; generating reactive 
oxygen species (ROS). Allopurinol and febuxostat, two xanthine oxidase inhibitors, partially reverted 
AICAR-induced apoptosis and ROS production in CLL cells (González-Gironès 2012). Nevertheless, 
here we show that the generation of ROS is a caspase-dependent event, which discards it as a putative 
cause of induction of apoptosis. Xanthine oxidase inhibitors decreased ZMP accumulation and 
partially reverted ATP depletion induced by AICAR in CLL cells through an unknown mechanism 
(González-Gironès 2012). As ZMP accumulation is essential for AICAR-induced apoptosis (Campàs 
et al. 2003), it is conceivable that allopurinol and febuxostat abrogate the pro-apoptotic effects of 
AICAR by inhibiting the alterations in the nucleotide pool. 
 
Taking our results together with the previous findings, we propose the following mechanism of 
apoptosis induction by AICAR (Fig. D.1). AICAR enters the cell through NBTI-sensitive 
transporters and is phosphorylated to ZMP by adenosine kinase. Through an unknown mechanism, 
BIM and NOXA are upregulated, which results in the release of cytochrome c to the cytosol and the 
subsequent induction of caspase-mediated apoptosis.ROS are produced as a consequence of caspase 
activation. The accumulation of ZMP leads to AMPK activation, though this event is not required for 
AICAR-induced apoptosis. In fact, AMPK seems to counteract the pro-apoptotic effects of AICAR. 
In addition, the mutational status of p53 and ATM does not influence the pro-apoptotic activity of 
AICAR. 
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Figure D.1. Proposed mechanism of action of AICAR. ROS, reactive oxygen species. Caspase-dependent events 
are indicated in dashed arrows. 
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2. FLUORIZOLINE REQUIRES PROHIBITINS TO TRIGGER THE 
MITOCHONDRIAL APOPTOTIC PATHWAY 
OPA1 PROCESSING UPON FLUORIZOLINE TREATMENT 
Loss of prohibitins (PHBs) was reported to induce optic atrophy 1 (OPA1) processing, fragmentation 
of the mitochondrial network and cristae disorganization. These defects are caused by the loss of L-
OPA1, as reexpression of a non-cleavable form of L-OPA reverts the phenotype (Merkwirth et al. 
2008). In the same line, downregulation of OPA1 induces mitochondrial fragmentation and 
disorganization of the cristae (Olichon et al. 2003, Arnoult et al. 2005, Ishihara et al. 2006, Frezza et 
al. 2006). Interestingly, HeLa cells treated with fluorizoline also showed disappearance of L-OPA1, 
fragmentation of the mitochondrial network and cristae remodelling (Pérez-Perarnau 2013). This 
suggested that fluorizoline-induced apoptosis was indeed mediated by PHBs. OPA1 is known to have 
a crucial role in the maintenance of cristae structure in the inner mitochondrial membrane (IMM), 
where most of the cytochrome c resides. Upon treatment with various apoptotic stimuli, OPA1 
complexes are disassembled (Frezza et al. 2006, Landes et al. 2010, Jiang et al. 2014), a step that is 
required for the reorganization of the mitochondrial cristae and the release of cytochrome c to the 
intermembrane space (Yamaguchi et al. 2008). Thus, bearing in mind the link between OPA1 and the 
induction of apoptosis, it was conceivable that other pro-apoptotic insults were also affecting OPA1 
protein levels. Indeed, we observed that not only fluorizoline, but also ActD, STS and capsaicin 
induced the loss of L-OPA1. Importantly, inhibition of caspase activation blocked ActD- and 
fluorizoline-induced phosphatidylserine exposure but not the loss of L-OPA1, showing that it is an 
apoptotic event occurring upstream of caspase activation. These findings are in agreement with other 
reports describing OPA1 processing after treatment with various pro-apoptotic stimuli (Alaimo et al. 
2014, Jiang et al. 2014), which could not be inhibited by the presence of the broad caspase inhibitor z-
VAD.fmk (Ishihara et al. 2006). Along this line, BIM-induced apoptosis led to the disassembly OPA1 
complexes and the release of OPA1 from the mitochondria, without requiring the activation of the 
caspases (Yamaguchi et al. 2008). 
It is worth mentioning that various stresses, such as loss of membrane potential or heat stress, induce 
OPA1 processing and mitochondrial network fragmentation. Nevertheless, cytochrome c remains in 
the mitochondria, since the mitochondrial outer membrane remains intact (Duvezin-Caubet et al. 
2006, Griparic et al. 2007, Baker et al. 2014). Hence, OPA1 processing does not always correlate with 
apoptosis induction; though apoptosis induction seems to imply OPA1 processing. 
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All in all, OPA1 processing cannot be only understood as a direct indicator of loss of PHBs 
functions, as other pro-apoptotic stimuli and stresses also result in the loss of L-OPA1. Therefore, it 
is not a valid proof-of-concept to demonstrate that fluorizoline induces apoptosis by targeting PHBs. 
 
FLUORIZOLINE REQUIRES PROHIBITINS TO INDUCE APOPTOSIS 
We sought to use another strategy in order to analyze whether PHBs were required for fluorizoline-
induced apoptosis. Downregulation of PHBs in HeLa cells resulted in cell detachment without 
reduction in viability (Pérez-Perarnau 2013), in line with previous reports showing altered phenotypes 
upon loss of PHBs in HeLa cells (Rajalingam et al. 2005, Kasashima et al. 2006, Sievers et al. 2010, 
Sato et al. 2011). Consequently, we moved to Phb2fl/fl MEFs model, as it was reported that loss of 
PHBs blocked cell proliferation without inducing apoptosis (Merkwirth et al. 2008). We proved that 
PHBs mediate the pro-apoptotic effects of fluorizoline using two different approaches. First, Phb2 
was depleted by Cre recombinase transduction in Phb2fl/fl MEFs; and second, Phb2 levels were 
downregulated by siRNA transfection in MEFs. In both cases, loss of PHBs conferred strong 
resistance to fluorizoline. Therefore, fluorizoline is as a new synthetic agent that reduces cell viability 
by specifically targeting PHBs.  
We tried to carry out a genetic rescue by using two different cell lines that re-express PHB2. 
Nevertheless, their sensitivity to various apoptotic insults was lower than WT and Phb2fl/fl MEFs. This 
ruled them out as suitable genetic rescue models, as putative different sensitivity to fluorizoline would 
not be caused by the distinct levels of PHBs but by intrinsic resistance to pro-apoptotic stimuli. 
PHBs have a key role in maintaining mitochondrial homeostasis. High expression of PHBs has been 
found in cells which heavily depend on mitochondrial function, notably proliferating cells. It is 
conceivable that these cells may be particularly susceptible to the lack of functional PHBs (Artal-Sanz 
and Tavernarakis 2009). In fact, downregulation of PHBs in various cell lines was reported to block 
cell proliferation (Merkwirth et al. 2008, Sievers et al. 2010, Jiang et al. 2015) as well as to induce 
apoptosis (Kasashima et al. 2006, Sánchez-Quiles et al. 2010, Kowno et al. 2014). Overexpression of 
PHBs protects cells from apoptosis induced by different stimuli (Fusaro et al. 2002, Zhou et al. 
2013a, 2013b, Thuaud et al. 2013, Chowdhury et al. 2013, Han et al. 2014, Wang et al. 2014), 
consistent with the cytoprotective role of PHB1 (Thuaud et al. 2013). PHBs exert their anti-apoptotic 
function via OPA1 in MEFs, as the increased sensitivity to apoptosis observed in the absence of 
PHBs can be counteracted by re-expression of a non-cleavable variant of OPA1 (Merkwirth et al. 
2008). In addition, it was reported that PHBs overexpression inhibited apoptosis through the 
induction of BCL-2 and BCL-XL (Chowdhury et al. 2013), and downregulation of PHBs reduced 
BCL-XL levels (Sripathi et al. 2011).  
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Importantly, PHBs therapeutic potential has been extensively discussed by many authors (Mishra et 
al. 2005, Thuaud et al. 2013). PHBs play a key role in regulating a diverse array of physiological 
processes and are amenable to modulation with small molecules. Hence, targeting PHBs would be a 
useful therapeutic approach for the treatment of a variety of diseases. In cancer, although some 
reports point to an anti-tumorigenic role of PHBs, most of the current data link PHBs to tumor 
development (Theiss and Sitaraman 2011, Thuaud et al. 2013, Han et al. 2014, Jiang et al. 2015, Ho et 
al. 2015). Fluorizoline was able to induce apoptosis in a wide range of cancer cell lines, including 
glioma or prostate cell lines (Pérez-Perarnau et al. 2014), in which PHBs were reported to be anti-
tumorigenic (Dart et al. 2012, Qian et al. 2013). Considering the pro-apoptotic capacity of 
fluorizoline, this new agent with fluorinated thiazoline scaffold emerges as a potential new strategy 
for cancer treatment. 
Stomatin-like protein 2 (SLP-2) is a member of the stomatin-prohibitin-flotilin-HflC/K (SPFH) 
superfamily. In the IMM, SLP-2 binds to cardiolipin and PHBs, forming membrane microdomains 
that facilitate mitochondrial biogenesis and function (Da Cruz et al. 2008, Christie et al. 2011). We 
observed that the loss of SLP-2 does not confer resistance to fluorizoline treatment. It was reported 
that shRNA-mediated downregulation of SLP-2 leads to a reduction of PHB1 protein levels, 
suggesting that SLP-2 is crucial for the stability of PHB1 (Da Cruz et al. 2008). However, PHBs 
protein levels in SLP-2 KO (SKO) MEFs were assessed by western blot by Hans Georg Sprenger 
(Dr. Langer’s group) and no differences were found between Phb2fl/fl and SKO MEFs. Accordingly, 
total protein levels of PHB and the assembly of PHB complexes were not affected in T cells lacking 
SLP-2, although the compartmentalization of these proteins within the cell was abnormal (Christie et 
al. 2012, Mitsopoulos et al. 2015). Regardless of this controversy, SKO MEFs were sensitive to the 
pro-apoptotic effects of fluorizoline, proving that SLP-2 is not required for fluorizoline-induced 
apoptosis. 
 
PROHIBITINS COMPLEXES IN THE INNER MITOCHONDRIAL MEMBRANE 
It was reported that Phb2-/- MEFs have impaired cell proliferation (Merkwirth et al. 2008). 
Nevertheless, we observed some cell proliferation in Phb2-/- MEFs and therefore we tried to generate 
a stable Phb2-/- cell line. Among 83 clones that were analyzed, none of them presented both Phb2 
alleles depleted. As PHBs are crucial for cell proliferation, the absence of Phb2-/- clones may be due to 
their reduced proliferation rate. Those cells with PHBs grow faster, while the Phb2-depleted clones 
have a clear disadvantage and grow more slowly. This is in agreement with a previous report in which 
shRNA-mediated PHB1 silencing was performed in various cancer cell lines. Prolonged culture of 
these cells led to a loss of shRNA-expressing cells, which was not due to increased apoptosis of this 
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population but due to faster growth of the non-transduced one (Sievers et al. 2010). A high 
percentage of the analyzed clones were heterozygous (Phb2fl/-), and we further studied their response 
to fluorizoline compared to homozygous clones (Phb2fl/fl). Interestingly, the heterozygous clones had 
lower protein levels of PHB 1 and 2, which were not enough to maintain the balance of L-OPA1 and 
S-OPA1 forms. However, the heterozygous and homozygous clones displayed similar sensitivity to 
fluorizoline-induced apoptosis. 
PHBs are found in very large complexes that presumably act as lipid and protein scaffolds, creating 
functional microdomains within the IMM. These platforms may be limiting the access of proteases to 
their substrates (Osman et al. 2009b, McBride and Soubannier 2010). OMA1 is a protease that cleaves 
OPA1 upon loss of membrane potential, heat stress or apoptosis induction (McBride and Soubannier 
2010, Zhang et al. 2014, Richter-Dennerlein et al. 2014, Jiang et al. 2014). Importantly, 
downregulation of PHBs reduces L-OPA1 levels in HEK293 cells, which are restored through 
OMA1 downregulation (Richter-Dennerlein et al. 2014). These results suggest that OMA1 is the 
protease responsible for OPA1 processing upon loss of PHBs (Fig. D.2). 
 
Figure D.2. Model of PHBs microdomains in the IMM that may control OPA1 processing. PHBs 
supercomplexes would form a microdomain sequestring OMA1 from OPA1. Mitochondrial dysfunction, loss of 
PHBs or pro-apoptotic stimuli would lead to the destabilization and/or disassembly of these platforms, allowing 
OMA1 to access OPA1 and accelerate processing of L-OPA1 to S-OPA1 forms. Adapted from McBride and 
Soubannier 2010. 
 
In Phb2fl/- MEFs, the reduced protein levels of PHBs may lead to the disruption of the microdomains 
in the IMM, allowing OMA1 to reach and cleave OPA1. The fact that fluorizoline is still capable of 
inducing apoptosis in Phb2fl/- MEFs suggests that its mechanism of action may not be based on the 
disruption of PHBs megacomplexes in the IMM. 
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Accordingly, BN-PAGE analysis revealed that PHBs complex and prohibitin/mAAA protease 
(PMA) supercomplexes are maintained in spite of fluorizoline treatment. In addition, western blot 
analyses show stable steady state levels of PHBs even after incubation with fluorizoline. The loss of 
either PHB1 or PHB2 might destabilize PHBs mitochondrial complex, leading to the activation of 
quality control mechanisms which would degrade the other partner (Browman et al. 2007, Osman et 
al. 2009b). Therefore, all these results suggest that fluorizoline may not be inducing apoptosis by 
massively affecting the assembly of PHBs complex and PMA supercomplexes.  
Of note, PHBs complexes have a huge molecular weight. Subtle changes in the composition of the 
complexes, e.g. loss or incorporation of small proteins, would not be detected by BN-PAGE. One 
possible mechanism of action of fluorizoline is affecting the specific binding of PHBs to other 
interacting partners, without grossly altering the complexes in the IMM. Thus, further experiments 
would be necessary to characterize more precisely fluorizoline-induced changes in PHBs complexes. 
In this sense, Phb2fl/fl::CNAP-Phb2 MEFs could be a very useful tool to study PHBs interactome in 
the presence or absence of fluorizoline.  
The proposed scaffold function of PHBs in the IMM contributes to the homeostasis of different 
phospholipids (Osman et al. 2009b, Richter-Dennerlein et al. 2014). Downregulation of PHBs in 
HEK293 cells resulted in a decrease in the amounts of cardiolipin (CL) and 
phosphatidylethanolamine (PEA) as well as an increase in phosphatidylinositol (PIN). Furthermore, 
PEA, CL, PIN, phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidic acid (PA), and 
phosphatidylglycerol (PG) showed longer and less saturated acyl chains in PHB-depleted cells 
(Richter-Dennerlein et al. 2014). Our analysis of the phospholipid composition of fluorizoline-treated 
or Cre-transduced Phb2fl/fl MEFs did not reveal major changes. Fluorizoline slightly increased the 
length of PEA and PC acyl chains but slightly decreased CL acyl chain length. Cre-mediated loss of 
PHBs increased PEA content as well as length and double bonds of PIN acyl chain length. 
There is an obvious disagreement between the reported alterations in the phospholipidome and our 
results. There are several experimental differences that could explain this incoherence: the analyzed 
cell line (human HEK293 versus MEFs), the technique used for reducing PHBs levels (siRNA 
transfection versus Cre recombinase transduction) and the analyzed cellular fraction (isolated 
mitochondria versus whole cell extract). 
Taken together, the sensitivity to fluorizoline of clones that cannot maintain L-OPA1 forms, the 
proper assembly of PHBs complex and PMA and the unaltered phospholipidome upon fluorizoline 
treatment strongly suggest that fluorizoline does not induce apoptosis by massively affecting the 
assembly PHBs complexes in the IMM. 
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PROHIBITINS MEDIATE FLUORIZOLINE-INDUCED CHANGES IN THE 
EXPRESSION OF BCL-2 FAMILY MEMBERS 
Treatment with fluorizoline induced changes in the mRNA expression of various BCL-2 family 
members in Phb2fl/fl MEFs, including Bim and Noxa mRNA levels. Importantly, these changes 
required the presence of PHBs, which proves that PHBs mediate fluorizoline-induced transcriptional 
modulations. Accordingly, BIM protein levels were increased in WT and Phb2fl/fl MEFs, while loss of 
PHBs blocked it in Phb2-/- MEFs. Noxa mRNA levels were significantly modulated upon fluorizoline 
treatment, though their protein levels could not be detected due to lack of proper antibodies. 
Therefore, we moved to HeLa cells as there are more available antibodies detecting human BCL-2 
family proteins. Treatment with fluorizoline upregulated BIM and NOXA mRNA and protein levels, 
in a time- and dose-dependent manner. Interestingly, protein increases preceded caspase activation, 
which could explain the apoptotic outcome. In contrast, caspase activation was required for 
fluorizoline-induced decreases in MCL-1 and PUMA protein levels, consistent with their known 
caspase-dependent proteolysis (Herrant et al. 2002, 2004, Hadji et al. 2010). 
In addition to their role in mitochondria, PHBs also localize in other cellular compartments, including 
the nucleus and the plasma membrane, in a wide range of cell types (Mishra et al. 2010, Thuaud et al. 
2013). In the plasma membrane, PHBs have been involved in the activation of the signaling pathways 
Ras-Raf-MAPK and the tyrosine kinase Syk (Rajalingam et al. 2005, Chiu et al. 2013, Kim et al. 2013, 
Chowdhury et al. 2014). In the nucleus, PHBs were reported to regulate the activity of various 
transcription factors such as p53, E2F1, and estrogen receptor (Thuaud et al. 2013). Whether the 
fluorizoline-induced transcriptional modulations are directly mediated by nuclear PHBs or indirectly 
mediated by PHBs in other cellular compartments requires further analysis. 
Other members of our group (Dr. Pérez Perarnau, José Saura and Sonia Núñez) analyzed the 
response to fluorizoline treatment of MEF and HeLa cells lacking Bim and Noxa, observing cell type 
differences. BIM and NOXA played a key role in fluorizoline-induced apoptosis in MEFs, while 
NOXA had a major role in HeLa cells. This is in agreement with the reported differences in the 
apoptotic potential of NOXA depending on the cell type (Ploner et al. 2008). Specifically, NOXA 
overexpression induced significant apoptosis in HeLa cells (Oda et al. 2000), but in MEFs it proved 
to be poorly apoptotic (Chen et al. 2005, Shibue et al. 2006). Fluorizoline-induced increases in 
NOXA mRNA levels were observed in 10 cancer cell lines from various tissues, including cervix, 
hematopoietic system or brain (Pérez-Perarnau 2013). This argues in favor of a major role of NOXA 
in fluorizoline-induced apoptosis, while other BCL-2 family members may also contribute to 
apoptosis induction in certain cell types. Further experiments are aimed at characterizing the 
mechanism by which fluorizoline upregulates Noxa. As mentioned before, Noxa expression is 
regulated by several transcription factors, including p73, HIF1α, E2F-1, CRE-binding proteins and 
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SP-1 (Nikiforov et al. 2007, Ploner et al. 2008, Grande et al. 2012). In MEFs, E2F-1 emerges as an 
interesting protein to analyze, as it is the transcription factor that regulates both Noxa and Bim (Piñon 
et al. 2008, Ploner et al. 2008). 
 
Taken together, these findings show that PHBs are required for fluorizoline-induced apoptosis. PHBs 
mediate the upregulation of Noxa and Bim, which are crucial for the pro-apoptotic effects of 
fluorizoline. Moreover, our findings demonstrate that PHBs are amenable to modulation with small 
molecules to ultimately induce apoptosis, and thus further contribute to highlight the suitability of 
PHBs as promising therapeutic targets for cancer treatment. 
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1. AICAR triggers ZMP-dependent but p53- and AMPK-independent apoptosis in MEFs. This 
mechanism is highly similar to the effects observed in CLL cells, and thus MEFs emerge as an 
alternative cellular system for the elucidation of the mechanism of apoptosis induction by AICAR.  
2. Addition of thymidine and uridine blocks AICAR-induced apoptosis, presumably by preventing 
AICAR entrance into the cell. 
3. Generation of ROS in AICAR-treated CLL cells is a caspase-dependent event and thus it is 
discarded as the responsible for the pro-apoptotic effects of this compound. 
4. Fluorizoline requires the presence of prohibitins to trigger the mitochondrial apoptotic pathway. 
Prohibitins mediate fluorizoline-induced changes in the expression of various BCL-2 family members, 
notably increases in Bim and Noxa. 
5. Fluorizoline and other pro-apoptotic stimuli trigger the loss of L-OPA1 upstream of caspases 
activation. This event is not a valid proof-of-concept to demonstrate that fluorizoline induces 
apoptosis by targeting prohibitins. 
6. Prohibitin complexes in the inner mitochondrial membrane and the phospholipid composition are 
not grossly altered upon fluorizoline treatment. 
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1. SAMPLES COLLECTION FROM CLL PATIENTS 
Chronic lymphocytic leukemia (CLL) patients were diagnosed by clinicians at the Hospital 
Universitari de Bellvitge following clinical, morphological, molecular, and immunophenotypic criteria, 
as proposed by the World Health Organization. Peripheral blood samples of CLL patients were 
collected in Servei d'Hematologia of Hospital Universitari de Bellvitge in tubes with anticoagulant 
EDTA. The information of the sample was collected in an internal database which scored diagnosis, 
date of collection, lymphocyte count and percentage of lymphocytes, as well as any information of 
interest, such as genetic anomalies, aggressiveness, treatment or chemoresistance. Each sample and 
each patient was assigned with an identification number, which was linked to the clinical history 
number given by Institut Català de la Salut. In addition, the database informs whether there are 
cryopreserved samples. We do not include any personal patient information as it is established by 
Universitat de Barcelona and Hospital de Bellvitge Ethical Committees. Written informed consent 
was obtained from all patients in accordance with Hospital de Bellvitge Ethical Committee. 
 
2. MONONUCLEAR CELLS ISOLATION FROM PERIPHERAL BLOOD OF CLL 
PATIENTS 
Mononuclear cells from peripheral blood samples were isolated by centrifugation on a Ficoll-
Hypaque (Seromed) gradient (Fig. M.1). Blood was diluted in phosphate buffered saline (PBS) to a 
final volume of 8 mL. This mixture was gently added above 4 mL of Ficoll solution (density = 1.077 
g/mL) trying to maintain the interface. The preparation was centrifuged for 20 min at 850 g at room 
temperature (RT). The centrifuge stop was conducted without brake to avoid breaking the gradient. 
In the resulting separation, erythrocytes and polimorphonucleated leukocytes are at the bottom of the 
tube due to their higher density; mononuclear cells form a ring above Ficoll, and plasma and platelets 
remain at the top, diluted in PBS. The ring of mononuclear cells was collected with a glass Pasteur 
pipette and deposited on 40 mL of PBS. A wash centrifugation was performed for 10 min at 480 g at 
RT and cell count was performed. Pellets were resuspended in complete medium and viability and 
percentage of B and T cells were analyzed by flow cytometry (see section 7). If the percentage of B 
cells was higher than 75%, samples were used to perform RNA and protein extractions, as well as 
annexin V and propidium iodide (PI) double staining viability analyses. If the percentage was below 
75%, samples were only used for viability analyses by triple staining with anti-CD19 antibody (for B 
cells), anti-CD3 antibody (for T cells) and annexin V. Cells were used right after the purification or 
cells were cryopreserved for later use. Table M.1 summarizes the characteristics of the CLL samples 
that were used. 
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Figure M.1. Purification of mononuclear cells from peripheral blood and ex vivo culture. 
Polymorphonucleated cells (PMN). Taken from Pérez-Perarnau 2013. 
  
 
Patient Sample Gender Date WBC % L % B % T Cytogenetics 
69 55/08 F 27/03/2008 65,3 88 87.37 3.96 ND 
108 56/13 M 02/10/2013 314 75 94.52 1.88 Normal 
188 124/08 F 19/09/2008 87,7 89 91.67 5.16 Normal 
320 192/05 M 14/10/2005 129 92 93.64 1.83 Del13q 20% 
342 27/11 F 21/11/2011 21,9 89 72.24 4.92 ND 
414 47/05 F 01/04/2005 111 93 93.04 3.33 Del 17p 
432 127/08 M 25/09/2008 52,2 91 85.81 4.18 ND 
815 1/13 M 28/01/2013 69 95 95.91 1.22 Del 13q11q 
818 15/11 F 16/06/2011 90,5 95 78.88 5.49 ND 
866 71/13 M 28/10/2013 77,8 87 73.36 10.48 ND 
884 94/13 F 12/12/2013 62 81 72.31 10 ND 
Table M.1. Characteristics of the samples of CLL patients. Female (F), male (M), date indicates the day of 
sample collection, white blood cell (WBC) count (109/L), percentage of lymphocytes (% L), percentage of B cells (% 
B), percentage of T cells (% T), not determined (ND), deletion (del). Genomic alterations were determined by 
fluorescent in situ hybridization or by multiplex ligation-dependent probe amplification for genomic alterations. 
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3. CELL LINES 
- WT mouse embryonic fibroblasts (MEFs) were generated at Dr. Korsmeyer’s laboratory (Wei et al. 
2001), kindly provided by Dr. Jacint Boix (Universitat de Lleida) or by Dr. Cristina Muñoz 
(IDIBELL, Barcelona). The former were used in Figures 1.1, 1.3, 1.4, 1.5, 1.7 and 1.8; and the latter 
were used in Figure 1.8.  
- WT and Ampkα1-/-/Ampkα2-/- (DKO) MEFs were provided by Dr. Benoit Viollet’s laboratory 
(Laderoute et al. 2006), and by Dr. Aramburu (Universitat Pompeu Fabra, Barcelona). 
- WT and Puma-/- MEFs were a kind gift of Dr. Andreas Villunger (Medical University Innsbruck, 
Austria).  
- p53-/- MEFs were a kind gift of Dr. Guillermina Lozano (McMasters et al. 1996).  
- WT, Phb2fl/fl, Phb2fl/fl::Phb2, Phb2fl/fl::CNAP-Phb2 and SLP-2 KO (SKO) MEFs were kindly provided 
by Dr. Thomas Langer (Institute for Genetics, CECAD, Cologne, Germany) (Merkwirth et al. 2008, 
Richter-Dennerlein et al. 2014). 
- HeLa cells: epithelial cell line derived from human cervix adenocarcinoma. It was supplied by the 
European Collection of Cell Culture.  
 
4. CELL CULTURE 
CLL cells were cultured at a concentration of 0.5 to 4x106 cells/mL in RPMI 1640 culture medium 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL 
penicillin, and 100 ng/mL streptomycin (all from Biological Industries). 
MEF and HeLa cells were cultured in DMEM (Biological Industries) supplemented with 10% FBS, 2 
mM L-glutamine, 100 U/mL penicillin, and 100 ng/mL streptomycin. Growing cells were not 
maintained for more than 1-2 months since many lines easily mutate in culture, being genetically 
unstable and changing their characteristics after several passages. 
Manipulation of the human primary samples was carried out in a flow laminar cabin of biosafety stage 
IIA, whereas cell lines were manipulated in a vertical laminar flow bench with an HEPA filter. CLL 
cells were grown in incubators for exclusive use for primary cells of human origin, and cell lines were 
grown in incubators only used for human or mouse cell lines, at 37ºC in a humidiﬁed atmosphere 
containing 5% carbon dioxide. 
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5. DETECTION OF MYCOPLASMA 
Mycoplasma is a prokaryotic organism that is a frequent and occult contaminant of cell cultures. 
Mycoplasma lacks a cell wall and thus it is unaffected by common antibiotics. This organism can 
modify many aspects of cell physiology, so the results obtained with contaminated cells may not be 
trustful (Young et al. 2010, Geraghty et al. 2014). All new cell lines entering to the laboratory were 
tested for the presence of mycoplasma by PCR or by DAPI staining. 
 
5.1. PCR-BASED DETECTION OF MYCOPLASMA  
Protocol 
Grow the cells for 5-7 days in a 60 mm plate in antibiotic-free medium. Get 1.5 mL of the medium 
and centrifuge at 300 g for 10 min at 4ºC. Transfer the supernatant to a new sterile tube and 
centrifuge at 13,000 g for 10 min at 4ºC. Remove the supernatant, resuspend the pellet with 50 µL of 
sterile H2O and heat at 95ºC for 10 min. Samples can be immediately used or frozen for later analysis. 
The PCR analysis was performed by the responsible of the cell cultures. PCR conditions: 95ºC, 5 min. 
[94ºC, 1 min. 60ºC, 1 min. 72ºC, 1 min 30 s.] 30-35 cycles. 72ºC, 7 min. 4ºC, ∞. 
 
5.2. DAPI STAINING 
Protocol 
Grow the cells on a sterile glass coverslip in antibiotic-free medium for 2 days. Remove the cell 
culture medium and incubate cells for 15 min with 4% paraformaldehid at RT. Wash the cells twice 
with PBS. Incubate cells with DAPI solution for 5 min. Wash the cells 2-3 times with PBS. Carefully 
remove the coverslips from the wells and blot to remove any excess water. Dispense 1 drop of anti-
fade mounting medium (ProLongTM Gold Antifade Mountant, Life Technologies) onto the 
microscope slide per coverslip. Mount the coverslip with the cells facing towards the microscope 
slide. Visualize using a fluorescence microscope (e.g. Nikon Eclipse E800).  
In case contamination was observed, cells were cultured in isolated laminar cabin and incubator to 
avoid cross-contamination to other cell lines. For decontamination, cells were treated with 1:100 or 
1:200 Baycip® Ótico (Ciprofloxacin, Bayer. 1 mg/0.5 mL) for three weeks and then Mycoplasma 
detection test was repeated to confirm the decontamination. 
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6. FREEZING AND THAWING CELLS 
Cryopreservation allows the storage of cells for later use as they maintain their characteristics and 
viability. Regarding cell lines, it is recommended to freeze cell lines right after thawing a tube and 
expanding the line in order to avoid changes occurring during the culture. The cryopreservation 
procedure is performed in cold DMSO as a membrane stabilizer. 
Protocol for cryopreserving primary CLL cells 
Resuspend the pellet of mononuclear cells in cold FBS (previously inactivated by heat for 30 min at 
56°C) so that there are 20-30x106 cells/0.75 mL FBS/tube. Maintain the suspension of cells in ice. 
Add slowly an equal volume of cold cryopreservation solution, prepared with RPMI 1640, inactivated 
FBS and DMSO in ratio 3:1:1. Finally, there will be 20-30x106 cells/1.5 mL/tube in 10% DMSO. 
Get the 1.5 mL sample into 2 mL cryopreservation tubes. Keep tubes at -80ºC for 12-24 hours in an 
isopropanol freezer or in polystyrene so that temperature decreases gradually. Then, move the tubes 
into a liquid nitrogen tank.  
Protocol for cryopreserving MEF and HeLa cells 
Collect cells in exponential growth phase and pellet down by centrifugation for 5 min at 480 g. On 
the basis of a 60 cm2 confluent plate we obtain 4 tubes. Resuspend the pellet in cold FBS so that cells 
are in 0.90 mL FBS/tube. Maintain the suspension of cells in Hospital Universitari de Bellvitge zice. 
Slowly add to the previous suspension 100 µL cold DMSO/tube. Get the final 1 mL sample into 2 
mL cryopreservation tubes. Keep tubes at -80ºC for 12-24 hours in an isopropanol freezer or in 
polystyrene so that temperature decreases gradually. Then, move the tubes into a liquid nitrogen tank.  
Protocol for thawing primary CLL cells 
Place the cryopreserved tube in a bath at 37ºC unless its content is partially unfrozen. Pour the tube 
content on 40 mL of RPMI 1640 medium supplemented with 20% of inactivated FBS, previously 
heated at 37ºC, so that frozen cells thaw in a volume at least 10 times higher. Clean cells from DMSO 
by centrifugation to 480 g for 10 min. Resuspend the pellet of cells in culture medium. 
Protocol for thawing MEF and HeLa cells 
Place the cryopreserved tube in a bath at 37ºC until its content is partially unfrozen. Pour the tube 
content on 40 mL of DMEM medium supplemented with 20% FBS, previously heated at 37ºC, so 
that frozen cells thaw in a volume at least 10 times higher. Clean cells from DMSO by centrifugation 
to 480 g for 5 min. Resuspend the pellet of cells in culture medium. 
 
 122 
7. ANALYSIS OF CELL VIABILITY BY FLOW CYTOMETRY 
The cell membrane is composed of a lipid bilayer of asymmetrical distribution. Phosphatidylserine 
(PS) is a phospholipid entirely located on the inner monolayer surface of the plasma membrane. 
When a cell undergoes apoptosis, PS is no longer restricted to the cytosolic part of the membrane, 
but becomes exposed to the surface of the cell, which plays an important role in the recognition and 
removal of apoptotic cells by macrophages. The translocation of PS to the outer layer is considered 
an initial event in the apoptotic process and it has become a marker of apoptosis in mammalian cells. 
The protein annexin V binds with great affinity to PS in a calcium-dependent manner (Fig. M.2). 
Annexin V is conjugated to fluorochromes such as fluorescein isothiocyanate (FITC) or 
allophycocyanin (APC) so that cells that expose PS can be detected by flow cytometry. On the other 
hand, plasma membrane integrity is lost during advanced apoptosis and necrosis so that it becomes 
permeable to substances like propidium iodide (PI), while it is excluded by viable cells. PI is a 
fluorescent molecule that intercalates between the bases of double-stranded nucleic acid with little or 
no sequence preference. 
 
Figure M.2. Staining of apoptotic cells. Phosphatidylserine (PS) translocates to the outer layer in early-apoptotic 
cells, which is recognized by annexin V. In late-apoptotic cells, the integrity of the plasma membrane is 
compromised, allowing the entrance of propidium iodide (PI). Modified from http://www.biomol.de. 
 
In this way, cell viability was determined by measuring PS exposure and membrane integrity. This was 
determined by double staining with annexin V conjugated with a fluorochrome and PI. Flow 
cytometry analysis generally show three cell populations: one cell population which does not emit any 
fluorescence (living cells), another population positive for annexin V (cells at an early stage of 
apoptosis) and another with double positivity staining (cells at a later stage of apoptosis). These three 
populations are characteristic of a typical apoptosis. There is the possibility of the emergence of a 
fourth population only stained with PI, which defines necrosis (Fig. M.3).  
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Figure M.3. Cell viability analysis by flow cytometry with annexin V-FITC/PI staining. Cells were untreated 
(control) or treated with a pro-apoptotic compound. Cell viability was analyzed by flow cytometry using a 
FACSCalibur. Viable cells are annexin V/PI double-negative (I); early-apoptotic cells are annexin V-positive (II) and 
late-apoptotic cells are annexin V/PI double-positive (III). Adapted from Cosialls 2011. 
 
Cell viability was measured as the percentage of annexin V-FITC/PI-negative cell population, and it 
is expressed as the percentage of non-apoptotic cells. In cases where cells were treated with 
fluorizoline, we used annexin V-APC to avoid interference. Then, cell viability was measured as the 
percentage of annexin V-APC negative cell population, and it is expressed as the percentage of non-
apoptotic cells. Cell viability analysis was performed using a FACSCalibur flow cytometer (Becton 
Dickinson) and CellQuest Pro Software for data acquisition and analysis (Becton Dickinson). 
Protocol for annexin V-FITC / PI staining of CLL cells 
Incubate CLL cells with the indicated drugs for a specific period of time according to the experiment 
setup. Collect 0.25x106 cells in a flow cytometry tube on annexin-binding buffer (ABB). Wash by 
centrifugation for 10 min at 480 g. Resuspend the cell pellet in 100 µL of ABB with 1 µL annexin V-
FITC. Incubate for 20 min at RT and in the dark. Add 50 µL of ABB with PI to a final concentration 
of 0.5 µg/mL. In the flow cytometer, acquire 10,000 events (cells) and analyze the data. 
Protocol for annexin V-FITC / PI staining or annexin V-APC staining of MEFs 
Incubate cells with the indicated drugs for a specific period of time according to the experiment 
setup. Collect around 0.25x106 cells in a flow cytometry tube on ABB. Wash by centrifugation for 5 
min at 480 g. Resuspend the cell pellet in 100 µL of ABB with 4 µL annexin V-APC or -FITC. 
Incubate for 20 min at RT and in the dark. Add 100 µL of ABB (for annexin V-APC staining) or 100 
μL of ABB with PI to a final concentration of 0.5 µg/mL (for annexin V-FITC / PI staining). In the 
flow cytometer, acquire 10,000 events (cells) and analyze the data. 
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1X Annexin Binding Buffer, pH 7.4 
HEPES-NaOH 10 mM 
NaCl 140 mM 
CaCl2 2.5 mM 
Table M.2. Composition of the annexin binding buffer used for viability analysis. 
 
Purified mononuclear leukocytes contain B cells, T cells and monocytes in various proportions 
according to the patient and the stage of the disease. The annexin V/PI protocol is suitable when the 
purity of B cell population in CLL samples is above 80%. When the percentage was lower, cell 
viability of each of population was analyzed separately using specific antibodies conjugated with 
fluorochromes, which are specifically directed against surface markers. In this case, we used CD19 
conjugated with phycoerythrin (PE) for human B cells, and CD3 conjugated with APC for human T 
cells (Becton Dickinson). By adding annexin V conjugated with FITC we can determine cell viability 
of both populations without sorting (Fig. M.4). 
 
Figure M.4. Cell viability analysis with triple staining. B cells are stained with anti-CD19 antibody (R2) while T 
cells are stained with anti-CD3 (R4). R3 shows double-negative population. The addition of annexin V enables the 
measurement of cell viability of each cell population. Adapted from Cosialls 2011. 
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Protocol for triple staining with anti-CD19/anti-CD3/annexin V of CLL cells 
Incubate mononuclear cells with the indicated drugs for a specific period of time according to the 
experiment setup. Collect 0.5x106 cells in a flow cytometry tube on ABB. Wash by centrifugation for 
10 min at 480 g. Resuspend the cell pellet in 50 µL of ABB with 2 µL anti-CD19-PE (for human B 
cells) and 2 µL of anti-CD3-APC (for human T cells). Incubate for 10 min at RT and in the dark. Add 
100 µL of ABB with 1 µL annexin V-FITC. Incubate for 15 min at RT and in the dark. In the flow 
cytometer, acquire 30,000 events (cells) and analyze the data. 
 
8. NUCLEIC ACID EXTRACTION AND ANALYSIS 
8.1. MEFs GENOTYPE ANALYSIS 
Protocol 
Pellet down MEFs by centrifugation for 5 min, 1,200 rpm at 4ºC. Remove the supernatant and 
resuspend in 480 µL lysis buffer and 400 µg/mL proteinase K. Shake overnight at 1,400 rpm, at 56ºC 
at the thermal cycler. Centrifuge for 10 min, 13,000 rpm at RT to pellet unsoluble debris. Transfer the 
supernatant to a new tube and add 500 µL isopropanol to precipitate DNA. Mix gently by inverting 
the tube 6-8 times until a viscous texture can be observed, do not vortex. Centrifuge for 30 min, 
13,000 rpm at RT to pellet chromosomal DNA. Discard the supernatant and add 500 µL 70% 
ethanol. Centrifuge for 30 min, 13,000 rpm at RT to wash the pellet. Discard the ethanol completely 
with a pipette and dry the pellet for 30 min at RT under a light or at the thermal cycler at 90ºC. 
Resuspend in 100 µL H2O (DNAse free) and store at 4ºC. PCR analysis for determining the genotype 
of MEFs was performed as previously described (Merkwirth et al. 2008).  
 
DNA ISOLATION BUFFER 
  
Lysis buffer (1X) 
 
Tris 
EDTA 
Sodium dodecyl sulfate 
NaCl 
100 mM, pH=8.5 
5 mM 
0.2% 
200 mM 
Table M.3. DNA isolation buffer. 
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8.2. GENE EXPRESSION ANALYSIS 
The study of gene expression was performed using two different techniques: quantitative PCR and 
retrotranscriptase multiplex ligation-dependent probe amplification. 
 
8.2.1. RNA EXTRACTION 
Total RNA was extracted from cells by using the RNeasy Micro Kit (QIAGEN). 2-5x106 cells were 
collected for each condition. Cells were centrifuged for 5-10 min at 480 g and proceeded according to 
the manufacturer's instructions while maintaining the samples at RT (as opposed to other methods of 
purification of RNA). Total RNA samples were quantified in the Nanodrop® spectrophotometer. To 
obtain and work with RNA solutions, all material used was sterile and RNAse free. 
 
8.2.2. QUANTITATIVE REAL-TIME PCR (RT-qPCR) ANALYSIS  
cDNA quantification by real-time PCR relies on measuring the Taqman probes-derived fluorescence, 
which is proportional to the amount of sample amplified. The fluorescence increases exponentially 
until it reaches a saturation phase at the end of the reaction. During the exponential amplification 
phase, the sequence of the cDNA target doubles every cycle. A threshold for detection of cDNA-
based fluorescence is automatically set. The number of cycles at which the fluorescence exceeds the 
threshold and the exponential phase begins is called the cycle threshold, Ct. The Ct value allows to 
estimate the amount of mRNA present in our samples. The normalization procedure is commonly 
called the ΔΔCt-method and permits comparison of expression of a particular gene among different 
samples, relative to the Ct values of a housekeeping gene in the same sample. 
Protocol 
First, 0.5-2 μg of total RNA were reverse-transcribed using a Ready-To-Go You-Prime First-Strand 
Beads Kit (GE Healthcare) and Random Hexamers (Applied Biosystems). The reaction was 
performed at 37ºC for 2 hours using a thermocycler.  
RT-qPCRs were performed to measure the amount of amplified product in real time. These 
experiments were carried out using an ABI Prism 7900 HT Fast Real-Time PCR System, and pre-
designed human TaqMan assays (Applied Biosystems) were used to quantify gene expression of Bim 
(Mm00437796_m1), Noxa (Mm00451763_m1), Puma (Mm00519268_m1) and Bcl-2 
(Mm00477631_m1) according to the manufacturer’s guidelines. The housekeeping gene Gapdh 
(Mm99999915_ g1) was used as a control for RNA quality and for normalization. PCR data were 
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captured and analyzed using the Sequence Detector Software (SDS version 2.2.2, Applied 
Biosystems). Each reaction was prepared as follows (Table M.4): 
 
 
 
 
 
Table M.4. RT-qPCR reaction mix composition per well. 
 
8.2.3. RETROTRANSCRIPTASE MULTIPLEX LIGATION-DEPENDENT PROBE 
AMPLIFICATION 
RNA content was analyzed by reverse transcriptase multiplex ligation–dependent probe amplification 
(RT-MLPA) using the SALSA MLPA KIT (R011-C1 human; RM002-B1 mouse) Apoptosis mRNA 
from MRC-Holland for the simultaneous detection of 40 messenger RNA molecules (Eldering et al. 
2003). In brief, RNA samples (200 ng total RNA) were first reverse transcribed using a gene-specific 
primer mix. The resulting cDNA was annealed overnight at 60°C to the MLPA probe mix. Annealed 
oligonucleotides were ligated by adding Ligase-65 (MRC-Holland) and incubated at 54°C for 15 min. 
Ligation products were amplified by PCR (35 cycles, 30 seconds at 95°C; 30 seconds at 60°C, and 1 
minute at 72°C) with one unlabeled and one FAM labeled primer. PCR fragments were separated by 
capillary electrophoresis on a 48-capillary ABI-Prism 3730 Genetic Analyzer (Applied Biosystems). 
Peak area and height were measured using the GeneScan analysis software (Applied Biosystems) (Fig. 
M.5 and Table M.5). Housekeeping genes were not used for normalizing as they were statistically 
modulated upon AICAR and fluorizoline treatment. The sum of all peak data was set to 100% to 
normalize for fluctuations in total signal between samples, and individual peaks were calculated 
relative to the 100% value. For fluorizoline experiments, data are shown as relative expression (fold 
induction over the control), which was calculated as the mean expression of treated conditions 
referred to the mean of the untreated conditions.  
 
 
RT-qPCR 384 wells reaction mix 
Sterile ultrapure Water 8.2 μL 
Taqman Universal Master Mix 10 μL 
cDNA (50 ng) 0.8 μL 
Gene Expression Assay 1 μL 
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Figure M.5. RT-MLPA steps. Adapted from www.mlpa.com. 
 
 
HUMAN (R011-C1) MOUSE (RM002-B1) 
GENE bp GENE bp GENE bp GENE bp 
TNFRSF21  116 HIAP1 310 BOK  130 XIAP 301 
CDKN1A  130 XIAP 321 SERPINB9  136 SURVIVIN 310 
HTRA2 136 SURVIVIN 328 BCL2-W 142 NAIP 319 
BCLW 142 BRUCE 337 BCL2-X 148 LIVIN 328 
FLIP (1) 148 LIVIN 346 FLIP  154 HIAP2 337 
BCLX 154 SERPINA 355 GUSB 160 HIAP1 346 
NOXA 160 PUMA 362 BCL2 166 NOXA 355 
BCL2 166 PARN 373 BFL1 172 PUMA 364 
BFL1 172 AIF 382 MCL1 L 178 BRUCE 373 
FLIP (2) 178 MOAP1 391 BAX 184 HTRA2 382 
MCL1 L 184 GUSB 400 BAK 190 B2M 391 
B2M 193 BNIP3L 409 BCLG 196 TBP 400 
BAD 202 APAF 418 BCL2-R 202 P21 409 
BAX 211 GZMB 427 BID 211 GZMB 418 
BOK 216 PRF1 436 BAD 220 PRF1 427 
BAK 229 BNIP3 445 BIK 229 SMAC 436 
BIM 238 SMAC 454 BIM 238 PAK2 445 
BID 247 BMF 463 BMF 254   
BCL-R 256 BIK 474 HRK 252   
BCL-G 265 BOO/DIVA 481 MOAP1 265   
HRK 274 HIAP2 (2) 488 APAF 274   
NAIP 292 FAS 496 AIF 283   
HIAP2 (1) 298   BOO/DIVA 292   
 
Table M.5. List of apoptosis-related genes analyzed by human and mouse RT-MLPA. Sizes of each PCR 
product (in base pairs, bp) are indicated according to the manufacturer specifications. Adapted from www.mlpa.com. 
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9. TRANSIENT TRANSFECTION 
MEFs were transfected with scramble (12935-300) or Phb2 siRNA (MSS236022) using the 
Lipofectamine RNAiMax Reagent (all from Life Technologies). MEFs were used in experiments 72 
hours after siRNA transfection, and the efficiency of the downregulation was assessed by western 
blot. 
Protocol 
Seed MEFs in two 10 cm plates, one for scramble siRNA and the other one for Phb2 siRNA, to be 
30% confluence at transfection. Prepare the following mix for each plate: 
A) 1 mL OptiMEM + 9 μL Lipofectamine RNAiMAX 
B) 1 mL OptiMEM + 10 μL siRNA 
Incubate the mix for 5 min at RT. Add the solution B into the solution A. Incubate for 20 min at RT. 
Meanwhile, aspirate the medium from the plates and add 5 mL complete medium without antibiotics. 
Add the complexes dropwise to the cells and incubate for 24 hours. Then, wash with PBS and add 
fresh DMEM for 24 hours. Split the cells to 10 cm plates, taking into account that siPhb2-transfected 
cells grow much slower than the scramble-transfected ones. Wait 24 hours for cells to attach. 
Incubate MEFs with the indicated drugs and harvest for further analysis. 
 
10. PROTEIN ANALYSIS 
10.1. TOTAL LYSIS EXTRACTION 
Lysing cells with reducing Laemmli Sample Buffer (SB) is a quick, simple and potent denaturing lysis 
procedure. It contains 2% sodium dodecyl sulfate (SDS), which ensures the total cell lysis by 
disrupting the membrane lipid bilayer, including the nucleus that results in the extraction of genomic 
DNA. 
Protocol 
Incubate cells with the indicated drugs for a specific period of time according to the experiment 
setup. Collect cells and wash with PBS by centrifugation for 5 min at 480 g. Resuspend the pellet with 
PBS and wash it again by centrifugation for 5 min at 480 g. Add on the pellet 50-100 µL of SB buffer 
and heat samples to 95°C for 10 min. Check the efficiency of lysis by various cycles of heating, vortex 
and centrifugation to dissolve the pellet. If the lysis process is not total, freeze samples at -20°C and 
repeat the cycles of heating at 95°C for 10 min and assess whether more SB buffer is required. 
Samples can be stored frozen at -20°C. 
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10.2. RIPA EXTRACTION 
RIPA buffer enables protein extraction from cytoplasmic, membrane and nuclear proteins. Protease 
or phosphatase inhibitors have to be added right before its use. RIPA extraction has been used for 
protein analysis of phospho-AMPK or phospho-ACC in MEF and CLL cells. 
Protocol 
Incubate cells with the indicated drugs for a specific period of time according to the experiment 
setup. Collect cells and wash by centrifugation at 480 g for 5 min (MEFs) or 10 min (CLL cells). 
Discard the supernatant. Resuspend the pellet with PBS and wash again by centrifugation. Discard 
the supernatant. Resuspend the pellet with 100 μL RIPA buffer. Pipette the mixture up and down to 
suspend the pellet. Gently shake the mixture for 15 min on ice. Centrifuge the mixture at 14,000 g for 
15 min to pellet the cell debris. Transfer the supernatant to a new tube for further analysis. Store the 
cell extracts at -20°C and keep them always cold. Before loading the gel, add sufficient volume of SB 
4X to make the final concentration of SB 1X in order to get completely denaturated proteins. Once 
added, heat samples for 10 min at 95°C. 
 
10.3. PROTEIN QUANTIFICATION BY BCA ASSAY 
To analyze proteins by western blot, it is necessary to quantify the protein concentration of the 
samples in order to load the same amount of protein for each sample. Protein quantification was 
conducted with the kit Micro BCA Protein Assay Reagent (Thermo Scientific), using a plate reader of 
550 nm. This kit is based on a colorimetric quantitative determination with bicinchoninic acid (BCA) 
to detect Cu2+ reduction to Cu+ due to the basic pH of the proteins. It is compatible with the 
presence of various detergents, including 1% SDS. Two molecules of BCA chelate one Cu+ molecule 
and the resulting complex present color, which is directly proportional to the amount of protein in 
the sample. 
 
10.4. PROTEIN ANALYSIS BY WESTERN BLOT 
Western blot allows the analysis of proteins, which become separated according to their molecular 
weight. Once proteins are transferred to a membrane, protein levels can be detected by specific 
antibodies. 
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10.4.1. PROTEIN SEPARATION BY SDS-PAGE ELECTROPHORESIS 
Prepare protein extracts with the same protein amount (10-50 µg) and final volume (20-35 μL) 
according to the quantification. Add SB buffer (contains SDS detergent which denatures and 
negatively charge all proteins), 100 mM dithiothreitol (breaks disulphide bridges) and bromophenol 
blue (indicates the progress of the protein front in the electrophoresis). Heat samples for 10 min at 
95ºC to completely denature the proteins before loading on the gel. Prepare the SDS-PAGE gel. The 
gel is formed by a concentrating/stacking gel (3% acrylamide) and a separating/running part which, 
on the basis of the proteins which you want to analyze, the percentage of acrylamide can vary from 5-
15% of 37.5:1, acrilamyde:bisacrylamide. Lower molecular weight protein analysis requires higher 
percentage of acrylamide. Load the samples and the molecular weight marker. Submerge the gel in 
appropriate buckets with electrophoresis buffer and apply an electric current of 125 V. 
 
10.4.2. PROTEINS TRANSFER TO PVDF MEMBRANES 
Activate a polyvinyl difluoride (PVDF) membrane Immobilon-P (Millipore) with methanol, and 
hydrate with water. Prepare a sandwich where we place the separating gel, the membrane, and several 
drying papers, avoiding the formation of bubbles. Apply an electric current of 400 mA for 1 hour 
with transfer buffer, in cold conditions and continuous agitation to avoid excessive heating. After the 
transfer, wash the membrane with TBS-T for 5 min. 
 
10.4.3. IMMUNOBLOT 
Incubate the membrane for one hour in blocking solution (TBS-T with 5% low-fat milk) to avoid 
non-specific bindings of the primary antibody. Incubate the membranes with the primary antibody 
against the protein of interest under the conditions recommended for each case (Table M.6). Wash 3 
times for 5 min with TBS-T. Incubate for 1½ hour with the secondary antibody prepared in blocking 
solution. The secondary antibody recognizes the primary antibody constant region. Wash 3 times for 
5 min with TBS-T and the last 10 min with TBS (optional). For the detection of the secondary 
antibody, enhanced chemiluminescence solution is used. When this solution contacts with the Horse 
Raddish Peroxidase (HRP) enzyme of the secondary antibody, it gets oxidized and emits 
chemiluminescence. Acquire the data by using the Las-3000 detection system (Fujifilm). 
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Antibody Source Dilution Reference Company 
ACC-P Ser-79 Rabbit 1:1000 3661 Upstate Biotechnology 
AMPK Rabbit 1:1000 2532 Cell Signaling 
AMPK-P Thr 172 Rabbit 1:1000 2531 Cell Signaling 
BCL-2 (human) Mouse 1:1000 M0887 Dako 
BCL-2 (mouse) Rabbit 1:1000 554279 BD Biosciences 
BIM Rabbit 1:1000 2933 Cell Signaling 
Cleaved caspase 3 Rabbit 1:1000 9661 Cell Signaling 
ERK2 Mouse 1:500 1B3B9 Upstate Biotechnology 
MCL-1 Rabbit 1:1000 S-19, sc-819 Santa Cruz Biotechnology  
NOXA Mouse 1:500 Ab13654 Abcam 
OPA1 Mouse 1:1000 612607 BD Biosciences 
p21 Rabbit 1:1000 C-19, SC-397 Santa Cruz Biotechnology 
PARP Rabbit 1:1000 9542 Cell Signaling 
Prohibitin 1 Rabbit 1:1000 H-80 Santa Cruz Biotechnology 
Prohibitin 2 Rabbit 1:1000 07-234 Upstate Biotechnology 
PUMA Rabbit 1:1000 4976 Cell Signaling 
Survivin Rabbit 1:1000 2803 Cell Signaling 
Tubulin Rabbit 1:1000 CP06 Millipore – Calbiochem 
β- Actin Mouse 1:5000 A5441 Sigma-Aldrich 
Anti-rabbit IgG, 
HRP linked 
Donkey 1:5000 NA934 GE Healthcare 
Anti-mouse IgG, 
HRP linked 
Sheep 1:5000 NA931 GE Healthcare 
Table M.6. List of primary antibodies.  
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PROTEIN ANALYSIS BUFFERS   
SB (Laemmli sample buffer)  
(1X) 
Tris-HCl pH 6.8 
SDS 
Glycerol 
DTT 
80 mM 
2% 
10% 
0.1 M 
RIPA lysis buffer (1X) Tris-HCl pH 7.5 
Triton X-100 
Na3VO4 
NaF 
EDTA 
β-Glycerophosphate 
NaCl 
PMSF 
Pepstatin 
Leupeptin 
Aprotinin 
Benzamidin 
50 mM 
1% 
1 mM 
50 mM 
5 mM 
40 mM 
100 mM 
1 mM 
1 µg/mL 
1 µg/mL 
1 µg/mL 
1 mM 
Upper buffer for electrophoresis  
pH=6.8 
Tris 
SDS 
0,5 M 
0.4% 
Lower buffer for electrophoresis  
pH=8.8 
Tris 
SDS 
1.5 M 
0.4% 
Electrophoresis buffer (1X) 
pH=8.3 
 
Tris 
Glycine 
SDS 
25 mM 
192 mM 
0.1% 
Transfer buffer (1X) 
pH=8.3 
 
Tris 
Glycine 
Methanol 
25 mM 
192 mM 
10% for >30kDa proteins 
20% for <30 kDa proteins 
TBS (Tris Buffered Saline) (1X) 
pH=7.4 
Tris-HCl 
NaCl 
20 mM 
137 mM 
TBS-T 
pH=7.4  
TBS 1x   
Tween-20 
1X 
0.1% 
Blocking solution 
 
TBS-T 
Non-fat dry milk 
1X 
5% 
Loading buffer (6X) Glycerol 
Bromophenol blue 
30% 
0.25% 
Table M.7. Buffers used for protein analysis. 
 
10.4.4. TRIS-ACETATE GRADIENT GELS 
Gradient gels were used to separate and analyze proteins with very high and very low molecular 
weight in the same electrophoresis gel. The protocol was previously described by the group headed 
by Dr. Rosa, in our department (Cubillos-Rojas et al. 2010, 2012). 
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Protocol 
Prepare two solutions with different percentage of acrylamide in separated tubes (Table M.8). 
 3% 15% 
3M Tris-acetate pH 7.0 (15X) 0.4 mL 0.4 mL 
40% Acrylamide solution 0.45 mL 2.25 mL 
mQ water 5.15 mL 3.35 mL 
TOTAL VOLUME 6 mL 6 mL 
TEMED 7.5 µL 7.5 µL 
APS 10% 28.5 µL 28.5 µL 
Table M.8. Composition of the solutions for preparing tris-acetate gels. 
 
Get a gradient maker (Hoefer®) and connect it to the glass plates through a thin cannula. Place the 
gradient maker on the right height so that the solution goes into the plates in a suitable speed. Add 
the 3% acrylamide solution in the left chamber, and the 15% one in the right chamber with a 
magnetic stir bar. First open the right valve in order to allow the 15% solution reaches the bottom of 
the glass plates. Then, open the left valve so that the 3% solution gets into the right chamber. It may 
be necessary to force its entrance by applying air pressure. This step allows the mixture of the 3% 
solution with the 15% one, generating the gradient. Let the solutions get into the glass plates until the 
top of the inner one and add the comb (Fig. M.6). 
 
 
Figure M.6. Schematic representation of the preparation of a gradient gel.  
 
Load the samples and the molecular weight marker. Submerge the gel in appropriate buckets with the 
gradient electrophoresis buffer and apply an electric current of 30-40 mA/gel (125 V). Transference 
was done at 200 mA for 2 hours at 4ºC using the gradient transference buffer.  
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TRIS-ACETATE GRADIENT GELS BUFFERS 
Tris-acetate gel buffer (15X) 
pH=7, adjust with acetic acid 
Store at 4ºC 
Tris acetate 3 M 
Running buffer (1X) 
pH=8.2, not necessary to adjust 
Store at 4ºC 
Tricine 
Tris 
SDS 
Sodium bisulfite 
50 mM 
50 mM 
0.1% 
1.3 mM 
Transfer buffer (1X) 
pH=7.2, not necessary to adjust 
Store at 4ºC 
Methanol 
Bicine 
Bis-Tris 
EDTA 
Sodium bisulfite 
20% 
25 mM 
25 mM 
1 mM 
1.3 mM 
Table M.9. Buffers used for tris-acetate gradient gels. 
 
11. DETERMINATION OF INTRACELLULAR SUPEROXIDE 
Dihydroethidium (DHE, Life Techonologies) is extensively used to monitor superoxide production. 
DHE reacts with superoxide anions and forms a red fluorescent product 2-hydroxyethidium which 
intercalates with DNA. 
Protocol 
Incubate cells with the indicated drugs for a specific period of time according to the experiment 
setup. At the time of interest, collect 2.5x105 cells in flow cytometry tubes, add 2 μM DHE (make the 
dilution in PBS right before its use, trying to protect DHE from light) and incubate for 30 min at 
37ºC in the dark. Wash cells with PBS, centrifuge and resuspend in 150 µL of PBS. Analyze 10,000 
cells by flow cytometry and measure the mean fluorescence intensity. 
 
12. CRE RECOMBINASE SYNTHESIS 
Expression and purification of HTNC Cre recombinase, a fusion protein formed by Histidines for 
protein purification, TAT peptide for celular absorption, Nuclear localization signal (NLS) and the 
enzyme Cre recombinase. Its synthesis was described (Peitz et al. 2002), and the following protocol is 
based on Dr. Langer’s laboratory one. 
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12.1. HTNC EXPRESSION IN BACTERIAL CULTURE 
Pre-culture 
Add 1% glucose, 50 μg/mL carbenecillin and 34 μg/mL chloramphenicol to 250 mL lysogeny broth 
(LB). Inoculate the growing medium with bacteria from the glycerol stock (TUNER (DE3)pLacI 
E.coli transformed with HTNC plasmid, (Peitz et al. 2002)). Shake overnight at 37°C, 160 U/min. 
Expression culture 
Prepare 12 L of LB, split 2 L in 6 sterile 5 L Erlenmeyer flasks and autoclave. Add 1% sterile glucose, 
100 μg/mL ampicillin and 34 μg/mL chloramphenicol. Inoculate each flask with 40 mL (1:50) of the 
overnight culture. Shake at 37°C at 160 U/min until an OD600 of 0.8 is reached (2.5 – 3.5 h). Get 100 
µL of the culture for later electrophoresis analysis (centrifuge 5 min, 6,000 rpm and resuspend the 
pellet with 100 µL SB 1X). 
Protein expression induction 
Induce protein expression by adding 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG). After 3 
or 4 hours of incubation, get 100 µL culture for later electrophoresis analysis (centrifuge 5 min, 6,000 
rpm and resuspend the pellet with 100 µL SB 1X). Centrifuge the rest of the culture in 1 L beakers at 
6,000 g for 20 min at 4°C. Discard supernatants except 50 mL in which the pellet is resuspended by 
vortexing. Pool the suspensions and centrifuge in a 500 mL beaker (10 min, 6,000 g, 4°C in Beckman 
Avanti J-20 AP; Rotor JA10). Discard supernatant completely. Shockfreeze the beaker containing the 
cell pellet in liquid nitrogen and store at -20°C. The protocol can be stopped at this step. 
 
12.2. HTNC PURIFICATION 
HTNC purification was performed by using nickel-nitrilotriacetic acid (Ni-NTA) agarose (Qiagen), an 
affinity chromatography matrix for purifying recombinant proteins carrying a Histidine tag. Cleared 
cell lysates are loaded onto the columns, histidine residues bind to immobilized nickel ions with high 
specificity and affinity, while most of the non-tagged proteins flow through. Residual contaminants 
and unspecific bound proteins are removed by washing with buffers of slightly reduced pH or with 
buffers containing a low concentration of imidazole. His-tagged proteins are eluted by adding a 
higher concentration of imidazole, which binds with more affinity to nickel and displaces His-tagged 
proteins. 
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Lysis 
Resuspend frozen cell pellet in 10 mL lysis buffer (PTB 1X) per litre flask culture in a beaker (120 
mL). Add 1 mg lysozyme per mL suspension (120 mg), mix for 20 min at RT in a 250 mL beaker 
using a magnetic shaker. Add 120 μL benzonase (purity > 90%; Novagen) and mix for 15 min at RT 
(120 μL). 
Sonicate 2 min with 0.5 sec pulses on ice (output 8, duty cycle 50). Change to a new beaker in order 
to get rid of the bubbles. Important: Add 1 mL cold TSB buffer per mL suspension (120 mL), mix 
gently and incubate for 5 min on ice (crucial step to avoid protein precipitation in the glycerol stock).  
Distribute in 50 mL Beckman centrifuge bottles, balance them precisely and centrifuge for 30 min at 
17,000 rpm (35,000 g), at 4°C (Beckman Avanti J-20 AP; Rotor JA25.50). The supernatant contains 
the soluble fraction; and the pellet, the insoluble one. Carefully transfer cleared supernatant into a 
clean 250 mL beaker without any residuals from the pellet. Get 100 µL of the supernatant and add 
100 µL SB 2X; get pellet sample and add SB 1X; and freeze both samples.  
Purification 
Ni-NTA agarose is provided as a 50% solution. For HTNC purification, 2 mL 50% Ni-NTA agarose 
per liter expression culture are needed (in total, 24 mL). Before using it, it is necessary to equilibrate 
with lysis buffer. Get 24 mL 50% Ni-NTA agarose and centrifuge at 800 rpm for 1 min. Ni-NTA 
agarose remains at the lower fraction (12 mL), get rid of the supernatant and resuspend the agarose in 
12 mL lysis buffer. 
Get the 250 mL beaker with the supernatant and add the 24 mL of equilibrated 50% Ni-NTA 
agarose. Shake gently for 60 min at 4°C in 250 mL glass flask by using a magnetic shaker.  
The approximate volume at this point is 264 mL (120 mL PTB + 120 mL TSB + 24 mL 50% Ni-
NTA). Apply the suspension carefully onto three 10 mL columns (BioRad), 88 mL per column, and 
let it flow through by gravity. 
Next, it is necessary to wash twice in order to get rid of unspecific proteins that bound to the resin. 
The volume of washing buffer is 5X of the resin volume. We used 24 mL 50% Ni-NTA that contain 
12 mL resin, which are divided into three columns, so 4 mL resin are in each column. Thus, use 20 
mL washing buffer for each column. 
Three columns  4 mL resin/column  2 times x 20 mL wash buffer/column. 
Finally, the specific His-tagged protein that is bound to the resin has to be eluted. The volume of 
elution buffer is 3X of the resin volume. Then, use 12 mL of elution buffer per column. 
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Three columns  4 mL resin/column  12 mL elution buffer/column. 
After each washing and elution step, get 100 µL supernatant for later electrophoresis analysis, add 100 
µL SB 2X and freeze. 
Because of its high protein concentration, the solution mostly gets turbid. In this case, add some 
more elution buffer and mix gently to clear the solution. 
The Ni-NTA resin and the columns can be reused up to 6 times. Get the Ni-NTA resin that is 
stacked in the columns with a spatula, add mQ H2O (1:2 dilution, so as to have again 50% Ni-NTA 
solution) and store at 4ºC.  
 
12.3. HTNC CONCENTRATION 
HTNC stock concentration can be increased in other to minimize the total volume needed for Cre 
recombinase transduction and the imidazole content, which is important for HTNC application to 
cell cultures. To this end, the eluted protein is dialyzed in high salt buffer and glycerol salt buffer. 
Protocol 
Get a dialysis membrane (SnakeSkin Pleated Dialysis Tubing, Life Technologies), and make knot at 
one end. Add the eluted protein into the membrane and make a knot at the other end, trying to avoid 
bubbles inside. Reinforce the knots with two sealing clips. Put the high salt dialysis buffer in a 2 L 
beaker, place the dialysis membrane floating at the top and dialyze 24 hours with continuous stirring 
with a magnetic shaker at 4ºC. Remove the high salt buffer, add glycerol salt buffer and dialyze 24 
hours with continuous stirring with a magnetic shaker at 4ºC. Important: in all steps, the 
buffer/sample ratio should be at least 50. Get 100 µL of the dialyzed protein, add 100 µL SB 2X and 
freeze. 
Determine protein concentration of the dialyzed Cre protein using the Nanodrop® 
spectrophotometer (sample diluted 1:100 in PBS; blank: glycerol salt buffer diluted 1:100 in PBS). 
Measure the A260 and the A280 and calculate the protein concentration by using the Warburg formula:  
Protein concentration (µg/mL)= [ (1.55 * A280) - (0.76 * A260) ] * 100 (dilution correction) 
Molarity (µM) = concentration (mg/mL) / 0.043 
HTNC stocks can be stored at -20 or -80°C for several months without loss of activity. 
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12.4. ELECTROPHORESIS ANALYSIS OF HTNC EXPRESSION AND PURIFICATION 
Run a standard SDS electrophoresis gel (12% acrylamide) with 10 µL of all the samples obtained 
along the HTNC synthesis and purification steps. Stain the gel with Bio-Safe Coomassie (Bio-Rad) 
and discolor it with mQ water. Ideally, it should be observed that IPTG induces the expression of the 
protein (~41 kDa), soluble fraction contains the protein of interest, washing buffers do not elute big 
amounts of protein, the protein was eluted as pure as possible and it is preserved after dialysis. 
HTNC EXPRESSION BUFFERS 
LB (per 12 L) 
pH= 7.0 
Bacto-tryptone 
NaCl 
Bacto-yeast extract 
120 g 
120 g 
60 g 
HTNC PURIFICATION BUFFERS 
 
Lysis buffer (PTB) (10X) 
pH=7.8 
Prepare 250 mL PTB 1X 
NaH2PO4 · 2 H2O 
Tris 
500 mM 
50 mM 
Tartaric salt buffer (TSB) (1X) 
Prepare 120 mL freshly 
Store at 4ºC 
NaH2PO4· 2 H2O 
Tris 
Sodium tartaric dibasic 
dihydrate* 
Imidazole 
50 mM 
5 mM 
2 M 
 
20 mM 
Washing buffer (1X) 
pH=7.4 
Prepare 200 mL freshly 
Store at 4ºC 
NaH2PO4· 2 H2O 
Tris 
NaCl 
Imidazole 
50 mM 
5 mM  
500 mM 
20 mM 
Elution buffer (1X) 
pH=7.4 
Prepare 100 mL freshly 
Store at 4ºC 
NaH2PO4· 2 H2O 
Tris 
NaCl 
Imidazole 
50 mM 
5 mM 
500 mM 
250 mM 
HTNC CONCENTRATION BUFFERS 
 
High salt buffer (1X) 
pH=7.4 
Prepare 2 L the day before 
NaCl 
HEPES 
600 mM 
20 mM 
Glycerol salt buffer (1X) 
pH=7.4 
Prepare 2 L the day before 
NaCl 
HEPES 
Glycerol 
600 mM 
20 mM 
50% 
* Sodium tartaric dibasic dehydrate is soluble at 0.1 M in H2O at 20ºC. To prepare 2 M sodium tartaric salt, heat it up 
to 95ºC. Once diluted, bring it to the cold room, stir it with a magnetic shaker and add PTB and imidazole. 
Otherwise, tartaric salt precipitates. 
Table M.10. Buffers used for HTNC synthesis. 
 
PTB 1X 
PTB 1X 
PTB 1X 
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13. CRE RECOMBINASE TRANSDUCTION 
Protocol 
Day 1 
For a complete experiment including RNA, protein and viability analysis, plate MEFs at ~40% of 
density in a 15 cm plate (2x106 cells). Let them attach for 4-5 hours. The final concentration of Cre 
recombinase to be used should be determined every time that a newly synthetized Cre recombinase 
was used for the first time (see results, section 2). Dilute the amount of Cre recombinase in a 1:1 
mixture of DMEM/PBS (without FBS, P/S nor glutamine), and use 12-15 mL for a 15cm plate. 
Remove the medium from the plate, and apply Cre recombinase solution by filtering it using a syringe 
and a 0.22 µm filter and incubate for 20 hours. 
Day 2 
Remove the Cre recombinase solution and add complete medium. Let MEFs grow for 24 hours. 
Day 3 
Split the cells into 10 cm plates, so that the following day the confluence is suitable for fluorizoline 
treatment. After Cre recombinase transduction, Phb2fl/fl MEFs grow more slowly than WT MEFs due 
to the lack of PHBs. 
Days 4 and 5 
Treat cells with fluorizoline for different times according to the experiment and collect the cells in a 
suitable manner for RNA, protein and viability analysis. It is highly recommendable to have at least 
viability analysis at 24 hours as a control for fluorizoline-induced pro-apoptotic effects. 
 
14. GENERATION OF A STABLE Phb2-/- CELL LINE 
Phb2fl/fl MEFs were transduced with Cre recombinase for 20 hours and further grown for 72 hours. 
Cells in a confluent 10 cm dish were resuspended in 1 mL PBS and single cells were sorted 
individually in each well of two 96-well plate (containing 200 µL complete medium/well) by using the 
FACSAria cell sorter (Becton Dickinson). Cells were then grown for several days until they reached 
confluence. Clones were selected and split to a 24-well plate, and then to a 6-well plate. At this point, 
some cells were collected for PCR analysis. The selection and amplification steps were repeated for 
four different days to ensure including clones with different proliferating rates. 
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15. ANALYSIS OF MITOCHONDRIAL PROTEIN COMPLEXES 
15.1. MITOCHONDRIAL ISOLATION 
Mitochondria from Phb2fl/fl MEFs were isolated in order to study PHB complexes. This protocol is 
based on the one written by Simon Troeder (Institute for Genetics, CECAD, Cologne, Germany). 
Protocol 
Incubate cells with the indicated drugs for a specific period of time according to the experiment 
setup. Use one 15 cm plate of MEFs for control conditions, and two 15 cm plates for fluorizoline-
treated conditions. Scrape cells from plate in cold PBS, wash once with cold PBS (600 g, 5 min, 4°C) 
and take up in appropriate volume of homogenization buffer (2 mL/15 cm plate). Incubate on ice for 
15 min to facilitate swelling. Homogenize the tissue by 15 strokes with Teflon® homogenizer, 
avoiding bubbles. Centrifuge the homogenate (1,000 g, 10 min, 4°C). Optional: Repeat the 
homogenization with pellet and pool the supernatant (containing mitochondria). Centrifuge the 
supernatant once again (1,000 g, 10 min, 4°C).  
Isolate mitochondrial fraction from supernatant by centrifugation (8,000 g, 10 min, 4°C, in 2 mL 
eppendorf tubes) and carefully resuspend the pellets all together in 100 µL of isolation buffer. 
Determine the protein concentration using the Bradford assay (Bio-Rad) according to the 
manufacturer’s instructions. Dilute the mitochondrial suspension to 10 mg protein/mL with isolation 
buffer. Mitochondria can be frozen and stored at ‐80°C, though freezing will severely retard the 
activity of mitochondria. To freeze mitochondria, isolate mitochondria by centrifugation (8,000 g, 10 
min, 4°C) and resuspend the pellet carefully in freezing buffer at 10 mg/mL. Freeze in small aliquots 
slowly at ‐80°C. 
 
MITOCHONDRIAL ISOLATION BUFFERS 
Homogenization buffer (1X) 
pH=7.4 
Prepare freshly 
Mannitol 
Sucrose 
EGTA 
Fatty acid free BSA 
HEPES-KOH 
Protease inhibitor 
complete EDTA-free 
220 mM 
70 mM 
2 mM 
0.1% (w/v) 
20 mM 
1X (Roche) 
Isolation buffer (1X) 
pH=7.4 
Prepare freshly 
 
Mannitol 
Sucrose 
EGTA 
HEPES-KOH 
Protease inhibitor 
complete EDTA-free 
220 mM 
70 mM 
2 mM 
20 mM 
1X (Roche) 
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Freezing buffer (1X) 
pH=7.4, sterile filtered 
Store at -20ºC 
Sucrose 
HEPES-KOH 
500 mM 
10 mM 
Table M.11. Buffers used for mitochondrial isolation. 
 
15.2. BLUE NATIVE-PAGE 
BLUE NATIVE-PAGE (BN-PAGE) is suitable for separation of water soluble or membrane-bound 
protein complexes in the range from 10 to 1,000 kDa. A charge shift on the proteins is induced by 
negatively charged Coomassie dye instead of SDS, so the separated protein complexes are in their 
native conformation and therefore mantain their enzymatic activity and oligomeric state. This method 
can be used for determining the subunit composition and degree of homogeneity of protein 
complexes. This protocol is based on the one written by Anne Korwitz (Institute for Genetics, 
CECAD, Cologne, Germany). 
Protocol for gels preparation 
Assemble glass plates and keep them cold. Prepare the gel solutions and make a gradient gel at 4°C 
using a Hoefer® gradient mixer. Do not fill the plates until the top. Once polymerized, add stacking 
gel solution on top of the separation gel, insert the comb and let the gel polymerize at 4°C. 
 
 
 3% 13% Stacking 
AB mix (49.5% T, 3% C) 0.48 mL 2.08 mL 0.36 mL 
3X gel buffer 
Glycerol 50% 
Glycerol 87% 
H2O 
2.67 mL 
0.32 mL 
 
4.45 mL 
2.67 mL 
 
2.76 mL 
0.5 mL 
2 mL 
 
 
3.64 mL 
APS (per gel) 20 µL 10 µL 10 µL 
TEMED (per gel) 2 µL 1 µL 1 µL 
Table M.12. Composition of the solutions for the preparation of 3 mini-gels for blue native-PAGE. 
 
Protocol for samples preparation 
Spin down 100 μg mitochondria per lane for 5 min at 16,100 g and 4°C to get rid of the freezing 
buffer. Discard supernatant, resuspend pellet in solubilization buffer with digitionin (20 µL 
solubilization buffer 2X + 14 µL H2O + 6 µL digitonin 10%). Shake samples for 30 min at 4°C. 
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Centrifuge samples for 30 min at 20,000 rpm to get rid of cell debris. Transfer the supernatant to new 
tube and add Coomassie Brilliant Blue (CBB) (36 μL sample + 4 μL CBB per lane → 45 μg). 
Protocol for gel running 
Fill the chamber with anode and deep blue cathode buffers. Wash slots with deep blue cathode 
buffer. Load marker (12.5 μL) and samples, and fill empty slots with 1X CBB. Let the gel run at 100 
V until the samples have entered the separation gel (~2 hours). Exchange deep blue cathode buffer 
with slightly blue cathode buffer and switch voltage to 300 V. 
Marker Mix: 2.5 μL Thioglobulin 25 mg/Ml, 2.5 μL Ferritin 25 mg/mL, 5 μL ADH 25 mg/mL, 2.5 
μL BSA 25 mg/mL, 5 μL Catalase 50 mg/mL. Add up to 100 μL with solubilization buffer 
Protocol for blotting 
Equilibrate the gel in blot buffer for 30 min. Cut PVDF membrane and shortly equilibrate it in 
methanol. Perform semi-dry blotting for 3h at 400 mA. Destain membrane with methanol and stain 
with Ponceau-S solution. Block the membrane with 5% dry milk in TBS-T for 1 hour. 
 
BLUE NATIVE PAGE BUFFERS 
  
Anode buffer (1X) 
pH=7 
Imidazole/HCl 25 mM 
Deep blue cathode buffer (1X) Tricine 
Imidazole 
Coomassie G250 
50 mM 
7.5 mM 
0.02% 
Slightly blue cathode buffer (1X) Tricine 
Imidazole 
Coomassie G250 
50 mM 
7.5 mM 
0.002% 
3X gel buffer (1X) Imidazole/HCl, pH=7 
6-aminohexanoic acid 
75 mM 
1.5 M 
Solubilization buffer (1X) NaCl 
6-aminohexanoic acid 
Imidazole/HCl, pH=7 
Glycerol 
KPi-buffer, pH=7.4 
50 mM 
5 mM 
50 mM 
10% 
50 mM 
CBB (1X) Coomassie G250 1% 
Blot buffer (1X) Methanol 
SDS 
Tris 
Glycine 
20% 
0.02% 
20 mM 
0.15 mM 
Table M.13. Buffers used for BN-PAGE. 
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16. MASS SPECTOMETRIC ANALYSIS OF THE PHOSPHOLIPIDOME IN MEFs 
Phb2fl/fl MEFs were untreated, treated with 20 µM fluorizoline for 24 hours, or Cre-transduced for 72 
hours (Phb2-/-). Phospholipidome analysis was performed by Dr. Takashi Tatsuta (Institute for 
Genetics, CECAD, Cologne, Germany) as previously described (Richter-Dennerlein et al. 2014). One 
milion cells were resuspended in 40 μL H2O and mixed with 360 μL chloroform/methanol/25% HCl 
(40:80:0.6 [v/v]). Cells were disrupted by vortexing 30 sec and 200 μL were taken for lipid extracts. 
H2O (0.4 mL) was added and vortexing was repeated. Next, 0.5 mL H2O and 0.5 mL chloroform 
were added, followed by vortexing and centrifugation at 800 g for 2 min to separate the phases. The 
lower chloroform phase was moved to a second tube, and the upper phase was washed with 0.5 mL 
chloroform and 0.8 mL H2O. The washed chloroform phase of the second tube was transferred to a 
third tube, and the chloroform phase of the initial tube was combined with the upper phase of the 
second tube, followed by re-extraction. Upon phase separation, the chloroform phases were merged 
and evaporated by a gentle stream of argon at 37ºC. HCl was removed from the extraction solution 
to suppress the deacylation of cardiolipin. Lipids were dissolved in 5 mM ammonium acetate and 
0.05% piperidine in methanol and analyzed on a 4000 QTrap® triple quadrupole mass spectrometer 
(Applied Biosystems) equipped with a Turbo VTM electrospray ion source. Identification and 
quantification of the lipids were done using the LipidViewTM Software Version 2.0 (AB Sciex). Lipid 
amounts (pmol) were corrected for response differences between internal standards and endogenous 
lipids. The length and saturation profile of the acyl chains in a phospholipid was calculated by 
summing the amounts of phospholipid species carrying acyl chains with the same number of total 
carbons or of double bonds and represented relative to the total amount of lipids. 
 
17. LICENSE AGREEMENT FOR REPRINTING FIGURES  
Figures from manuscripts by other authors are reprinted with written permission from the different 
publishers (Nature publishing group, Elsevier and Company of Biologists Ltd). 
 
18. STATISTICAL ANALYSIS 
The results are shown as the mean ± standard error of the mean (SEM) of values obtained in a 
number of independent experiments indicated in each figure legend. Statistical analysis was 
determined using two-tailed unpaired Student’s t test by using the GraphPad Prism® 6.0 Software Inc. 
The p values below 0.05 were considered statistically significant (*p < 0.05; **p < 0.01; ***p < 0.001). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES
References 
147 
A 
Adams, J. M., and S. Cory. 2007. The Bcl-2 apoptotic switch in cancer development and therapy. 
Oncogene 26:1324–37. 
Alaimo, A., R. M. Gorojod, J. Beauquis, M. J. Muñoz, F. Saravia, and M. L. Kotler. 2014. 
Deregulation of mitochondria-shaping proteins Opa-1 and Drp-1 in manganese-induced 
apoptosis. PloS one 9:e91848. 
Arnoult, D., A. Grodet, Y.-J. Lee, J. Estaquier, and C. Blackstone. 2005. Release of OPA1 during 
apoptosis participates in the rapid and complete release of cytochrome c and subsequent 
mitochondrial fragmentation. The Journal of biological chemistry 280:35742–50. 
Artal-Sanz, M., and N. Tavernarakis. 2009. Prohibitin and mitochondrial biology. Trends in 
endocrinology and metabolism: TEM 20:394–401. 
Artal-Sanz, M., W. Y. Tsang, E. M. Willems, L. A. Grivell, B. D. Lemire, H. van der Spek, L. G. J. 
Nijtmans, and M. A. Sanz. 2003. The mitochondrial prohibitin complex is essential for 
embryonic viability and germline function in Caenorhabditis elegans. The Journal of biological 
chemistry 278:32091–9. 
B 
Bae, J., C. P. Leo, S. Y. Hsu, and A. J. Hsueh. 2000. MCL-1S, a splicing variant of the antiapoptotic 
BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 
domain. The Journal of biological chemistry 275:25255–61. 
Baker, M. J., P. A. Lampe, D. Stojanovski, A. Korwitz, R. Anand, T. Tatsuta, and T. Langer. 2014. 
Stress-induced OMA1 activation and autocatalytic turnover regulate OPA1-dependent 
mitochondrial dynamics. The EMBO journal 33:578–93. 
Balasubramaniam, S., J. A. Duley, and J. Christodoulou. 2014. Inborn errors of pyrimidine 
metabolism: clinical update and therapy. Journal of inherited metabolic disease 37:687–98. 
Balmanno, K., and S. J. Cook. 2009. Tumour cell survival signalling by the ERK1/2 pathway. Cell 
death and differentiation 16:368–77. 
Bardeleben, C., S. Sharma, J. R. Reeve, S. Bassilian, P. Frost, B. Hoang, Y. Shi, and A. Lichtenstein. 
2013. Metabolomics identifies pyrimidine starvation as the mechanism of 5-aminoimidazole-4-
carboxamide-1-β-riboside-induced apoptosis in multiple myeloma cells. Molecular cancer 
therapeutics 12:1310–21. 
Baumann, P., S. Mandl-Weber, B. Emmerich, C. Straka, and R. Schmidmaier. 2007. Activation of 
adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. 
Experimental cell research 313:3592–603. 
 148 
Bellosillo, B., N. Villamor, D. Colomer, G. Pons, E. Montserrat, and J. Gil. 1999. In vitro evaluation 
of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic 
lymphocytic leukemia. Blood 94:2836–43. 
Vanden Berghe, T., A. Linkermann, S. Jouan-Lanhouet, H. Walczak, and P. Vandenabeele. 2014. 
Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nature 
reviews. Molecular cell biology 15:135–47. 
Boise, L. H., M. González-García, C. E. Postema, L. Ding, T. Lindsten, L. A. Turka, X. Mao, G. 
Nuñez, and C. B. Thompson. 1993. bcl-x, a bcl-2-related gene that functions as a dominant 
regulator of apoptotic cell death. Cell 74:597–608. 
Bratton, S. B., and G. S. Salvesen. 2010. Regulation of the Apaf-1-caspase-9 apoptosome. Journal of 
cell science 123:3209–14. 
Browman, D. T., M. B. Hoegg, and S. M. Robbins. 2007. The SPFH domain-containing proteins: 
more than lipid raft markers. Trends in cell biology 17:394–402. 
Byrd, J. C., S. Stilgenbauer, and I. W. Flinn. 2004. Chronic lymphocytic leukemia. Hematology / the 
Education Program of the American Society of Hematology. American Society of Hematology. 
Education Program:163–83. 
C 
Campàs, C. 2004. Bases moleculars de la teràpia de la leucèmia limfàtica crònica de cèl·lules B. 
Recerca de nous agents inductors d’apoptosi. PhD Thesis, Universitat de Barcelona. 
Campàs, C., J. M. Lopez, A. F. Santidrián, M. Barragán, B. Bellosillo, D. Colomer, and J. Gil. 2003. 
Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells 
but not in T lymphocytes. Blood 101:3674–80. 
Campàs, C., A. F. Santidrián, A. Domingo, and J. Gil. 2005. Acadesine induces apoptosis in B cells 
from mantle cell lymphoma and splenic marginal zone lymphoma. Leukemia 19:292–4. 
Cantó, C., Z. Gerhart-Hines, J. N. Feige, M. Lagouge, L. Noriega, J. C. Milne, P. J. Elliott, P. 
Puigserver, and J. Auwerx. 2009. AMPK regulates energy expenditure by modulating NAD+ 
metabolism and SIRT1 activity. Nature 458:1056–60. 
Chan, T. C., and S. B. Howell. 1989. Unexpected synergy between N-phosphonacetyl-L-aspartate and 
cytidine against human tumor cells. European journal of cancer & clinical oncology 25:721–7. 
Chander, H., M. Halpern, L. Resnick-Silverman, J. J. Manfredi, and D. Germain. 2010. Skp2B 
attenuates p53 function by inhibiting prohibitin. EMBO reports 11:220–5. 
Chen, J., and N. A. J. McMillan. 2008. Molecular basis of pathogenesis, prognosis and therapy in 
chronic lymphocytic leukaemia. Cancer biology & therapy 7:174–9. 
References 
149 
Chen, L., S. N. Willis, A. Wei, B. J. Smith, J. I. Fletcher, M. G. Hinds, P. M. Colman, C. L. Day, J. M. 
Adams, and D. C. S. Huang. 2005. Differential targeting of prosurvival Bcl-2 proteins by their 
BH3-only ligands allows complementary apoptotic function. Molecular cell 17:393–403. 
Chiorazzi, N. 2007. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia 
B cells. Best practice & research. Clinical haematology 20:399–413. 
Chiorazzi, N., K. R. Rai, and M. Ferrarini. 2005. Chronic lymphocytic leukemia. The New England 
journal of medicine 352:804–15. 
Chiu, C.-F., M.-Y. Ho, J.-M. Peng, S.-W. Hung, W.-H. Lee, C.-M. Liang, and S.-M. Liang. 2013. Raf 
activation by Ras and promotion of cellular metastasis require phosphorylation of prohibitin in 
the raft domain of the plasma membrane. Oncogene 32:777–87. 
Chowdhury, I., A. Branch, M. Olatinwo, K. Thomas, R. Matthews, and W. E. Thompson. 2011. 
Prohibitin (PHB) acts as a potent survival factor against ceramide induced apoptosis in rat 
granulosa cells. Life sciences 89:295–303. 
Chowdhury, I., W. E. Thompson, and K. Thomas. 2014. Prohibitins role in cellular survival through 
Ras-Raf-MEK-ERK pathway. Journal of cellular physiology 229:998–1004. 
Chowdhury, I., W. E. Thompson, C. Welch, K. Thomas, and R. Matthews. 2013. Prohibitin (PHB) 
inhibits apoptosis in rat granulosa cells (GCs) through the extracellular signal-regulated kinase 
1/2 (ERK1/2) and the Bcl family of proteins. Apoptosis  : an international journal on 
programmed cell death 18:1513–25. 
Chowdhury, I., W. Xu, J. K. Stiles, A. Zeleznik, X. Yao, R. Matthews, K. Thomas, and W. E. 
Thompson. 2007. Apoptosis of rat granulosa cells after staurosporine and serum withdrawal is 
suppressed by adenovirus-directed overexpression of prohibitin. Endocrinology 148:206–17. 
Christie, D. A., C. D. Lemke, I. M. Elias, L. A. Chau, M. G. Kirchhof, B. Li, E. H. Ball, S. D. Dunn, 
G. M. Hatch, and J. Madrenas. 2011. Stomatin-like protein 2 binds cardiolipin and regulates 
mitochondrial biogenesis and function. Molecular and cellular biology 31:3845–56. 
Christie, D. A., P. Mitsopoulos, J. Blagih, S. D. Dunn, J. St-Pierre, R. G. Jones, G. M. Hatch, and J. 
Madrenas. 2012. Stomatin-like protein 2 deficiency in T cells is associated with altered 
mitochondrial respiration and defective CD4+ T cell responses. Journal of immunology 
(Baltimore, Md.  : 1950) 189:4349–60. 
Coates, P. J., R. Nenutil, A. McGregor, S. M. Picksley, D. H. Crouch, P. A. Hall, and E. G. Wright. 
2001. Mammalian prohibitin proteins respond to mitochondrial stress and decrease during 
cellular senescence. Experimental cell research 265:262–73. 
Corton, J. M., J. G. Gillespie, S. A. Hawley, and D. G. Hardie. 1995. 5-aminoimidazole-4-
carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in 
intact cells? European journal of biochemistry / FEBS 229:558–65. 
 150 
Cosialls, A. M. 2011. Estudio de la respuesta a inhibidores de proteínas reguladoras de la apoptosis, 
análisis de la mutación en la treonina 169 de BAX y validación del ensayo ex vivo y del método 
MS-MLPA en células leucémicas. PhD Thesis, Universitat de Barcelona. 
Creagh, E. M. 2014. Caspase crosstalk: integration of apoptotic and innate immune signalling 
pathways. Trends in immunology 35:631–640. 
Da Cruz, S., P. A. Parone, P. Gonzalo, W. V Bienvenut, D. Tondera, A. Jourdain, M. Quadroni, and 
J.-C. Martinou. 2008. SLP-2 interacts with prohibitins in the mitochondrial inner membrane and 
contributes to their stability. Biochimica et biophysica acta 1783:904–11. 
Cubillos-Rojas, M., F. Amair-Pinedo, I. Tato, R. Bartrons, F. Ventura, and J. L. Rosa. 2010. 
Simultaneous electrophoretic analysis of proteins of very high and low molecular mass using 
Tris-acetate polyacrylamide gels. Electrophoresis 31:1318–21. 
Cubillos-Rojas, M., F. Amair-Pinedo, I. Tato, R. Bartrons, F. Ventura, and J. L. Rosa. 2012. Tris-
acetate polyacrylamide gradient gels for the simultaneous electrophoretic analysis of proteins of 
very high and low molecular mass. Methods in molecular biology (Clifton, N.J.) 869:205–13. 
Czabotar, P. E., G. Lessene, A. Strasser, and J. M. Adams. 2014. Control of apoptosis by the BCL-2 
protein family: implications for physiology and therapy. Nature reviews. Molecular cell biology 
15:49–63. 
D 
Dart, D. A., G. N. Brooke, A. Sita-Lumsden, J. Waxman, and C. L. Bevan. 2012. Reducing prohibitin 
increases histone acetylation, and promotes androgen independence in prostate tumours by 
increasing androgen receptor activation by adrenal androgens. Oncogene 31:4588–98. 
Duvezin-Caubet, S., R. Jagasia, J. Wagener, S. Hofmann, A. Trifunovic, A. Hansson, A. Chomyn, M. 
F. Bauer, G. Attardi, N.-G. Larsson, W. Neupert, and A. S. Reichert. 2006. Proteolytic 
processing of OPA1 links mitochondrial dysfunction to alterations in mitochondrial 
morphology. The Journal of biological chemistry 281:37972–9. 
E 
Eldering, E., C. A. Spek, H. L. Aberson, A. Grummels, I. A. Derks, A. F. de Vos, C. J. McElgunn, 
and J. P. Schouten. 2003. Expression profiling via novel multiplex assay allows rapid assessment 
of gene regulation in defined signalling pathways. Nucleic acids research 31:e153. 
Estañ, M. C., E. Calviño, E. de Blas, M. del C. Boyano-Adánez, M. L. Mena, M. Gómez-Gómez, E. 
Rial, and P. Aller. 2012. 2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis 
in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-
1/AMPK signaling pathways. Biochemical pharmacology 84:1604–16. 
 
References 
151 
F 
Fadok, V. A., and P. M. Henson. 2003. Apoptosis: giving phosphatidylserine recognition an assist--
with a twist. Current biology  : CB 13:R655–7. 
Faubert, B., G. Boily, S. Izreig, T. Griss, B. Samborska, Z. Dong, F. Dupuy, C. Chambers, B. J. 
Fuerth, B. Viollet, O. A. Mamer, D. Avizonis, R. J. DeBerardinis, P. M. Siegel, and R. G. Jones. 
2013. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. 
Cell metabolism 17:113–24. 
Faubert, B., E. E. Vincent, M. C. Poffenberger, and R. G. Jones. 2015. The AMP-activated protein 
kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer letters 356:165–70. 
Fernald, K., and M. Kurokawa. 2013. Evading apoptosis in cancer. Trends in cell biology 23:620–33. 
Fernández-Calotti, P. X., D. Colomer, and M. Pastor-Anglada. 2011. Translocation of nucleoside 
analogs across the plasma membrane in hematologic malignancies. Nucleosides, nucleotides & 
nucleic acids 30:1324–40. 
Fletcher, C. E., D. A. Dart, A. Sita-Lumsden, H. Cheng, P. S. Rennie, and C. L. Bevan. 2012. 
Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate 
cancer. Human molecular genetics 21:3112–27. 
Frezza, C., S. Cipolat, O. Martins de Brito, M. Micaroni, G. V Beznoussenko, T. Rudka, D. Bartoli, R. 
S. Polishuck, N. N. Danial, B. De Strooper, and L. Scorrano. 2006. OPA1 controls apoptotic 
cristae remodeling independently from mitochondrial fusion. Cell 126:177–89. 
Fulda, S., and D. Vucic. 2012. Targeting IAP proteins for therapeutic intervention in cancer. Nature 
reviews. Drug discovery 11:109–24. 
Fusaro, G., P. Dasgupta, S. Rastogi, B. Joshi, and S. Chellappan. 2003. Prohibitin induces the 
transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. The 
Journal of biological chemistry 278:47853–61. 
Fusaro, G., S. Wang, and S. Chellappan. 2002. Differential regulation of Rb family proteins and 
prohibitin during camptothecin-induced apoptosis. Oncogene 21:4539–48. 
G 
Galluzzi, L., J. M. Bravo-San Pedro, I. Vitale, S. A. Aaronson, J. M. Abrams, D. Adam, E. S. Alnemri, 
L. Altucci, D. Andrews, M. Annicchiarico-Petruzzelli, E. H. Baehrecke, N. G. Bazan, M. J. 
Bertrand, K. Bianchi, M. V Blagosklonny, K. Blomgren, C. Borner, D. E. Bredesen, C. Brenner, 
M. Campanella, et al. 2014. Essential versus accessory aspects of cell death: recommendations of 
the NCCD 2015. Cell death and differentiation 22:58–73. 
 152 
Gamble, S. C., D. Chotai, M. Odontiadis, D. A. Dart, G. N. Brooke, S. M. Powell, V. Reebye, A. 
Varela-Carver, Y. Kawano, J. Waxman, and C. L. Bevan. 2007. Prohibitin, a protein 
downregulated by androgens, represses androgen receptor activity. Oncogene 26:1757–68. 
Geraghty, R. J., A. Capes-Davis, J. M. Davis, J. Downward, R. I. Freshney, I. Knezevic, R. Lovell-
Badge, J. R. W. Masters, J. Meredith, G. N. Stacey, P. Thraves, and M. Vias. 2014. Guidelines 
for the use of cell lines in biomedical research. British Journal of Cancer 111:1021–1046. 
González-Gironès, D. M. 2012. AICAR and new therapeutic agents for chronic lymphocytic 
leukemia: Mechanism of apoptosis induction. PhD thesis, Universitat de Barcelona. 
Gonzalvez, F., and A. Ashkenazi. 2010. New insights into apoptosis signaling by Apo2L/TRAIL. 
Oncogene 29:4752–65. 
Grande, L., G. Bretones, M. Rosa-Garrido, E. M. Garrido-Martin, T. Hernandez, S. Fraile, L. Botella, 
E. de Alava, A. Vidal, X. Garcia del Muro, A. Villanueva, M. D. Delgado, and J. L. Fernandez-
Luna. 2012. Transcription factors Sp1 and p73 control the expression of the proapoptotic 
protein NOXA in the response of testicular embryonal carcinoma cells to cisplatin. The Journal 
of biological chemistry 287:26495–505. 
Green, D. R., and G. Kroemer. 2004. The pathophysiology of mitochondrial cell death. Science (New 
York, N.Y.) 305:626–9. 
Gregory-Bass, R. C., M. Olatinwo, W. Xu, R. Matthews, J. K. Stiles, K. Thomas, D. Liu, B. Tsang, 
and W. E. Thompson. 2008. Prohibitin silencing reverses stabilization of mitochondrial integrity 
and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. 
International journal of cancer. Journal international du cancer 122:1923–30. 
Griparic, L., T. Kanazawa, and A. M. van der Bliek. 2007. Regulation of the mitochondrial dynamin-
like protein Opa1 by proteolytic cleavage. The Journal of cell biology 178:757–64. 
Guigas, B., N. Taleux, M. Foretz, D. Detaille, F. Andreelli, B. Viollet, and L. Hue. 2007. AMP-
activated protein kinase-independent inhibition of hepatic mitochondrial oxidative 
phosphorylation by AICA riboside. The Biochemical journal 404:499–507. 
Gyrd-Hansen, M., and P. Meier. 2010. IAPs: from caspase inhibitors to modulators of NF-κB, 
inflammation and cancer. Nature Reviews Cancer 10:561–574. 
H 
Hadji, A., C. Clybouw, M.-T. Auffredou, C. Alexia, K. Poalas, A. Burlion, O. Feraud, G. Leca, and A. 
Vazquez. 2010. Caspase-3 triggers a TPCK-sensitive protease pathway leading to degradation of 
the BH3-only protein puma. Apoptosis  : an international journal on programmed cell death 
15:1529–39. 
Hallek, M. 2015. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and 
treatment. American Journal of Hematology 90:446–460. 
References 
153 
Han, J., C. Yu, R. F. Souza, and A. L. Theiss. 2014. Prohibitin 1 modulates mitochondrial function of 
Stat3. Cellular signalling 26:2086–95. 
Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144:646–74. 
Hardie, D. G., and D. R. Alessi. 2013. LKB1 and AMPK and the cancer-metabolism link - ten years 
after. BMC biology 11:36. 
Hardie, D. G., F. A. Ross, and S. A. Hawley. 2012. AMPK: a nutrient and energy sensor that 
maintains energy homeostasis. Nature reviews. Molecular cell biology 13:251–62. 
Hayden, R. E., G. Pratt, C. Roberts, M. T. Drayson, and C. M. Bunce. 2012. Treatment of chronic 
lymphocytic leukemia requires targeting of the protective lymph node environment with novel 
therapeutic approaches. Leukemia & lymphoma 53:537–49. 
He, B., Q. Feng, A. Mukherjee, D. M. Lonard, F. J. DeMayo, B. S. Katzenellenbogen, J. P. Lydon, 
and B. W. O’Malley. 2008. A repressive role for prohibitin in estrogen signaling. Molecular 
endocrinology (Baltimore, Md.) 22:344–60. 
Hermansson, M., K. Hokynar, and P. Somerharju. 2011. Mechanisms of glycerophospholipid 
homeostasis in mammalian cells. Progress in lipid research 50:240–57. 
Herrant, M., A. Jacquel, S. Marchetti, N. Belhacène, P. Colosetti, F. Luciano, and P. Auberger. 2004. 
Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. 
Oncogene 23:7863–73. 
Herrant, M., F. Luciano, A. Loubat, and P. Auberger. 2002. The protective effect of phorbol esters 
on Fas-mediated apoptosis in T cells. Transcriptional and postranscriptional regulation. 
Oncogene 21:4957–68. 
Hishikawa, D., T. Hashidate, T. Shimizu, and H. Shindou. 2014. Diversity and function of membrane 
glycerophospholipids generated by the remodeling pathway in mammalian cells. Journal of lipid 
research 55:799–807. 
Ho, M.-Y., C.-M. Liang, and S.-M. Liang. 2015. MIG-7 and phosphorylated prohibitin coordinately 
regulate lung cancer invasion/metastasis. Oncotarget 6:381–93. 
Hotchkiss, R. S., A. Strasser, J. E. McDunn, and P. E. Swanson. 2009. Cell death. The New England 
journal of medicine 361:1570–83. 
I 
Ido, Y., D. Carling, and N. Ruderman. 2002. Hyperglycemia-induced apoptosis in human umbilical 
vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 
51:159–67. 
 154 
Isebaert, S. F., J. V Swinnen, W. H. McBride, A. C. Begg, and K. M. Haustermans. 2011. 5-
aminoimidazole-4-carboxamide riboside enhances effect of ionizing radiation in PC3 prostate 
cancer cells. International journal of radiation oncology, biology, physics 81:1515–23. 
Ishihara, N., Y. Fujita, T. Oka, and K. Mihara. 2006. Regulation of mitochondrial morphology 
through proteolytic cleavage of OPA1. The EMBO journal 25:2966–77. 
Ising, C., S. Koehler, S. Brähler, C. Merkwirth, M. Höhne, O. R. Baris, H. Hagmann, M. Kann, F. 
Fabretti, C. Dafinger, W. Bloch, B. Schermer, A. Linkermann, J. C. Brüning, C. E. Kurschat, R.-
U. Müller, R. J. Wiesner, T. Langer, T. Benzing, and P. T. Brinkkoetter. 2015. Inhibition of 
insulin/IGF-1 receptor signaling protects from mitochondria-mediated kidney failure. EMBO 
molecular medicine 7:275–87. 
J 
Jackson, S. P., and J. Bartek. 2009. The DNA-damage response in human biology and disease. Nature 
461:1071–8. 
Jacobs, R. L., S. Lingrell, J. R. B. Dyck, and D. E. Vance. 2007. Inhibition of hepatic 
phosphatidylcholine synthesis by 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside is 
independent of AMP-activated protein kinase activation. The Journal of biological chemistry 
282:4516–23. 
Jeon, S.-M., N. S. Chandel, and N. Hay. 2012. AMPK regulates NADPH homeostasis to promote 
tumour cell survival during energy stress. Nature 485:661–5. 
Jiang, L., P. Dong, Z. Zhang, C. Li, Y. Li, Y. Liao, X. Li, Z. Wu, S. Guo, S. Mai, D. Xie, Z. Liu, and 
F. Zhou. 2015. Akt phosphorylates Prohibitin 1 to mediate its mitochondrial localization and 
promote proliferation of bladder cancer cells. Cell death & disease 6:e1660. 
Jiang, X., H. Jiang, Z. Shen, and X. Wang. 2014. Activation of mitochondrial protease OMA1 by Bax 
and Bak promotes cytochrome c release during apoptosis. Proceedings of the National Academy 
of Sciences of the United States of America 111:14782–7. 
Jones, R. G., D. R. Plas, S. Kubek, M. Buzzai, J. Mu, Y. Xu, M. J. Birnbaum, and C. B. Thompson. 
2005. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Molecular 
cell 18:283–93. 
K 
Kasahara, A., and L. Scorrano. 2014. Mitochondria: from cell death executioners to regulators of cell 
differentiation. Trends in Cell Biology 24:761–70. 
Kasashima, K., E. Ohta, Y. Kagawa, and H. Endo. 2006. Mitochondrial functions and estrogen 
receptor-dependent nuclear translocation of pleiotropic human prohibitin 2. The Journal of 
biological chemistry 281:36401–10. 
References 
155 
Keating, M. J. 1993. Immunosuppression with purine analogues--the flip side of the gold coin. Annals 
of oncology  : official journal of the European Society for Medical Oncology / ESMO 4:347–8. 
Kelly, P. N., and A. Strasser. 2011. The role of Bcl-2 and its pro-survival relatives in tumourigenesis 
and cancer therapy. Cell death and differentiation 18:1414–24. 
Kim, D. K., H. S. Kim, A.-R. Kim, G. H. Jang, H. W. Kim, Y. H. Park, B. Kim, Y. M. Park, M. A. 
Beaven, Y. M. Kim, and W. S. Choi. 2013. The scaffold protein prohibitin is required for 
antigen-stimulated signaling in mast cells. Science signaling 6:ra80. 
Kim, J.-W., M. Akiyama, J.-H. Park, M.-L. Lin, A. Shimo, T. Ueki, Y. Daigo, T. Tsunoda, T. 
Nishidate, Y. Nakamura, and T. Katagiri. 2009. Activation of an estrogen/estrogen receptor 
signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast 
cancer. Cancer science 100:1468–78. 
Ko, K. S., M. L. Tomasi, A. Iglesias-Ara, B. A. French, S. W. French, K. Ramani, J. J. Lozano, P. Oh, 
L. He, B. L. Stiles, T. W. H. Li, H. Yang, M. L. Martínez-Chantar, J. M. Mato, and S. C. Lu. 
2010. Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and 
hepatocellular carcinoma in mice. Hepatology (Baltimore, Md.) 52:2096–108. 
Kowno, M., K. Watanabe-Susaki, H. Ishimine, S. Komazaki, K. Enomoto, Y. Seki, Y. Y. Wang, Y. 
Ishigaki, N. Ninomiya, T. K. Noguchi, Y. Kokubu, K. Ohnishi, Y. Nakajima, K. Kato, A. Intoh, 
H. Takada, N. Yamakawa, P.-C. Wang, M. Asashima, and A. Kurisaki. 2014. Prohibitin 2 
regulates the proliferation and lineage-specific differentiation of mouse embryonic stem cells in 
mitochondria. PloS one 9:e81552. 
Kumar, V., A. Abbas, and J. Aster. 2014. Robbins & Cotran Pathologic Basis of Disease. Page 1472. 
9th editio. Elsevier. 
Kuramori, C., M. Azuma, K. Kume, Y. Kaneko, A. Inoue, Y. Yamaguchi, Y. Kabe, T. Hosoya, M. 
Kizaki, M. Suematsu, and H. Handa. 2009. Capsaicin binds to prohibitin 2 and displaces it from 
the mitochondria to the nucleus. Biochemical and biophysical research communications 
379:519–25. 
Kvansakul, M., H. Yang, W. D. Fairlie, P. E. Czabotar, S. F. Fischer, M. A. Perugini, D. C. S. Huang, 
and P. M. Colman. 2008. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-
swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell death 
and differentiation 15:1564–71. 
L 
Labi, V., and M. Erlacher. 2015. How cell death shapes cancer. Cell death & disease 6:e1675. 
Labi, V., M. Erlacher, S. Kiessling, and A. Villunger. 2006. BH3-only proteins in cell death initiation, 
malignant disease and anticancer therapy. Cell death and differentiation 13:1325–38. 
 156 
Laderoute, K. R., K. Amin, J. M. Calaoagan, M. Knapp, T. Le, J. Orduna, M. Foretz, and B. Viollet. 
2006. 5’-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose 
deprivation conditions found in solid-tumor microenvironments. Molecular and cellular biology 
26:5336–47. 
Landes, T., L. J. Emorine, D. Courilleau, M. Rojo, P. Belenguer, and L. Arnauné-Pelloquin. 2010. The 
BH3-only Bnip3 binds to the dynamin Opa1 to promote mitochondrial fragmentation and 
apoptosis by distinct mechanisms. EMBO reports 11:459–65. 
Lanner, J. T., D. K. Georgiou, A. Dagnino-Acosta, A. Ainbinder, Q. Cheng, A. D. Joshi, Z. Chen, V. 
Yarotskyy, J. M. Oakes, C. S. Lee, T. O. Monroe, A. Santillan, K. Dong, L. Goodyear, I. I. 
Ismailov, G. G. Rodney, R. T. Dirksen, and S. L. Hamilton. 2012. AICAR prevents heat-
induced sudden death in RyR1 mutant mice independent of AMPK activation. Nature medicine 
18:244–51. 
Lee, M., J.-T. Hwang, H.-J. Lee, S.-N. Jung, I. Kang, S.-G. Chi, S.-S. Kim, and J. Ha. 2003. AMP-
activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity 
and its target gene expression under hypoxic conditions in DU145 cells. The Journal of 
biological chemistry 278:39653–61. 
Liang, J., and G. B. Mills. 2013. AMPK: a contextual oncogene or tumor suppressor? Cancer research 
73:2929–35. 
Linkermann, A., and D. R. Green. 2014. Necroptosis. The New England journal of medicine 
370:455–65. 
Liu, L., J. Ulbrich, J. Müller, T. Wüstefeld, L. Aeberhard, T. R. Kress, N. Muthalagu, L. Rycak, R. 
Rudalska, R. Moll, S. Kempa, L. Zender, M. Eilers, and D. J. Murphy. 2012. Deregulated MYC 
expression induces dependence upon AMPK-related kinase 5. Nature 483:608–12. 
Liu, T., H. Tang, Y. Lang, M. Liu, and X. Li. 2009. MicroRNA-27a functions as an oncogene in 
gastric adenocarcinoma by targeting prohibitin. Cancer letters 273:233–42. 
Liu, X., R. R. Chhipa, S. Pooya, M. Wortman, S. Yachyshin, L. M. L. Chow, A. Kumar, X. Zhou, Y. 
Sun, B. Quinn, C. McPherson, R. E. Warnick, A. Kendler, S. Giri, J. Poels, K. Norga, B. Viollet, 
G. A. Grabowski, and B. Dasgupta. 2014. Discrete mechanisms of mTOR and cell cycle 
regulation by AMPK agonists independent of AMPK. Proceedings of the National Academy of 
Sciences of the United States of America 111:E435–44. 
Lomonosova, E., and G. Chinnadurai. 2008. BH3-only proteins in apoptosis and beyond: an 
overview. Oncogene 27 Suppl 1:S2–19. 
López, J. M., A. F. Santidrián, C. Campàs, and J. Gil. 2003. 5-Aminoimidazole-4-carboxamide 
riboside induces apoptosis in Jurkat cells, but the AMP-activated protein kinase is not involved. 
The Biochemical journal 370:1027–32. 
 
References 
157 
M 
Mahmood, Z., and Y. Shukla. 2010. Death receptors: targets for cancer therapy. Experimental cell 
research 316:887–99. 
Martelli, A. M., F. Chiarini, C. Evangelisti, A. Ognibene, D. Bressanin, A. M. Billi, L. Manzoli, A. 
Cappellini, and J. A. McCubrey. 2012. Targeting the liver kinase B1/AMP-activated protein 
kinase pathway as a therapeutic strategy for hematological malignancies. Expert opinion on 
therapeutic targets 16:729–42. 
McBride, H., and V. Soubannier. 2010. Mitochondrial function: OMA1 and OPA1, the grandmasters 
of mitochondrial health. Current biology  : CB 20:R274–6. 
McMasters, K. M., R. Montes de Oca Luna, J. R. Peña, and G. Lozano. 1996. mdm2 deletion does 
not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene 13:1731–6. 
Meley, D., C. Bauvy, J. H. P. M. Houben-Weerts, P. F. Dubbelhuis, M. T. J. Helmond, P. Codogno, 
and A. J. Meijer. 2006. AMP-activated protein kinase and the regulation of autophagic 
proteolysis. The Journal of biological chemistry 281:34870–9. 
Merino, R., L. Ding, D. J. Veis, S. J. Korsmeyer, and G. Nuñez. 1994. Developmental regulation of 
the Bcl-2 protein and susceptibility to cell death in B lymphocytes. The EMBO journal 13:683–
91. 
Merkwirth, C., S. Dargazanli, T. Tatsuta, S. Geimer, B. Löwer, F. T. Wunderlich, J.-C. von Kleist-
Retzow, A. Waisman, B. Westermann, and T. Langer. 2008. Prohibitins control cell proliferation 
and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes & 
development 22:476–88. 
Merkwirth, C., and T. Langer. 2009. Prohibitin function within mitochondria: essential roles for cell 
proliferation and cristae morphogenesis. Biochimica et biophysica acta 1793:27–32. 
Merkwirth, C., P. Martinelli, A. Korwitz, M. Morbin, H. S. Brönneke, S. D. Jordan, E. I. Rugarli, and 
T. Langer. 2012. Loss of prohibitin membrane scaffolds impairs mitochondrial architecture and 
leads to tau hyperphosphorylation and neurodegeneration. PLoS genetics 8:e1003021. 
Meynet, O., B. Zunino, L. Happo, L. A. Pradelli, J. Chiche, M. A. Jacquin, L. Mondragón, J.-F. Tanti, 
B. Taillan, G. Garnier, J. Reverso-Meinietti, N. Mounier, J.-F. Michiels, E. M. Michalak, M. 
Carles, C. L. Scott, and J.-E. Ricci. 2013. Caloric restriction modulates Mcl-1 expression and 
sensitizes lymphomas to BH3 mimetic in mice. Blood 122:2402–11. 
Mishra, S., S. R. Ande, and B. L. G. Nyomba. 2010. The role of prohibitin in cell signaling. The FEBS 
journal 277:3937–46. 
Mishra, S., L. C. Murphy, B. L. G. Nyomba, and L. J. Murphy. 2005. Prohibitin: a potential target for 
new therapeutics. Trends in molecular medicine 11:192–7. 
 158 
Mitsopoulos, P., Y.-H. Chang, T. Wai, T. König, S. D. Dunn, T. Langer, and J. Madrenas. 2015. 
Stomatin-like Protein-2 is Required for In vivo Mitochondrial Respiratory Chain Supercomplex 
Formation and Optimal Cell Function. Molecular and cellular biology. 
Moldoveanu, T., A. V. Follis, R. W. Kriwacki, and D. R. Green. 2014. Many players in BCL-2 family 
affairs. Trends in biochemical sciences 39:101–11. 
Montraveta, A., S. Xargay-Torrent, M. López-Guerra, L. Rosich, P. Pérez-Galán, I. Salaverria, S. Beà, 
S. G. Kalko, M. de Frias, C. Campàs, G. Roué, and D. Colomer. 2014. Synergistic anti-tumor 
activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody 
rituximab in in vivo and in vitro models of mantle cell lymphoma. Oncotarget 5:726–39. 
N 
Nabhan, C., and S. T. Rosen. 2014. Chronic Lymphocytic Leukemia. JAMA 312:2265. 
Van Den Neste, E., G. Van den Berghe, and F. Bontemps. 2010. AICA-riboside (acadesine), an 
activator of AMP-activated protein kinase with potential for application in hematologic 
malignancies. Expert opinion on investigational drugs 19:571–8. 
Van Den Neste, E., B. Cazin, A. Janssens, E. González-Barca, M. J. Terol, V. Levy, J. Pérez de 
Oteyza, P. Zachee, A. Saunders, M. de Frias, and C. Campàs. 2013. Acadesine for patients with 
relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study. Cancer 
chemotherapy and pharmacology 71:581–91. 
Nikiforov, M. A., M. Riblett, W.-H. Tang, V. Gratchouck, D. Zhuang, Y. Fernandez, M. Verhaegen, 
S. Varambally, A. M. Chinnaiyan, A. J. Jakubowiak, and M. S. Soengas. 2007. Tumor cell-
selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proceedings of 
the National Academy of Sciences of the United States of America 104:19488–93. 
O 
Oda, E., R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, T. Yamashita, T. Tokino, T. Taniguchi, and N. 
Tanaka. 2000. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-
induced apoptosis. Science (New York, N.Y.) 288:1053–8. 
Olichon, A., L. Baricault, N. Gas, E. Guillou, A. Valette, P. Belenguer, and G. Lenaers. 2003. Loss of 
OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to 
cytochrome c release and apoptosis. The Journal of biological chemistry 278:7743–6. 
Osman, C., M. Haag, C. Potting, J. Rodenfels, P. V. Dip, F. T. Wieland, B. Brügger, B. Westermann, 
and T. Langer. 2009a. The genetic interactome of prohibitins: coordinated control of cardiolipin 
and phosphatidylethanolamine by conserved regulators in mitochondria. The Journal of cell 
biology 184:583–96. 
Osman, C., C. Merkwirth, and T. Langer. 2009b. Prohibitins and the functional compartmentalization 
of mitochondrial membranes. Journal of cell science 122:3823–30. 
References 
159 
P 
Pacher, P., A. Nivorozhkin, and C. Szabó. 2006. Therapeutic effects of xanthine oxidase inhibitors: 
renaissance half a century after the discovery of allopurinol. Pharmacological reviews 58:87–114. 
Park, S.-E., J. Xu, A. Frolova, L. Liao, B. W. O’Malley, and B. S. Katzenellenbogen. 2005. Genetic 
deletion of the repressor of estrogen receptor activity (REA) enhances the response to estrogen 
in target tissues in vivo. Molecular and cellular biology 25:1989–99. 
Pastor-Anglada, M., M. Molina-Arcas, F. J. Casado, B. Bellosillo, D. Colomer, and J. Gil. 2004. 
Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 18:385–93. 
Pastor-Anglada, M., and S. Pérez-Torras. 2015. Nucleoside transporter proteins as biomarkers of drug 
responsiveness and drug targets. Frontiers in pharmacology 6:13. 
Patel, N., S. K. Chatterjee, V. Vrbanac, I. Chung, C. J. Mu, R. R. Olsen, C. Waghorne, and B. R. 
Zetter. 2010. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer 
cells. Proceedings of the National Academy of Sciences of the United States of America 
107:2503–8. 
Peitz, M., K. Pfannkuche, K. Rajewsky, and F. Edenhofer. 2002. Ability of the hydrophobic FGF and 
basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for 
efficient genetic engineering of mammalian genomes. Proceedings of the National Academy of 
Sciences of the United States of America 99:4489–94. 
Pérez-Perarnau, A. 2013. Histone deacetylase inhibitors and diaryl (mono and bis)thiazoles: new 
strategies independent of p53 pathway for cancer treatment. PhD thesis, Universitat de 
Barcelona. 
Pérez-Perarnau, A., S. Preciado, C. M. Palmeri, C. Moncunill-Massaguer, D. Iglesias-Serret, D. M. 
González-Gironès, M. Miguel, S. Karasawa, S. Sakamoto, A. M. Cosialls, C. Rubio-Patiño, J. 
Saura-Esteller, R. Ramón, L. Caja, I. Fabregat, G. Pons, H. Handa, F. Albericio, J. Gil, and R. 
Lavilla. 2014. A Trifluorinated Thiazoline Scaffold Leading to Pro-apoptotic Agents Targeting 
Prohibitins. Angewandte Chemie International Edition 53:10150–10154. 
Piñon, J. D., V. Labi, A. Egle, and A. Villunger. 2008. Bim and Bmf in tissue homeostasis and 
malignant disease. Oncogene 27 Suppl 1:S41–52. 
Ploner, C., R. Kofler, and A. Villunger. 2008. Noxa: at the tip of the balance between life and death. 
Oncogene 27 Suppl 1:S84–92. 
Polager, S., and D. Ginsberg. 2009. p53 and E2f: partners in life and death. Nature reviews. Cancer 
9:738–48. 
Polier, G., J. Neumann, F. Thuaud, N. Ribeiro, C. Gelhaus, H. Schmidt, M. Giaisi, R. Köhler, W. W. 
Müller, P. Proksch, M. Leippe, O. Janssen, L. Désaubry, P. H. Krammer, and M. Li-Weber. 
 160 
2012. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by 
targeting prohibitin 1 and 2. Chemistry & biology 19:1093–104. 
Pop, C., and G. S. Salvesen. 2009. Human caspases: activation, specificity, and regulation. The Journal 
of biological chemistry 284:21777–81. 
Pradelli, L. A., M. Bénéteau, C. Chauvin, M. A. Jacquin, S. Marchetti, C. Muñoz-Pinedo, P. Auberger, 
M. Pende, and J.-E. Ricci. 2010a. Glycolysis inhibition sensitizes tumor cells to death receptors-
induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 
29:1641–52. 
Pradelli, L. A., M. Bénéteau, and J.-E. Ricci. 2010b. Mitochondrial control of caspase-dependent and -
independent cell death. Cellular and molecular life sciences  : CMLS 67:1589–97. 
Puente, X. S., M. Pinyol, V. Quesada, L. Conde, G. R. Ordóñez, N. Villamor, G. Escaramis, P. Jares, 
S. Beà, M. González-Díaz, L. Bassaganyas, T. Baumann, M. Juan, M. López-Guerra, D. 
Colomer, J. M. C. Tubío, C. López, A. Navarro, C. Tornador, M. Aymerich, et al. 2011. Whole-
genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 
475:101–5. 
Q 
Qian, X., P. Zhao, W. Li, Z.-M. Shi, L. Wang, Q. Xu, M. Wang, N. Liu, L.-Z. Liu, and B.-H. Jiang. 
2013. MicroRNA-26a promotes tumor growth and angiogenesis in glioma by directly targeting 
prohibitin. CNS neuroscience & therapeutics 19:804–12. 
Quesada, V., L. Conde, N. Villamor, G. R. Ordóñez, P. Jares, L. Bassaganyas, A. J. Ramsay, S. Beà, 
M. Pinyol, A. Martínez-Trillos, M. López-Guerra, D. Colomer, A. Navarro, T. Baumann, M. 
Aymerich, M. Rozman, J. Delgado, E. Giné, J. M. Hernández, M. González-Díaz, et al. 2012. 
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic 
lymphocytic leukemia. Nature genetics 44:47–52. 
R 
Raemy, E., and J.-C. Martinou. 2014. Involvement of cardiolipin in tBID-induced activation of BAX 
during apoptosis. Chemistry and physics of lipids 179:70–4. 
Rajalingam, K., C. Wunder, V. Brinkmann, Y. Churin, M. Hekman, C. Sievers, U. R. Rapp, and T. 
Rudel. 2005. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell 
migration. Nature cell biology 7:837–43. 
Reed, J. C. 2003. Apoptosis-targeted therapies for cancer. Cancer cell 3:17–22. 
Renault, T. T., and J. E. Chipuk. 2014. Death upon a kiss: mitochondrial outer membrane 
composition and organelle communication govern sensitivity to BAK/BAX-dependent 
apoptosis. Chemistry & biology 21:114–23. 
References 
161 
Renshaw, S. A., C. E. Dempsey, F. A. Barnes, S. M. Bagstaff, S. K. Dower, C. D. Bingle, and M. K. B. 
Whyte. 2004. Three novel Bid proteins generated by alternative splicing of the human Bid gene. 
The Journal of biological chemistry 279:2846–55. 
Ribeiro, N., F. Thuaud, Y. Bernard, C. Gaiddon, T. Cresteil, A. Hild, E. C. Hirsch, P. P. Michel, C. G. 
Nebigil, and L. Désaubry. 2012. Flavaglines as potent anticancer and cytoprotective agents. 
Journal of medicinal chemistry 55:10064–73. 
Ricci, J.-E., C. Muñoz-Pinedo, P. Fitzgerald, B. Bailly-Maitre, G. A. Perkins, N. Yadava, I. E. 
Scheffler, M. H. Ellisman, and D. R. Green. 2004. Disruption of mitochondrial function during 
apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron 
transport chain. Cell 117:773–86. 
Richter-Dennerlein, R., A. Korwitz, M. Haag, T. Tatsuta, S. Dargazanli, M. Baker, T. Decker, T. 
Lamkemeyer, E. I. Rugarli, and T. Langer. 2014. DNAJC19, a mitochondrial cochaperone 
associated with cardiomyopathy, forms a complex with prohibitins to regulate cardiolipin 
remodeling. Cell metabolism 20:158–71. 
Robert, G., I. Ben Sahra, A. Puissant, P. Colosetti, N. Belhacene, P. Gounon, P. Hofman, F. Bost, J.-
P. Cassuto, and P. Auberger. 2009. Acadesine Kills Chronic Myelogenous Leukemia (CML) 
Cells through PKC-Dependent Induction of Autophagic Cell Death. PLoS ONE 4:e7889. 
S 
Samatar, A. A., and P. I. Poulikakos. 2014. Targeting RAS–ERK signalling in cancer: promises and 
challenges. Nature Reviews Drug Discovery 13:928–942. 
Sánchez-Quiles, V., E. Santamaría, V. Segura, L. Sesma, J. Prieto, and F. J. Corrales. 2010. Prohibitin 
deficiency blocks proliferation and induces apoptosis in human hepatoma cells: molecular 
mechanisms and functional implications. Proteomics 10:1609–20. 
Sanford, D. S., W. G. Wierda, J. A. Burger, M. J. Keating, and S. M. O’Brien. 2015. Three Newly 
Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and 
Obinutuzumab into Clinical Practice. Clinical lymphoma, myeloma & leukemia. 
Santidrián, A. F., D. M. González-Gironès, D. Iglesias-Serret, L. Coll-Mulet, A. M. Cosialls, M. de 
Frias, C. Campàs, E. González-Barca, E. Alonso, V. Labi, B. Viollet, A. Benito, G. Pons, A. 
Villunger, and J. Gil. 2010. AICAR induces apoptosis independently of AMPK and p53 through 
up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. 
Blood 116:3023–32. 
Sato, S., A. Murata, T. Orihara, T. Shirakawa, K. Suenaga, H. Kigoshi, and M. Uesugi. 2011. Marine 
natural product aurilide activates the OPA1-mediated apoptosis by binding to prohibitin. 
Chemistry & biology 18:131–9. 
Schleicher, M., B. R. Shepherd, Y. Suarez, C. Fernandez-Hernando, J. Yu, Y. Pan, L. M. Acevedo, G. 
S. Shadel, and W. C. Sessa. 2008. Prohibitin-1 maintains the angiogenic capacity of endothelial 
 162 
cells by regulating mitochondrial function and senescence. The Journal of cell biology 180:101–
12. 
Schug, Z. T., and E. Gottlieb. 2009. Cardiolipin acts as a mitochondrial signalling platform to launch 
apoptosis. Biochimica et biophysica acta 1788:2022–31. 
Scorrano, L., M. Ashiya, K. Buttle, S. Weiler, S. A. Oakes, C. A. Mannella, and S. J. Korsmeyer. 2002. 
A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during 
apoptosis. Developmental cell 2:55–67. 
Seiffert, M., S. Dietrich, A. Jethwa, H. Glimm, P. Lichter, and T. Zenz. 2012. Exploiting biological 
diversity and genomic aberrations in chronic lymphocytic leukemia. Leukemia & lymphoma 
53:1023–31. 
Shackelford, D. B., E. Abt, L. Gerken, D. S. Vasquez, A. Seki, M. Leblanc, L. Wei, M. C. Fishbein, J. 
Czernin, P. S. Mischel, and R. J. Shaw. 2013. LKB1 inactivation dictates therapeutic response of 
non-small cell lung cancer to the metabolism drug phenformin. Cancer cell 23:143–58. 
Shalini, S., L. Dorstyn, S. Dawar, and S. Kumar. 2014. Old, new and emerging functions of caspases. 
Cell death and differentiation 22:526–39. 
Shao, D., S.-I. Oka, T. Liu, P. Zhai, T. Ago, S. Sciarretta, H. Li, and J. Sadoshima. 2014. A redox-
dependent mechanism for regulation of AMPK activation by Thioredoxin1 during energy 
starvation. Cell metabolism 19:232–45. 
Shaw, R. J., M. Kosmatka, N. Bardeesy, R. L. Hurley, L. A. Witters, R. A. DePinho, and L. C. Cantley. 
2004. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates 
apoptosis in response to energy stress. Proceedings of the National Academy of Sciences of the 
United States of America 101:3329–35. 
Shibue, T., S. Suzuki, H. Okamoto, H. Yoshida, Y. Ohba, A. Takaoka, and T. Taniguchi. 2006. 
Differential contribution of Puma and Noxa in dual regulation of p53-mediated apoptotic 
pathways. The EMBO journal 25:4952–62. 
Shindiapina, P., J. R. Brown, and A. V Danilov. 2014. A new hope: novel therapeutic approaches to 
treatment of chronic lymphocytic leukaemia with defects in TP53. British journal of 
haematology 167:149–61. 
Sievers, C., G. Billig, K. Gottschalk, and T. Rudel. 2010. Prohibitins are required for cancer cell 
proliferation and adhesion. PloS one 5:e12735. 
Smith, S. W. 2009. Chiral toxicology: it’s the same thing...only different. Toxicological sciences  : an 
official journal of the Society of Toxicology 110:4–30. 
Souers, A. J., J. D. Leverson, E. R. Boghaert, S. L. Ackler, N. D. Catron, J. Chen, B. D. Dayton, H. 
Ding, S. H. Enschede, W. J. Fairbrother, D. C. S. Huang, S. G. Hymowitz, S. Jin, S. L. Khaw, P. 
J. Kovar, L. T. Lam, J. Lee, H. L. Maecker, K. C. Marsh, K. D. Mason, et al. 2013. ABT-199, a 
References 
163 
potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature 
medicine 19:202–8. 
Sripathi, S. R., W. He, C. L. Atkinson, J. J. Smith, Z. Liu, B. M. Elledge, and W. J. Jahng. 2011. 
Mitochondrial-nuclear communication by prohibitin shuttling under oxidative stress. 
Biochemistry 50:8342–51. 
Strasser, A. 2005. The role of BH3-only proteins in the immune system. Nature reviews. Immunology 
5:189–200. 
Supale, S., F. Thorel, C. Merkwirth, A. Gjinovci, P. L. Herrera, L. Scorrano, P. Meda, T. Langer, and 
P. Maechler. 2013. Loss of prohibitin induces mitochondrial damages altering β-cell function 
and survival and is responsible for gradual diabetes development. Diabetes 62:3488–99. 
Suter, M., U. Riek, R. Tuerk, U. Schlattner, T. Wallimann, and D. Neumann. 2006. Dissecting the role 
of 5’-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein 
kinase. The Journal of biological chemistry 281:32207–16. 
T 
Tait, S. W. G., and D. R. Green. 2010. Mitochondria and cell death: outer membrane 
permeabilization and beyond. Nature reviews. Molecular cell biology 11:621–32. 
Tait, S. W. G., G. Ichim, and D. R. Green. 2014. Die another way--non-apoptotic mechanisms of cell 
death. Journal of cell science 127:2135–44. 
Tang, Y.-C., B. R. Williams, J. J. Siegel, and A. Amon. 2011. Identification of aneuploidy-selective 
antiproliferation compounds. Cell 144:499–512. 
Taylor, R. C., S. P. Cullen, and S. J. Martin. 2008. Apoptosis: controlled demolition at the cellular 
level. Nature reviews. Molecular cell biology 9:231–41. 
Theiss, A. L., and S. V Sitaraman. 2011. The role and therapeutic potential of prohibitin in disease. 
Biochimica et biophysica acta 1813:1137–43. 
Thuaud, F., N. Ribeiro, C. G. Nebigil, and L. Désaubry. 2013. Prohibitin ligands in cell death and 
survival: mode of action and therapeutic potential. Chemistry & biology 20:316–31. 
V 
Vaux, D. L., and A. Strasser. 1996. The molecular biology of apoptosis. Proceedings of the National 
Academy of Sciences of the United States of America 93:2239–44. 
Viana, R., C. Aguado, I. Esteban, D. Moreno, B. Viollet, E. Knecht, and P. Sanz. 2008. Role of AMP-
activated protein kinase in autophagy and proteasome function. Biochemical and Biophysical 
Research Communications 369:964–968. 
 164 
Vincent, E. E., P. P. Coelho, J. Blagih, T. Griss, B. Viollet, and R. G. Jones. 2014. Differential effects 
of AMPK agonists on cell growth and metabolism. Oncogene. 
Vousden, K. H., and D. P. Lane. 2007. p53 in health and disease. Nature reviews. Molecular cell 
biology 8:275–83. 
W 
Walensky, L. D. 2006. BCL-2 in the crosshairs: tipping the balance of life and death. Cell death and 
differentiation 13:1339–50. 
Wang, K., C.-Y. Liu, X.-J. Zhang, C. Feng, L.-Y. Zhou, Y. Zhao, and P.-F. Li. 2014. miR-361-
regulated prohibitin inhibits mitochondrial fission and apoptosis and protects heart from 
ischemia injury. Cell death and differentiation. 
Wang, S., N. Nath, M. Adlam, and S. Chellappan. 1999a. Prohibitin, a potential tumor suppressor, 
interacts with RB and regulates E2F function. Oncogene 18:3501–10. 
Wang, S., N. Nath, G. Fusaro, and S. Chellappan. 1999b. Rb and prohibitin target distinct regions of 
E2F1 for repression and respond to different upstream signals. Molecular and cellular biology 
19:7447–60. 
Wang, S., P. Song, and M.-H. Zou. 2012. Inhibition of AMP-activated protein kinase α (AMPKα) by 
doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and 
cardiomyocytes: role of p53 and SIRT1. The Journal of biological chemistry 287:8001–12. 
Wang, S., B. Zhang, and D. V Faller. 2002. Prohibitin requires Brg-1 and Brm for the repression of 
E2F and cell growth. The EMBO journal 21:3019–28. 
Wei, M. C., W. X. Zong, E. H. Cheng, T. Lindsten, V. Panoutsakopoulou, A. J. Ross, K. A. Roth, G. 
R. MacGregor, C. B. Thompson, and S. J. Korsmeyer. 2001. Proapoptotic BAX and BAK: a 
requisite gateway to mitochondrial dysfunction and death. Science (New York, N.Y.) 292:727–
30. 
Westphal, D., R. M. Kluck, and G. Dewson. 2014. Building blocks of the apoptotic pore: how Bax 
and Bak are activated and oligomerize during apoptosis. Cell death and differentiation 21:196–
205. 
Wilson, P. M., P. V. Danenberg, P. G. Johnston, H.-J. Lenz, and R. D. Ladner. 2014. Standing the 
test of time: targeting thymidylate biosynthesis in cancer therapy. Nature Reviews Clinical 
Oncology 11:282–298. 
 
 
 
References 
165 
Y 
Yamaguchi, R., L. Lartigue, G. Perkins, R. T. Scott, A. Dixit, Y. Kushnareva, T. Kuwana, M. H. 
Ellisman, and D. D. Newmeyer. 2008. Opa1-mediated cristae opening is Bax/Bak and BH3 
dependent, required for apoptosis, and independent of Bak oligomerization. Molecular cell 
31:557–69. 
Yoshimaru, T., M. Komatsu, E. Tashiro, M. Imoto, H. Osada, Y. Miyoshi, J. Honda, M. Sasa, and T. 
Katagiri. 2014. Xanthohumol suppresses oestrogen-signalling in breast cancer through the 
inhibition of BIG3-PHB2 interactions. Scientific reports 4:7355. 
Youle, R. J., and A. Strasser. 2008. The BCL-2 protein family: opposing activities that mediate cell 
death. Nature reviews. Molecular cell biology 9:47–59. 
Young, J. D., S. Y. M. Yao, J. M. Baldwin, C. E. Cass, and S. A. Baldwin. 2013. The human 
concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Molecular 
aspects of medicine 34:529–47. 
Young, L., J. Sung, G. Stacey, and J. R. Masters. 2010. Detection of Mycoplasma in cell cultures. 
Nature protocols 5:929–34. 
Z 
Zenz, T., D. Mertens, R. Küppers, H. Döhner, and S. Stilgenbauer. 2010. From pathogenesis to 
treatment of chronic lymphocytic leukaemia. Nature reviews. Cancer 10:37–50. 
Zhang, K., H. Li, and Z. Song. 2014. Membrane depolarization activates the mitochondrial protease 
OMA1 by stimulating self-cleavage. EMBO reports 15:576–85. 
Zhou, T.-B., Y.-H. Qin, F.-Y. Lei, W.-F. Huang, and G. P. C. Drummen. 2013a. Prohibitin is 
associated with antioxidative protection in hypoxia/reoxygenation-induced renal tubular 
epithelial cell injury. Scientific reports 3:3123. 
Zhou, T.-B., Y.-H. Qin, F.-Y. Lei, W.-F. Huang, and G. P. C. Drummen. 2013b. Prohibitin attenuates 
oxidative stress and extracellular matrix accumulation in renal interstitial fibrosis disease. PloS 
one 8:e77187. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JOURNAL ARTICLES
Journal articles 
169 
The journal articles derived from this thesis are: 
 
*D. M. González-Gironès, *C. Moncunill-Massaguer, D. Iglesias-Serret, A. M. Cosialls, A. Pérez-
Perarnau, C. M. Palmeri, C. Rubio-Patiño, A. Villunger, G. Pons, and J. Gil. 2013. AICAR induces 
Bax/Bak-dependent apoptosis through upregulation of the BH3-only proteins Bim and 
Noxa in mouse embryonic fibroblasts. Apoptosis : an international journal on programmed cell 
death 18:1008–1016. Imapct Factor: 4.788. 
*These authors contributed equally to this study. 
 
A. Pérez-Perarnau, S. Preciado, C. M. Palmeri, C. Moncunill-Massaguer, D. Iglesias-Serret, D. M. 
González-Gironès, M. Miguel, S. Karasawa, S. Sakamoto, A. M. Cosialls, C. Rubio-Patiño, J. Saura-
Esteller, R. Ramón, L. Caja, I. Fabregat, G. Pons, H. Handa, F. Albericio, J. Gil, and R. Lavilla. 2014. 
A Trifluorinated Thiazoline Scaffold Leading to Pro-apoptotic Agents Targeting Prohibitins. 
Angewandte Chemie International Edition 53:10150–10154. Impact factor: 13.734. 
  
 
